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Heterozygous deficiency ofC4A is a common inherited abnormality in patients with SLE
who also acquire a reduction of erythrocyte (E) complement receptor type 1 (CR1)
numbers. These factors could contribute to disease expression by reducing the efficiency
of complement and ECR1 mediated mechanisms for the physiological disposal of
circulating immune complexes (CIC). I therefore studied aspects ofthe physiology ofC4A
and C4B, the isotypes of the fourth complement component and the mechanisms of
reduced ECR1 expression.
C4A binds preferentially to amino groups, while C4B is more efficient in forming ester
bondswith hydroxyl moieties. I therefore examined the differential binding ofC4A and
C4B to SLE erythrocytes in vivo and to heat aggregated IgG ICs in vitro. My results
demonstrate an excess ofC4B associated with erythrocytes and a stronger correlation of
serum C4A levels with immune complex deposition. These findings reflect factors which
may be of importance during periods ofdisease activity and high CIC levels in SLE. The
twin C4 loci are highly polymorphic including null and duplicated alleles. I have studied
the serum levels ofC4A and C4B amongst carefully genotyped normal subjects and have
confirmed observations ofthe extensive phenotypic overlap between subjects with differing
C4 gene numbers. Factors contributing to phenotypic overlap including age, gender, acute
phase responses and abnormal serological reactivitywere also studied. I also found that
the C4B deficient extended haplotype associated with Felty's syndrome encodes expressed
homoduplicated C4A alleles, making impairment of CIC clearance an unlikely
pathophysiological mechanism for this association.
Erythrocyte complement deposition and CR1 reduction are found in SLE. The presence of
antiphospholipid antibodies (aPL) has been correlated with positive direct antiglobulin
reactions, as have low CR1 numbers. I therefore studied the possibility that anticardiolipin
antibodies (aCL) were associated with CR1 reduction in SLE and found significant
negative correlations between aCL levels (IgG and IgM) and CR1 numbers which were not
explicable by an association with disease activity. IgM aCL were also associated with E-
surface C4 and C3 suggesting that aCL bind directly to erythrocytes. I then showed that
aCL are a frequent finding amongst Coombs' positive subjects (suggesting theymay be a
common anti-erythrocyte autoantibody) and that aPL in these subjects showed increased
reactivitywith neutral PLs (a component of the E membrane). Observations suggesting
direct binding by polyclonal (but not monoclonal) aCL lend further support to the
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The Physiology of Circulating Immune Complexes (CIC) and Abnormalities
in Patients with Systemic Lupus Erythematosus (SLE)
Section 1
Classical Pathway Opsonisation of Immune Complexes
Introduction
Opsonisation by complement is mediated principally by the deposition ofC3 and C4
fragments on pathological surfaces ("opsonisation" specifically refers to interactionswhich
increase the efficiency ofphagocytosis, however, I will use the term to describe other
reactionswhich result in and from the deposition ofcomplement on an activating surface).
While classical and alternate pathway activation both contribute to IC opsonisation,
classical pathway deposition ofC4 is ofgreater relevance to the work of this thesis and I
will therefore omit discussion of the alternate pathway. The complement system is highly
evolved to localise activation to pathological surfaces and to avoid the potentially
deleterious deposition ofactive C fragments on host tissue. The existence of cell surface
and fluid phase regulatory proteins is thus an important feature ofcomplement physiology.
Themajor classical pathway regulatory proteins are therefore discussed here, alongwith a
description of the catabolism ofactivated C4 and C3, factors which are of importance in the
understanding of immune complex processing.
Nomenclature
I have here retained the original nomenclature for C2 where the larger surface-bound
fragment ofC2 is designated C2a. For other complement proteins the smaller activation
fragments are designated "a", while the larger activated portion is designated "b". For
typographical reasons I have not adopted the practice of indicating activatedmolecules with
a line above the character but have tried tomake the activation state ofthe molecule clear in
the text.
1.11 Initiation of classical pathway binding and opsonisation by immuno¬
globulin
Recognition ofantigen by antibody leads to classical pathway activation. Aggregated IgG,
or the presence of IgM in the surface bound, planar, configuration, is required and
activation results from binding of the globular head of Clq to the aggregated
immunoglobulin (reviewed in [2-4]). Clq binds by hydrophobic interaction close to the
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IgG hinge region in the Cy2 region ofthe constant domain ofall IgG Fc regions except for
the IgG 4 subclass, and to the C|j3 region of IgM. Attachment ofC lq results in the firm
binding of the loosely associated Clns2 tetrameric protein complex, in the autocatalytic
activation ofC1 r and in the subsequent activation, by C1 r, ofC1s. The association of
Clq and Clr2S2 is calcium dependent and is abrogated by calcium chelators such as
ethylenediaminetetiaacetic acid (EDTA).
Immunoglobulin class and isotypes have marked effects on classical pathway activating
abilities. Human IgGl, IgG3 (when aggregated) and IgM are potent classical pathway
activators, while IgG4 and IgA are not (reviewed in [5]). Species differences also exist,
mouse immunoglobulins show marked differences in their ability to activate the classical
(and alternative) pathway, and in the C solubility of ICs containing different murine
immunoglobulins [6].
1.12 Activation ofC4 by CIs
Activated Cls has serine esterase activity and is able to cleave a 77 amino acid activation
fragment, C4a, from the carboxyterminal of the C4a chain (figure 1, overleaf). Liberation
of this fragment induces a conformational changewhich is associated with the activation of
the C4 intrachain thiolester bond (see chapter 1, section 2). The larger activation fragment
of the C4 molecule (C4b) is then able to bind to nucleophile groups in the vicinity via the
reactive carbonylmoietyof the activated intrachain thiolester bond. The rapid hydrolysis of
C4bwith tissue water inactivates the intrachain thiolester for covalent binding and places a
powerful time, and thus spatial, constraint on the diffusion of the active fragment. By
analogy with hydrolysis ofC3, the lifetime ofactivated C4 may be in the order of60psec
during which time it may diffuse around 40nm. While the cleavage ofC4 by C Is is an
amplification step, the fixation ofC4 to surfaces is inefficient (<5% is deposited) and it is
estimated that approximately 30 molecules ofC4 attach for eachCls.
1.13 The formation ofC3/C5 convertase and C3 activation
C4 functions as amatrix protein, localising complement activation to surfaces previously
recognised by IgG and bearing the activated C1 complex. As will be discussed (chapter 1,
section 2), the susceptibility of the C4 intrachain thiolester to nucleophilic attack has an
important role in determining the efficiency of complement localisation to differing
surfaces. Once deposited, C4b forms a complex with nascent C2 and Mg++, which
localises C2 for hydrolytic activation to C2a by release of the smaller C2b fragment.
Activated Cls is also responsible for the activation ofC2 and is capable ofactivating both
fluid phase and surface bound C2. .
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Figure 1 : The structure, activation, nucleophile binding
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Figure 1: Diagrammatic stmcture ofC4 showing the changes that occur on activation
by Cls with the liberation ofC4a and the activation of the intrachain thiolester bond in
C4b. Covalent binding in ester linkage favoured by C4B is illustrated on the left,
while the opposite amide linkage formed preferentially by C4A is on the right. Factor
I cleaves the C4 alpha chain in 2 places liberating the laiger C4c fragment and leaving
the C4d region covalently bound to the activating surface.
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However, only C2a which is formed in situ in associationwith C4 has serine esterase
activity and is capable of forming the C3/C5 convertase, fluid phase C2a has no catalytic
activity. Only C42 molecules within the molecular radius of the CI complex (approx
60nm) can be activated, a further factor restrictingC activation. The active catalytic site of
C2a so formed is then able to cleave C3 by the liberation ofthe 77 amino acid C3a from the
NH2 terminal of the C3 a chain in a manner analagous to the activation of C4. C3a
diffuses from the site and acts as an anaphylotoxin. Like C4, proteolytic activation ofC3
results in formation ofan active carbonyl residue in the intrachain thiolester bondwhich is
transiently able to covalently bind C3 via a transacylation reactionwith nearby surface-
nucleophile groups (figure 2, overleaf). Activated C3b becomes surface-bound and
associateswith C42 to form the C5 convertase, acting as the site ofattachment ofC5 for
cleavage by activated C42.
While C3 activation is an amplification step, constraints similar to those described for C4
apply and the diffusion distance/binding of C3 is limited by rapid hydrolysis of the
intrachain thiolester by tissue water. Approximately 200 C3 molecules may be
deposited/C42 complex and under optimal circumstances itmay be possible to generate
some 100,000 surface bound C3 molecuWsheep E in 1 minute. However, C3 activation
is generally less efficient. Estimates of 2000-4000 C3/sheep E for phagocytosis and
5000/E for lysis give an indication of the numbers ofmolecules required for functional
interactions. The subsequent binding ofC5 to surface bound C3 and its activation by C2
with liberation of the 74 amino acid C5a anaphylotoxin is analogous to the activation ofC4
andC3
1.14 Classical pathway regulatory proteins
While essentially an amplifying cascade, the process ofclassical pathway activationmay be
seen to incorporate a number of features which act to limit C deposition to activating
surfaces. The requirement for polymerised IgG or IgM in the staple conformation, the
requirement for both C2 and C5 to be bound to C4 and C3 on the activating surface for
convertase activity, the steric limitation ofCls and the short half-life of the activated
thiolester ofC4 and C3, may all be considered to reduce the possibility ofheterotopic
complement activation. However, in addition to these factors, a number of specific cell
surface and fluid phase regulatory proteins exist.
17











































Figure 2: Diagrammatic structure of C3 showing the formation of the active
intrachain thiolester bond after cleavage by C42. The designation of intermediary
and catabolic fragments of surface bound C3 is given in bold type, while the fluid
phase regulatory proteins Factor I (FI), Factor H and complement receptor type 1
(CR1) are shown on the left opposite the C3 fraction they act upon
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C1 inhibitor (CI -INH) is a heavily glycosylated non enzymatic inhibitor ofactivated C1,
which also functions as a specific inhibitor ofkallikrein, plasmin and clotting factors IX
and XII. One -to-one binding ofCl-INH to the active catalytic sites ofClr and Cls results
in irreversible inactivation of these molecules, consuming Cl-INH in the process. The
presence ofClr-Cls-Cl-INH2 complexes in the serum can therefore be used as an
indicator ofcomplement activation. Cl-INHbinding is rapid, and active Clsmayhave a
half-life of<20s at physiological temperatures. Indeed, the whole process ofcomplement
activation of test immune complexes in serum has probably ceased after 3 minutes in vitro.
Inactivation ofthe C3/C5 convertase takes place in two phases. The first, acceleration of
the autocatalytic dissociation ofC2 from C4 is accomplished by two proteins. C4 binding
protein (C4bp) is a fluid phase spider-like regulatory proteinwhich binds to C4 near the C2
binding site and can bind up to 6 C4 molecules simultaneously. Decay accelerating factor
(DAF) is amembrane glycoprotein molecule which also acts to accelerate the dissociation
ofC2 andwill be described in detail below. The second phase, catabolism ofmembrane
bound C4b is accomplished primarilyby Factor I, with C4bp and CR1 as co-factors.
Factor I is the principal fluid phase regulator of complement activation and is an 80kD
glycoprotein present in serum at about 30-50jjg/ml. In the presence ofcofactors, I cleaves
C4 at 2 sites in the a chain liberating the larger C4c fraction and leaving the thiolester
containing C4d region bound to the surface. In the absence ofcofactor activity, only one
site is cleaved leading to the inactivation ofC4b and leaving the partially catabolised
fragment (iC4b) in situ. In this instance, there is no dissociation into C4c and C4d (see
figure 1). The inactivation ofC3b take place in a similar fashion. In the first step either
Factor H (a 150kD glycoprotein formerly termed B1H) or CR1 may function as cofactors,
in the second CR1 is the sole cofactor. The initial step is the binding ofH or CR1 to the
C3b molecule followed by cleavage of the a chain at 2 sites leading to the liberation ofa
small fragment (C3f) and the formation ofiC3b, which remains membrane bound. In the
presence ofCR1 full catabolism of iC3b occurs by a 3rd cleavage in the a chain which
releases the larger part of the molecule as C3c, leaving C3dg bound to the activating
surface. The activation and catabolism ofC3 is illustrated in figure 2.
DAF is a 70kD cell surface protein which shares an unusual method of membrane
attachment with a number ofother molecules including acetyl cholinesterase (AChE),
alkaline phosphatase, 5' nucleotidase and a trypanosome surface glycoprotein [7]. The
molecule is attached to the membrane by a phosphatidylinositol group, which is itself
linked to the functional moiety by a "tail" ofamine and oligosaccharide groups. Medofand
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colleagues [8] noted that purified DAF was able to re-incorporate into the erythrocyte
membrane with retention of functional activity. This unusual property is ascribed to the
nature of the membrane attachment group. In addition to C42 decay accelerating activity,
Medof noted that DAF acted prior to this step to inhibit the incorporation of C2 to
membrane bound C4. Their studies suggested that as few as 70 DAF molecules could
prevent C mediated lysis of sheep E. By comparing the effects ofcell surface DAF and
CR1 on C molecules on neighbouring cells, the conclusionwas reached that DAF can only
act on C localised to the "parent" cell surface while CR1 may also act extrinsically, on
nearby cells. These studies emphasise the protective effect ofendogenous DAF which is
present on all human cell membranes and is deficient (along with AChE and other cell
surface proteins) in the clonal disorder paroxysmal nocturnal haemoglobinuria (PNH) [9].
Patients with this disorder sufferC-mediated intravascular haemolysis.
1.15 Bystander C deposition, C binding to immunoglobulin and non Ig
dependent C activation
The foregoing concentrates on the deposition ofC proteins on activating (cell) surfaces via
aggregated immunoglobulin and the classical pathway, however, a number of other
mechanismsmay operate in defined situations. Cell surface complement depositionmay be
secondary to the fluid phase activation ofC as a "bystander" phenomenon, without the cell
having taken part directly in immune complex formation. The cellular "processing" ofICs,
principally by the erythrocyte CR1 mechanism may also lead to the secondary cell surface
deposition ofC3 and C4 fragments without the erythrocyte having been directly involved
as antigen (see chapter 1, section 5).
Complement may bind directly to the variable regionofthe heavy chain ofcomplexed IgG
[ 10], rather than the cell surface. Immunoglobulins are known to differ in their C
activating properties on the basis of isotype and species and differences between isotypes
are found at the level ofClq binding and subsequent C4 activation and surface attachment
[11]. In general, C activation is independent of Ig binding specificity (eg monoclonal
myeloma proteins), but in some cases the nature of the antigen may also be important.
Using monoclonal IgM rheumatoid factor from cryoprecipitate ofpatientswith essential
mixed cryoglobulinaemia, Ng and colleagues [12] demonstrated that ICs of these
antibodies and IgG were able to activate complement in the fluid phase, but did not
themselves fix C and did not bind to erythrocyte CR1. Given the importance of rheumatoid
factors in rheumatological disease, such details of complement physiology may be of
pathological significance. Taylor and co-workers have measured the deposition ofC3b on
soluble IgM DNA/anti-dsDNA complexes [ 13]. They noted these complexes fixed little
C3b, and that the majority bound to the IgM antibody. E-CR1 binding by these ICs was
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correspondingly low. These findings were considered to emphasise the potential
importance ofcharacteristics ofthe antigen, particularly DNA, in IC physiology.
A variety ofantibody-independent mechanisms ofclassical pathway activation have also
been described, for example with group B Streptococci [ 14] and Cardiolipin (CL) [15].
This latter mechanism was critically dependent onCL and when present at a critical density
on artificial liposome surfaces, CL bound Clq sufficiently strongly to resists Cl-INH
inhibition ofC1 rs incorporation. Alternatively, plasma and bacterial enzymes are capable
of inducing formation ofa classical pathway C3 convertase from fluid phase C4 and C2
without the mediation ofaggregated immunoglobulin orCI [16]. An autoantibody derived
from SLE B cells has been shown to stabilise C42, the classical pathway C3 convertase,
analogous to C3 nef [17] andmay contribute to hypocomplementaemia in some patients.A
recent study purports to show a disease specific deficiency ofC4 function (in insulin
dependent diabetes) [18]. However, the function tested was sheep cell haemolysis and the
differences between disease and control groups observed could readily be due to unequal
inheritance ofC4A (orC4B null alleles) Differences in C4 haemolytic function were not
noted amongst disease discordantmonozygotic twins studied.
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Section 2
C4A and C4B, the Isotypes of the Fourth Component ofComplement:
Molecular Genetics, Structure, Serological Reactivity and Function
Introduction
The isotypes ofC4, C4A and C4B are highly homologous proteinswhich appear to have
arisen by gene duplication with putative gene conversion events contributing to the high
degree ofpolymorphism which characterises this genetic region. Despite their similarity,
important physiochemical and functional differences exist between them andmay contribute
to the association ofgenetically determined deficiencies ofC4 isotypeswith a number of
diseases including SLE (see chapter 1, section 3). A variety ofpolymorphisms are
exhibited by C4 including extensive allotypic variation and polymorphism ofgene number
and size. In addition, C4 proteins exhibit a number of serological markers which have a
complex relationship to the genetically defined molecular sequence, specifically in that part
of the C4d region which determines the isotype and contains the intra-chain thiolester bond.
I will here describe important features of the structure, function, serological reactivity and
molecular genetic characteristics of these isotypic proteins.
1.21 The organisation of the human MHC and polymorphism of class III
genes
C4A and C4B are encoded byhighly polymorphic tandem loci in the classHI region ofthe
MHC cluster on the short arm ofhuman chromosome 6. Alongwith these C4 genes and
their associated steroid 21 hydroxylase (2 lOH) loci, the class EI region also encodes C2
and Factor B (Bf) A detailed molecular map of this region, based on the alignment of4
overlapping cosmid clones ofcDNA has recently been published [19]. The overall layout
ofthe MHC is illustrated in figure 3 (overleaf). The entireMHC is thought to be encoded
by approximately 2xl06bp, ofwhich a 98kb segment comprises the class HI region. The
Bfand C2 genes lie 2kb apart and are about 30kb from the duplicated C4 and steroid 2 lOH
genes, themselves separated by lOkb. Human C2 and Bf have probably arisen as a
duplication from a common ancestral gene and their genetic structure appear to be
phylogenetically stable (reviewed in [20]). In contrast, murine and human C4 are highly
variable, although a greater degree of conservation is observed around the thiolester
binding site in the mouse and human C4a chain and in the y chain where homology is
93%.
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Figure 3. Diagrammatic map of the human MHC and
class III region
Figure 3. Diagrammatic map of the human MHC and class III region. For legend see text.
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Ford used the term "genetic polymorphism" in 1942 [21] to describe the appearance of
structural genetic variants at a frequency too great to be explained by mutation alone, and
there is usually assumed to be a functional difference between the polymorphic variants
(reviewed ref [20]). These differences are thought to underlie the genetic pressurewhich
conserves the polymorphism, though a similar effect would result from linkage of the
polymorphic site with a second locus. Functional properties such as haemolysis may be
utilised in C4 allotyping and electrophoretic recognition ofC4A and C4B allotypes is based
on the technique ofhigh resolution agarose gel electrophoresis ofneuraminidase treated
plasma followed by haemolytic overlay in agarose [22,23]. An improvement in this
technique based on Carboxypeptidase B treatment ofplasma has recently been reported
[24], Using these techniques, serological typing [25-27] and direct DNA sequencing [28-
30] >40 C4 alleles have been recognised.
1.22 C4: structure, activation and internal thiolester bond
Human C4 is a 200Kd molecule synthesised as a single polypeptide chain and split
posttranslationally by a plasmin-like enzyme into three disulphide-linked chains (oc,(3,y) of
93, 75 and 32Kd respectively (figure 1) (reviewed in [31]). Electron microscopy reveals
that C4 is an irregular, globular protein.
C4, along with C3 and a-2 macroglobulin, shares a conserved region of 9 amino acids
which encodes a reactive intrachain thiolester bond. This is located at residues 991 -994 in
the C4 a chain and comprises a glutamic acid residue whose COOHmoiety is bound to the
SH of a neighbouring cysteine. Activation of nascent C4 to C4b results from the Cls
mediated proteolytic cleavage of the 77 amino acid fragment C4a from the N terminal end
of the a chain. Upon activation, a conformational change takes place in the molecule (see
below) which contributes to the reactivity ofthe intrachain thiolester bond responsible for
C4 covalent surface binding. Specifically, a reactive carbonyl (acyl) group is formed and
becomes receptive to transacylation reactions with nearby surface bound nucleophilic
proton donors. The activated thiolester bond ofC4b (and C3b) can form either amide
bonds with amino groups or ester bonds with hydroxyl moieties [32-34].
1.23 C4A and C4B: differential reactivity of the intrachain thiolester
Initial observations of the functional characteristics of the electrophoretic bands ofC4 [35]
were followed by the recognition that C4B (the basic allele) was more efficient inmediating
haemolysis ofsheep erythrocytes in the haemolytic overlay assay [22,36]. Differences in
immune haemolysis reactivity could arise at several stages including: the activation of
isotypes byCls, the efficiency of thiolester to surface-nucleophile transacylation, binding
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and activation ofC2 to form an efficient C3 convertase and susceptibility of the C42
molecule to inactivation by regulatory proteins. Law, Dodds and Porter [37] and Isenman
and Young [38] have been principally responsible for elucidating the basis of the
differential functional capacities ofC4A and C4B.
Isenman and Young performed an extensive series ofexperiments using C4 isotypes
purified from Chido and Rodgers negative sera. Their results confirmed that C4B was
more efficient than C4A in the sheep erythrocyte haemolytic assay, with a ratio of
C4B/C4A activity of 4:1. This was due entirely to greater binding ofC4B to the
erythrocyte surface and no differences were noted between C4A and C4B in the rate of
activation by C Is or in the formation or decay ofan active C3 convertase. Treatment of
nascent C4b with methylamine was used as a test ofthe overall reactivity of the activated
thiolester bond and no difference between the isotypes was noted. The nature of the
covalent bond linking C4 to the erythrocyte surface was examined. Hydroxylamine at
alkaline pH readily cleaves ester but not amide linkages. Itwas found that hydroxylamine
treatment ofEC4 ghosts resulted in the liberation of 80% of C4B but <20% ofC4A
implying that the greater efficiency ofC4B was due to the formation ofester linkages with
the erythrocyte surface, while C4A forms amide bonds. This was further confirmed by
observing the potent inhibition of 125I-C4A binding to E byprior fluid phase reactionwith
the small the amino groups lysine and glycine, while sugarmolecules were more effective
in inhibiting C4B binding.
The importance of these studies lies not only in defining the nucleophile preferences of the
thiolester bond in nascent C4b, but also in suggesting that the reduced haemolytic activity
ofC4Amay be related to the characteristics ofthe activating surface nucleophile groups and
not to functional impairment of C4A itself, i.e. that C4A is not a hypofunctional C4
molecule.
Law, Dodds and Porter examined the haemolytic activity ofsera from donors ofknownC4
genotypewith sheep E. Though there was considerable variation in the haemolytic activity
noted, the ratios ofactivity/pgC4 in serum are very close to 3 for C4B only, 2 in mixed
sera and 1 in the presence ofC4A alone. These ratios appear to argue against competitive
interaction ofC4 isotype binding. Binding ofan equimolarmixture ofpurified C4 isotypes
to haemolysin coated E and to BSA/anti-BSA immune complexes was quantified by
radioligand binding with 125I-F(ab')2 anti C4. A maximal two-fold excess ofC4B binding
to erythrocytes was found, while C4A was more efficient in binding to the protein antigen,
though only 30% excess C4A binding was detected. These authors also report that C4
activity is stable in bufferat 37°C for up to 77hrs and independently confirmed the results
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obtained by Isenman and Young with regard to small molecule (glycerol/glyceride)
transacylation preferences.
Further studies reported by Isenman and Young [39] point to differences between human
and sheep cells in the binding ofC4 isotypes. The ratio ofdeposition ofC4B/C4A was
again found to be around 4:1 for sheep EA, but fell to notmore than 2:1 for human E and
other cells. Thismay be due to differences in the availability ofacceptor groups between
the human and ovine E surface as the authors conclude, or due to the presence in human
cells of regulatory proteins such as DAF. Alterations in the membrane concentrations of
these regulatory factor could account for differences in experimental results and I have
therefore studied the role ofcell surface DAF numbers in determining SLE erythrocyteC4
isotype deposition (see results, chapter 5 ). Otherwork reported in this study is also at
variancewith the unitary hypothesis that C4 surface binding is solely determined by the
availability of surface transacylation sites. The bindingofC4A to cell surface glycophorin
A via amide linkages was found to be relativelymore efficient than C4B, despite the fact
that hydroxyl moieties outnumber amino groups by several orders ofmagnitude in this
molecule. The authors propose that these data may be explained by the existence ofa
secondary substrate binding site on nascent C4b.
1.24 Differential function ofC4A and C4B in vitro
The role of the classical pathway in the physiological processing of immune complexes in
vivo is discussed in chapter 1, section 5. However it is appropriate to refer to differences
which have been demonstrated between C4A and C4B in the inhibition of immune
precipitation (IIP, see section 1.51) and the complement/CRl mediated adherence of
immune complexes to erythrocytes at this point. Schifferli and colleagues have studied
these functions ofC4 isotypes in vitro. Initially [40], the relative HP and haemolytic
activities ofC4A and C4B deficient serawere comparedwith serum from a donor known
to posses 4 C4 alleles. The ratio of haemolytic activity of C4B/C4A (sheep E) was
approximately 3:1, and C4B alone was more efficient in inducing haemolysis than the
mixed isotypes in normal serum. IIP activity of the isotypes favoured C4A, with a ratio of
1.66, though in this case there was little obvious difference between C4A alone and mixed
C4 isotypes in normal serum. This suggests that competition between isotypes when both
are present may mask the subtle functional differences which exist. In this study it was
noted that a quantity ofsemm containing C4 equivalent to 1% of the haemolytic activityof
normal serum was sufficient to restore full IIP activity to C4 deficient serum.
Concentration of C4 was the limiting factor since 1% normal semm on its own did not
restore IIP activity. Paul and colleagues [41] have elucidated the reaction kinetics of IIP
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using serum-free mixtures ofC1 and C4 isotypes and aBSA-antiBSA complex similar to
that employed by Schifferli. When the rates ofIIP are compared, a greater difference in
function was noted, with an average ratio of reaction rates of2.8 between representative
C4A3 and C4B1 containing sera. The steady state ormaximal IIP observed showed a very
similar increased efficiencyofC4A compared with C4B to that observed by Schifferli. In
comparing the efficiency ofC4A and C4B in opsonising tetanus toxoid-anti-tetanus toxoid
(IT/anti-TT) IC for binding to human erythrocyte CR1, Schifferli [42] concluded that
C4A isotypes were 1.5-foldmore efficient than C4B.
The preferential binding ofC4A to amino groups could thus influence the relative efficiency
ofC4 isotypes in the processingof ICs ofprotein antigens in 2 main ways, either related to
the efficiency ofHP reactions, or to the opsonisation of ICs for E-CR1 binding. Using
purified, functional C4A and C4B, Gatenby [43] was able to compare the relative
efficiency of these proteins in dynamic and steady state studies with both preformed and
nascent immune complexes. While the difference in IIP functionwas slight in favour of
C4A, there was amuch more marked increase in the efficiency ofC4A with regard to
opsonisation for E-CR1 binding implying that alterations in C4A concentration in vivo
may have disproportionate effects upon this facet of IC physiology.
The differential reactivity ofC4 isotypes towards nucleophile substrate may also be of
consequence in the pathogenesis of certain drag related lupus-like illnesses [44,45]. Sim
and co-workers have hypothesised that the association ofhydralazine and metabolites of
procainamide and practolol with SLE-like syndromes may be due to the presence of
nucleophilic residues in the drugs which are able to hydrolyse the C4 (and C3) thiolester
bond, leading to potential reduction ofC-related protective functions. In addition, D-
penicillamine [D(-)-BB-dimethylcysteine] (DPA), which can cause glomerulonephritis,
showed preferential covalent binding to the activated thiolester ofC4A, with concomitantly
greater reduction in the haemolytic activity ofC4A than C4B. While it is possible that the
pathogenic (or therapeutic) effects of DPA are related to inhibition of C4 mediated
functions, corroborative data such as linkagewith C4A null alleles is missing.
The clearance kinetics of 125I-C4 from plasmawere studied [46]. The conventional view is
a bi-exponential model, suggesting distribution through 2 "compartments". In contrast,
these authors [46] found that a 3-exponential model gave the best computed fit to the
experimental data, suggesting a 3rd compartment ofdistribution. The fractional catabolic
and synthetic rates suggested by this model were 2.41+/-0.98%/hr and 0.165+/-
0.089mg'Tcg/hr respectively. The ratio of distribution of C4 between extra and
intravascular space predicted was 2.24, while the usually reported figure is 0.54.
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1.25 Comparison ofC4A and C4B
For reference, an overviewof the major structural and functional differences between C4A
















3. Functional correlates (comparisonwith mixedA andB = 1)
(a) haemolytic activity















Table 1: Comparison ofthemajor properties ofC4A and C4B
1.26 C4 isotype serological activity and molecular structure
A complex relationship exists between the molecular basis ofC4 polymorphism and
serological reactivity. Many studies, including work presented here depend on anti-C4
monoclonals to quantify C4 isotypes. The difference between the serological determination
ofC4 molecules and the molecular substitutions which confer isotypic identity is therefore
of importance, since the equivalence between isotype and serotype is not absolute and this
may lead to errors ifnot recognised.
Rodgers (Rg) and Chido (Ch) are human erythrocyte and plasma antigens originally
defined by the alloantibodies anti-Rg [47] and anti-Ch [48], produced by individuals
lacking the antigenic determinant after transfusion with Rg or Ch+ve blood. The genes
encoding Rg and Ch were initially mapped to the HLA region by serological studies [49]
and were subsequently localised to the a chain of the C4d fragment of C4 [50]. The
identification of the Rodgers antigen as C4A and Chido as C4B was made byO'Neill [51 ].
These specificities are now known to result from the deposition on erythrocytes ofsmall
quantities ofC4 from semm.
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Methods based on inhibition ofhaemagglutination have been used extensively in the
serological typing of the Rg and Ch antigens [52]. Plasma containing unknown C4 is
incubated with anti-Rg/Ch ofknown specificity (or vice versa). The reaction mixture is
then incubated with erythrocytes coated artificially with C4 from pool serum, and
agglutination induced, after washing, by anti-human IgG. Recognition ofantibody/antigen
in the first reactionwill reduce or abrogate binding to the erythrocyte/C4 reagent and will
abolish agglutination. As an alternative approach erythrocytesmay be coatedwith testC4
and the cell examined directly for its ability to be agglutinated by anti-Rg/Ch. If the anti¬
serum is completely absorbed in the first reaction, and no inhibition occurs, the plasma is
referred to as a "complete inhibitor", failure ofabsorption and subsequent agglutination is
termed a "negative inhibitor" plasma [52].
It was observed that certain plasmas produced only partial inhibition (pi) [47 ] which was
not due to quantitative variation in C4. Further studies with specific C4 allotypes led to the
conclusion that anti-Ch and anti-Rg were polyspecific and that there may be more than one
antigenic determinant ofRg or Ch [53]. Giles [54,55] proposed amodel of2 Rg (Rg: 1, 2)
and 3 Ch (Ch: 1,2,3) antigenic determinants and in all models Rg: 1 and Ch: 1 are the
commonest. Further serological subdivisions ofcommon allotypes were detected by the
application ofstandardised polyspecific allo-antisera and comparison ofthis serologic data
with isotypic characterisation soon led to the breakdown of the conventional division
between C4A/Rg and C4B/Ch [56] with the recognition of a further 3 Ch determinants
(Ch:3,4, 6) [27]. These cumulative serological observations have enabled the following
conclusions to be drawn.
1. Rg: 1 and Ch: 1 are alternative antigenic determinants but are not uniquely associated
with C4A and C4B
2. Some C4A molecules may not express Rg: 1 or 2 and may express Ch determinants
but never Ch:2 and 4
3. All C4B molecules express Ch:4
4. Ch:2 and 5 are never split on the C4B molecule
5. Ch:3,1 and 6 appear to be related on both C4A and C4B molecules
The molecular mechanisms underlying these serological relationships have been
summarised [57]. C4A and C4B do not differ inpost-translational structural modifications
such as disulphide bond structure, degree ofglycosylation and sulphation implying that
inter-isotype differences are sequence related. The amino acid sequences derived from full
length and partial cDNA clones ofC4A4, C4A3 and C4B2 alleles, and limited genomic
sequence of the C4Bla, C4Blb and C4B2 alleles [28-30] and other data [58] suggest there
is < 1% sequence variation (17 changes amongst 1725 amino acids) between C4A and C4B
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and that 12 ofthese changes are clustered in a region of 140 amino acids approximately 230
residues C-terminal to the thiolester site.
Yu and colleagues [30] have compared sequence and serological data amongst 4 patients
with informative C4 genotypes. The alleles C4A3a and C4B3 represent the "classical"
serological findings, with C4A3a showing Rg: 1, 2 and no Ch determinants, while C4B3
shows no Rg but all Ch reactivities. Alternatively the C4A1 and C4B5 alleles show
reversed antigenicity: C4A1 is Rg -ve but expresses Ch: 1,3,5 and 6 (not 2 and 4, as
above), while C4B5 is Rg:l+ve and also expresses Ch:4 and 6. Sequence variations
common to the two C4A proteins but not shared by the 2 C4B proteins must therefore be
associatedwith isotypic, not serotypic determinants and vice-versa. Similarities between
C4A3a and C4B5 allowed recognition of the Rg specific amino acids while comparisons
amongst the C4B3, C4A1 and C4B5 sequences, plus cDNA and genomic sequences of
other informative alleles have allowed conclusions to be drawn about the sequence
determinants ofChido reactivities. On this basis the model illustrated in figure 4 (overleaf)
was constructed. The main features ofeach of these informative haplotypes are shown in
figure 5 (p32), a comparison ofsimilar data relating to haplotypes helpful in the analysis of
Chido specificities is shown in figure 6 (p33).
These serological differenceswere associated with 8 amino acid substitutions grouped in 4
regions as shown in figure 4. Regions I and III are single amino acid substitutions at
positions 1054 and 1157 respectively, while the 4 changes comprising group II are found
amongst the 6 bases between positions 1101-1106. The 2 changes comprising group IV
are clustered in the 4 residues at positions 1188-1191. The only residues shared
exclusively by both C4A and both C4B molecules are found in group II (1101-1106),
whichmust therefore determine isotypic specificity (C4A molecules show PCPVLD, while
C4B molecules show LSPVIH. variable amino acids are underlined). The C4B5, Rg+ve
molecule shows the C4B isotype specific pattern in group II but acquires the same residues
as the Rg expressing C4A3amolecule at region I (D) and group IV (VDLL). The opposite
substitutions at group IV (ADLR) were seen in molecules expressing Ch: 1. This reactivity
is thus separate from the isotypic moieties and is exclusive ofRg: 1. The C4B5 molecule
studied here (results, chapter 3) expressed Ch:4 and 6.
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Figure 4. Proposed structural model of the isotypic
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Figure 4. Proposed structural model of the isotypic and serological determinants of human C4.
For legend see text.
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Figure 5. Correlation of serological and structural data in 4
cloned C4 genes
CO > a
0 0 0 0 ! ■
8
§ 0 0 0 K>
0 0 0 0 -
0 0 0 0 K)
0 0 0 0 U> 9
0 0 0 0 4^
0 0 0 0 LA
0 0 0 0 On
o o o o
O
£ HH
G g £ s —o
H
5 s 5 o>
C/5 on en z
—J
s











Figure 5. Correlation of serological and structural data in 4 cloned C4 genes. For legend see
text.
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Figure 6. Comparison* of the Chido determinants and amino
acid sequence of some C4 allotypes with a typical
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rigure 6. Comparison of the Chido determinants and amino acid sequence of some C4
illotypes with a typical Chido positive allele (eg C4B3). The negative symbol in the right hand
lanel denotes absence of the typical Chido amino acids. Substitutions are not shown.
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By comparison with other C4B molecules it was concluded that the C4B isotype specific
residues at group II specify Ch:4, which is therefore specific to C4B. In addition, the
C4B5 isotype shares the S at region III (1157) with other Ch:6+ve C4B molecules, this
substitution was therefore considered to specify Ch:6. The opposite (N) substitutionmay
contribute to Rg:2 reactivity, though this is not certain. Finally, the G residue at region I
(1054) is thought to determine Ch:5, while the reciprocal substitution seems to have no
effect on Rg specificity though it does have other effects on Ch reactivities. These
specificities appear to be determined by sequence variations alone, but there is not a unique
relationship between amino acid substitutions and the Ch:2 and 3 determinants. For
example, C4A1 differs from C4B3 only in the C4 isotype encoding region II, but loses
both Ch:4 (as expected from the foregoing) and Ch:2, which is not explained on the basis
ofsequential data alone. A similar aigument applies for Ch:3. It was therefore concluded
that these are conformationally determined specificities and appear to be dependent on the
correct apposition ofCh:5 and 4, and Ch:6 and 1 respectively. In practical terms, this
model reemphasises that the serological recognition ofRg: 1/Ch: 1 is close to, but not
identicalwith, the isotype of the molecule.
C4A and C4B isotypes are determined by the sequences PCPVLD and LSPVIH at
positions 1101-1106 respectively. These amino acids therefore appear to determine many
ofthe functional and physical differences between these 2 molecules including thiolester
reactivity. The isotypic and thiolester regions are separated by 106 amino acids. Analysis
of regional hydropathy suggests that the isotypic residues occupy a hydrophilic sitewhich
may be exposed in the tertiary structure of the molecule, while the thiolester bond is in a
hydrophobic region, likely to be hidden in nascent C4. The conformational changewhich
occurs on activation ofC4 [59] contributes to activation ofthiolester binding by exposing
the thiolester site on the surface andmay approximate the isotypic and thiolester sites. This
would allow the interaction of residues at both sites and may explain the influence of
isotypic residues on the binding reactivityofthe molecule. The negatively charged Asp at
1106 in C4A may increase the nucleophilicity ofnearby amine/amine groups towards the
thiolester bond and thus lead to the observed preferential reactivity of these groups with
C4A [37]. Alternatively, the positively charged HIS 1106 ofC4B may participate in
hydrogen-bonding charge shift in hydroxyl substrates resulting in more the efficient
binding of C4B to hydroxyl groups of carbohydrate antigens. The activation
conformational shift may thus both expose the thiolester for reactivity and contribute
towards creating an environment which may be catalytic for the nucleophilic attack of
preferred aminodiydroxyl groups upon the thiolester carbonyl.
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Certain other molecules may contribute towards isotypic differences, for example, Pro
1101 in C4A (alongwith Cys 1102 and the shared Pro 1103) may induce conformational
constraints on the molecule and result in the slower electrophoretic mobility of the C4A a
chain found in modified SDS-PAGE gel electrophoresis [57]. It is of interest that the
mouse has one functional C4 gene and shows a hybrid structure /.e.PCPVIH. Dieli and
colleagues [60] have noted that C4 from BALB/c and CBA/I differ in their capacity to
inhibit the transfer ofdelayed hypersensitivity bymurine lymph node cells. Pretreatment of
the C4 with glycine and glucose produced opposite effects on the C4 function ofeach
species arguing that the binding reactivity of the thiolestermoiety in each of these mouse
strains favour amide or esterbond formation unequally. The amino acid sequences ofthe
C4 isotypic sites in these strains has not been ascertained.
1.27 The macromolecular arrangement of the C4 loci: polymorphism of C4
gene number and size
A feature of the C4 locus is the high frequency of silent, null or non-expressed alleles
(designated quantity 0, C4Q0) at either locus. A variety ofcDNA genomic probes and
specific restriction enzyme cleavage sites have allowed RFLP analysis ofvariation in gene
size, the macromolecular arrangement ofalleles within the C4 locus (see figure 3) and the
structural basis ofgenetic deletions leading to common C4 null alleles (figure 7, overleaf).
Taq 1 digestion ofgenomic DNA separates the C4 loci and their associated steroid 21 -OH
genes by restriction of a site near the 5' end of the molecule, but is not affected by the
nature of the C4 gene encoded. Using this enzyme, Carroll and others [61,62] have shown
that the C4Q0 found in a large proportion ofhaplotypes is due to deletion of a C4 gene.
The defect in some non deleted haplotypes was elucidated by Yu and Campbell [63] who
used a C4d specific, 927kb Bam HI probe in Southern blot analysis of restriction
fragments after digestion with Nla IV, EcoO 109 and Taq 1. Isotypic differences are
associated with 2 Nla IV fragments for C4A (276 and 19lbp respectively), while
restriction of a C4B gene results in a single 467bp fragment. EcoO 109 separates C4
molecules by recognition ofsite related to the Rodgers and Chido epitopes, rather than
isotype. Thus a Rgl bearing C4 gene is represented by a 565bp EcoO 109 fragment, while
a Ch: 1 bearing C4 gene shows a 458bp fragment with this enzyme. Comparison of the
RFLP produced by these enzymes with the taq 1 polymorphism demonstrated that the C4B
null allele in the haplotype B44, DR6, C4A3, C4BQ0 was associated with the presence ofa
homoduplicated C4A gene in the C4B locus. In this thesis I will present data which
suggest that this homoduplicated C4A gene may be expressed. No non-expressed or

































































































































The macromolecular organisation of the C4/steroid 21-OH complex, and the detailed
intron/exon structure of the C4 genes have been studied in detail [30,62,63]. The two C4
genes are separated by lOkb, and each has a cytochrome-p450 steroid 21-OH genewithin
2kb of the 3' end. The 21-OHA and 21-OHB genes are each 3.5kb and show an overall
sequence homology of98%, but only the 21-OHB gene is transcriptionally active. Taq 1
RFLP analysis divides the C4 locus into locus I usually encoding aC4A gene and 21 -OH
A gene, while locus II usually encodes C4B and the 21-OH B gene. Locus I is
characterised by a 7.0kb 5' fragment, while locus II shows a 6.0 or 5.4kb fragment. The
size of these genes differs with the presence of a 6.5kb intron 2-2.5kb 3' to the
transcription start site at the 5' end of the gene. C4 genes may therefore be long (approx
22kb) or short (approx 16kb). To date both long and short C4B genes have been identified
but no short C4A genes have been found. Otherwise the detailed intron/exon structure of
the C4 locus seems to be stable between both loci [30].
1.28 The regulation of C4 gene expression
Little is known directly about the genetic mechanisms which regulate C4 expression in
humans, though information relating to murine C4 and Sip (sex-linked protein, the non¬
functional murine C4 analogue) is available. Observations relating to the role ofC4 in the
murine acute phase response and to the relationship between C4 genotype and phenotype
are also of relevance.
Sip and C4 are homologous proteins encoded by duplicated genes in the S region of the
murine H-2 (major histocompatability complex). Murine C4 levels are primarily
determined by S region genes for high and low expression. Sip may be present (Slpa), or
genetically deficient (SlpO). Slpa expression is influenced by an androgen sensitive
controller situated in the 5' flanking region [64], though a variety of other regulatory
influences have also been reported [65]. Pre-translational, Non-H-2 (trans-regulatory)
[65], tissue specific [66] effects were found on the expression ofbothmurine hepatic Gl¬
and Sip. These data point to the complexity of regulation in the murine C4 and Sip genes
where both cis and trans-regulatory mechanisms are apparent and may be due to the
incorporation ofa retroviral controller sequence [67 ]. No equivalent data is available in
humans, but the observations ofTuedsson and colleagues [68] that there is considerable
variability in the expression of C4 isotypes in subjects with the same MHC extended
haplotypes, may suggest similar multiple regulatorymechanisms. However, variation in
G1 turnover rates would have to be established before the evidence for this was considered
exhaustive.
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While the majority ofC4 is synthesised in the liver in humans, there is recent evidence of
tissue specific regulation ofC4 synthesis in the kidney. Deposition ofclassical pathway
components in renal tissue is usually considered evidence ofimmunopathology. However,
Feucht and colleagues detected both C4A and C4B in the mesangium ofnormal renal
glomeruli [69]. More recently, members of the same group have reported the finding ofC4
messengerRNA in renal interstitial cells at levels 25% of those found in liver, suggesting
that in-situ production ofC4 may be related to normal renal (mesangial?) function [70]
In themouseMRL/lpr model ofSLE, intraperitoneal administration of inflammatory stimuli
induced differing effects on the expression ofC4 and Bf [71 ]. Murine C4 production in
response to C. parvum. and C. bovis. was found to be dependent on the consitutive
genetic level ofC4 production [72]. No data is available on the acute phase expression of
C4A and C4B in humans in vivo, but the behaviour ofhuman C4A and C4B genes has
been studied in a mouse fibroblast transfectant model [73]. In this system, expression of
C4 genes was not affected by interleukin-1 or tumour necrosis factor, while interferon
alpha induced a greater increased in the expression ofC4A than C4B, suggesting potential
heterogeneity in the acute phase responses of C4 isotypes. An attempt was made to




Complement Deficiency and Inherited Heterozygous
Deficiency ofC4A in SLE
Introduction
Homozygous deficiency of classical pathway proteins are amongst the most powerful
genetic factors known to contribute to disease susceptibility in SLE. Complete deficiency
ofC4 is virtually sufficient in itself to induce disease and most individuals describedwith
this deficiency have SLE or a similar illness. While homozygous C4 deficiency is rare,
heterozygous deficiency at the C4A locus is common and is also associated with SLE. The
theory has been advanced that this association is the result of reduced efficiency of immune
effector mechanisms (complement mediated IC clearance) which allows persistence of
antigen and prolonged stimulation of the immune response [ 1 ]. In this chapter, I will
discuss evidence for the association between inherited deficiency ofcomplement and SLE
with special reference to heterozygous C4A deficiency.
1.31 Complement deficiency and disease
Genetic deficiencies ofnearly all of the complement components have been described and
the subject has been extensively reviewed [74-76]. The arguments linking effector
mechanisms and SLE have recently been summarised [ 1 ]. Homozygous deficiency of
complement is associated with 2 main sets ofclinical problems, infection and immune
complex disease. The relative incidence of these problems in described complement
deficiency states is summarised in table 2 (overleaf, redrawn from [ 1 ]). This data is likely
to be incomplete and may be influenced by selection bias ofvarious types It may therefore
not represent an absolutely rigorous treatment of the overall problem of the incidence and
disease associations of C deficiency [1]. However, the overall pattern of disease
associations is unlikely to be altered by addition of further information and, specifically, no
homozygous C4 deficiency has been ascertained in the healthy populations screened to
date. The preponderance ofNeisserial infections in deficiency ofC3 and the laterpathway
components is explained by the relative protection from specific immunity conferred by the
intracellular localisation of these bacteria and thus the greater requirement for fluid phase,
alternative pathway mediated bacterial lysis.
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Component Number with Numbers with associated diseases
deficiency IC disease Infection
Classical pathway
manywith pyogenic infections
few with pyogenic infections
Clq 15 14
Clr or Cls 8 6
C4 16 14
C2 66 38
CI inhibitor >500 2-5%





10 pyogenic (mainly Neisseria)
pyogenic
2 Neisseria








C5 12 1 9 Neisseria
C6 17 2 10 Neisseria
C7 14 1 6 Neisseria
C8 14 1 8 Neisseria
C9 many no disease association
Table 2. Reported cases ofcomplement deficiencies and associated diseases. From [1]
1.32 Null alleles of C4 in SLE: inheritance and molecular genetics
Homozygous deficiency ofC4 is a rare condition, especially given the frequency ofpartial
deficient C4 haplotypes [76]. The C4A and C4B loci are closely linked to each other and
segregate together in marked linkage disequilibrium as C4 haplotypes. Moreover, the 4
complement genes of the class III region C2, BfC4A and C4B are inherited together as
single genetic units in man, called "complotypes" [77] which also show pronounced
linkage disequilibrium. Complotypes are described in the orderwritten above which
reflects the known chromosomal arrangement of the genes. Complotypes themselves show
a further level of linkage disequilibrium and are inherited in association with extensive
regions ofMHC DNA in "extended haplotypes" [22] sometimes referred to as "supralypes"
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[78]. The degree ofpolymorphism within the C4 loci has been described in chapter 1,
section 2. An unusual feature ofC4 polymorphism is the high frequency ofnull alleles,
which have been found in all populations studied (figure 8: overleaf). From the frequency
of C4 null alleles, the proportion of individuals with 4, 3, 2, and 1 alleles may be
estimated (shown in figure 8). From these estimates itwill be seen that only 50-60% ofthe
normal population posses 4,30-38% posses 3 and 5-10% posses 2 C4 alleles, making
heterozygous deficiency the commonest immunogenetic abnormality described [80]. G4Q0
are also inherited in strong linkage disequilibrium and table 3 (below) shows some of the
commoner extended haplotypes encoding this deficiency.
HLA Complotype HLA Frequency
A Cw B C2 Bf C4A C4B ER
1 7 8 C S 0 (del) 1 3 0.0815
2/11A 5 44 C S 3 0 (no del) 4 0.0636
3 4 35 C F 3,2b 0 (no del) 1 0.0359
30 5 18 C F1 3 0 (del) 3 0.0191
23/29 A 4 44 C F 0 1 7 0.0089
2 3 W60 C S 0 2 w6 0.0065
Table 3: The commonest extended haplotypes encoding a C4A orC4B null allele
A alternative alleles, del/no del = deleted or non deleted
b duplication ofthe C4A allele or gene conversion B toA
ThehaplotypeAl,B8,DR3,BfS,C21, encodes C4AQ0,C4B1 and is the commonest of
all caucasoids haplotypes (the extent of this molecular deletion is shown in figure 3). Most
C4B null alleles are also found in a small number ofspecific extended haplotypes. Itmight
be expected that crossover events amongst common single null haplotypes would lead to
existence ofa number of double null haplotypes. However, the double null haplotype is
exceptionally rare [ 1 ] and does not occurwithin specific extended haplotypes [79]. The
molecular basis of the C4A deficiency in the cases examined by Uring-lambert was
different from the gene deletion found in the common A1, B8, DR3 haplotype (see below)
and resulted from parental consanguinity. Moreover, the genetic mechanisms leading to
homozygous deficiency seem to involve crossover between individually rare haplotypes
more frequently than expected. The conclusion is that the genetic events leading to the
occurence ofhomozygous deficient C4 haplotypes seem unique to each individual.
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Figure 8: Estimates of the proportion of individuals
with 4,3,2,1 and 0 functional C4 genes in the normal
Caucasoid, Negroid and Mongoloid populations.





B = C4A gene Q = C4AQ0 gene
^ = C4B gene Q = C4BQ0 gene
Figure 8: Gene frequencies ofC4 deletions calculated from the Hardy-Weinberg
expectations with the frequency of C4A and C4B alleles established during the IXth
International Histocompatibility Workshop, (redrawn from table 3 in Hauptmann et al
1988, [80])
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By contrast to the individually unique mechanisms seen in homozygous C4 deficiency, a
relatively restricted number ofgenetic mechanisms seem to explain themajorityofcommon
C4 null bearing haplotypes.
These include:
1) the presence ofa defective ormutant C4 gene
2) conversion ofa C4B gene to a C4A gene.
This can lead to two different patterns ofgene expression:
(i) 2 identical allotypes at each locus (homo-expression, homo-duplication)
(ii) 2 alleles ofthe same isotype but differing allotype egA3, A2, BQO
(iso-expression)
3) gene deletion: the extent and distribution ofcommon gene deletions are shown in
figure 7
DNA analysis has shown that about 50% ofcommon null alleles are due to deletion ofa
28kb fragment involving either the 21 -OHA or 21 -OHB genes and 3 common patterns have
been found [61,62]. These include (A) the C4A and 21-OHA genes, (B) the C4B and 21-
OHA or (C) the C4B and 21-OHB genes, but not both C4A and C4B genes together
(figure 7).
1.33 Homozygous C4 deficiency and immune complex disease
The clinical findings associated with complete C4 deficiency have recently been reviewed
[80]. Themajorityofpatients have presented with SLE or, in the absence of full diagnostic
criteria, an SLE-like illness. These patients have been characterised by early onset
(majority <10yrs), prominent skin lesions (orDiscoid LE) and Raynaud's phenomenon but
mild renal disease. Serologically, antinuclear antibodies are seen in 58%, but anti-dsDNA
have not been described. Interestingly, 5 of 12 patients possessed Ro but no patients had
La antibodies, a pattern similar to that seen in C2 deficient patients. The association of
C4AQ0 with SLE has been documented in at least five series ofstudies (see Hauptmann
[76] for review) and homozygous deficiencywas found in an average of 11.7% ofpatients
compared with 0.9% ofnormal controls.
Recently, a Canadian family have been reported in whom C4 deficiency and Ro antibody
production appear to segregate separately [81 ]. This emphasises the finding from other
familial cases that multiple influences, including genetic loci outwith chromosome 6 are
involved in the development ofsusceptibility to SLE in the majority of cases. A further
family have been studied in whom almost complete deficiency (2-5% normal levels) ofC4
was inherited as a non-HLA linked autosomal dominant gene [82].
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1.34 Heterozygous C4A deficiency and SLE
An association ofC4QO encoding extended haploypeswith several autoimmune diseases,
including Graves disease and insulin dependent diabetes mellitus as well as connective
tissue diseases such as Sjogren's syndrome, Henoch-Schonlein purpura and SLE has been
noted [76,78,83]. Heterozygous deficiency ofC4 alleles, specifically C4A, is associated
with SLE. The family study ofFielder et al [84] was the first to report the presence ofnull
alleles and the associated extended HLA haplotype ofa group ofSLE patients and their
families. Null alleles (ofC4A, C4B orC2) were found in 83% ofpatients and in 43% of
controls. Themajority ofdeficiencies in patientswere heterozygous C4AQ0 (78% ofnull
alleles). 82% ofC4 nulls were present on extended haplotypes which also encoded DR3.
Of these, the Al ,B8, DR3 haplotype was the most frequent and was present in 15/22
C4AQO haplotypes in patients. The authors concluded that linkage disequilibrium made it
impossible to tell whether the C4 null allele, DR3 or another, linked gene was most
important in determining the disease association, though Green et al [85] have reanalysed
the data by the empirical logistic method and concluded that the association is strongest
with the C4A null allele.
Evidence to suggest that it may be the C4A null allele which is the important gene comes
from genetic studies in other populations,where C4Q0 also show associationwith SLE but
are encoded with different HLA alleles (extended haplotypes). In the Japanese, DR3 is a
rare allele and DR2 was found to be the most commonHLA antigen in patients with SLE
[86,87]. Similarly, in a Chinese population C4A null and DR2 were statistically associated
with SLE, while C4BQ0 alleles were not [88]. In Black American SLE patients the most
powerful association waswith DR3 [89]. Howard and colleagues [90] have demonstrated
an independent contribution of risk from C4AQ0 genes and DR2 in a study ofCaucasoid
and Black American patientswith SLE. In this population, C4AQ0 linked B8 and DR3
genes did not contribute a separate risk factor, while in Green's analysis ofFielder's data
there did appear to be an additive risk from the presence ofboth C4AQ0 and DR3. So and
colleagues have confirmed a small increase ofDR 2 in British Caucasoid patientswith SLE
[91]. This was unrelated to the predominant association of disease with the C4AQ0
bearing A1, B8, DR3 haplotype. Despite differences inHLA linked genes, calculations of
relative risk ofC4AQ0 for SLE from the study ofFielder and from a Japanese population
(quoted by Lachmann and Walport [ 1 ]) demonstrated an association between C4AQ0 and
SLE in both ethnic groups. The presence ofC4AQ0 has a relative risk of8.2 in Caucasoid
SLE and 4.3 in the Japanese population, while C4BQ0 showed relative risks of0.65 and
0.13 in these populations respectively. The molecular basis ofC4A deficiency in SLE is
heterogeneous [92,93], though most cases are due to the C4A steroid 21-OH deletion
typical of the Caucasoid A1, B8, DR3 haplotype.
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1.35 Acquired Complement deficiency and immune complex disease
A second line ofevidence linking functional deficiency ofclassical pathway components
and disease expression in SLE comes from the occurence of IC disease in individuals with
acquired C deficiency. Heterozygous C1 esterase inhibitor deficiency is one of the
commonest genetic C deficiency states and leads to an acquired reduction ofC4 andC2 due
to excessive CI-mediated turnover secondary to depletion ofCl-INH at times of
physiological stress [74]. In addition to hereditary angioneurotic oedema, approximately
2-5% also have an illness which is described as similar to SLE. Themajority have LE-like
skin disease, with photosensitvity and may have a positive lupus-band test [94]. Anti-
nuclear antibodies are usual and mild abnormalities ofurinary sediment are common. More
severe proliferative glomerulonephritis has also been reported (see [94]). The locus
controlling C1-INH production is not liked to the HLA, excluding genetic linkage as a
cause for this association and suggesting that it is the loss ofC function which is important.
1.36 Correlation of C4 genotype with phenotype and the measurement of
C4 isotypes
The relationship between phenotype and genotype in subjects with heterozygous C4A
deficiency has been difficult to ascertain exactly. It would be predicted that absence of 1
allele would lead to reduction of25% of total C4, and 50% ofC4A. The ratio ofC4A to
C4B in the presence of 1 C4AQ0 should be 0.5. When either 2 or 1 copy of each allele is
present the ratiowill be 1, while a single null C4B will produce a ratio of 2. The use of
densitometric scanning of electrophoretic gels and confidence intervals for observed
C4A/C4B ratios may thus help in the identification C4 genotype from phenotypic
information [95,96], but are prone to error in a number ofways. Firstly, the presence of
both C4A and C4B nulls cannot be differentiated from the presence of4 alleles. Secondly,
an expressed homoduplicated C4A allele is likely be incorrectly assigned, probably as a B
null gene. More direct measurement bymeans ofan ELISA assay utilising monoclonal and
C4A and GIB antibodies has been obtained [97].While the ranges ofserum C4A orGIB
concentration show broad correlation with C4 gene numbers the range ofserum values
associated with each genotype is verywide and phenotypic overlap is extensive. There is
also evidence that different individuals with identical extended haplotypes show marked
variation in GI phenotype [68]. These factors, and the problems related to the serological
recognition ofC4 isotypes (chapter 1 .section 2) make the relationship between phenotype
and genotype inexact even in normal populations. In patients with SLE, who are likely to
be subject to variable rates ofGI turnover and who are generally hypocomplementaemic,
the relationship is likely to be further obscured. However, there are reports of an
identifiable effect ofGIQO on total GI levels in SLE. Wilson and colleagues [98] did find
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a reduction in mean total C4 in SLE patients and controls with known homozygous
deficiency ofC4A or C4B, though in one C4B deficient patient, C4A levels were
supranormal [99], In a further study by this group [ 100], an association was found
between disease activity, the presence ofaCL antibodies and hypocomplementaemia in
patients who had a single null allele, as estimated by plasma densitometry. During periods
ofdisease quiescence no differences between serum C4 in patientswith orwithout C4 null
alleles, or associated with aCL antibodies were found. However, the difficulties in
accurately determining the initial genotype from phenotype in these patients must be borne
inmind, and to date there is no study in which C4 isotypes have been measured in a group
ofSLE patientswho have been accurately genotyped by family study.
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Section 4
Erythrocyte Complement Receptor Type 1 and other Complement Receptors
Introduction
Complement activation is one ofthe earliest events in host immune responses to foreign
antigens. Coating ofantigen, or immune complex, with complement opsonises it for
interaction with immunocompetent cells and also, in primates, for processing by
erythrocyte CR1. These effector functions aremediated, on a variety of immune and other
cells, by surface receptors for complement fragments.
Fourmajor receptors have been characterised and are primarily receptors for the activation
and catabolic fragments ofC3 and C4. A number ofother cell surface proteins such as
DAF and C4bp (reviewed in [ 101 ]) also have complement binding activity and function
principally as regulatory factors in the complement cascade. It is a feature of these
receptors that ligand binding preferences overlap extensively. Functional specificity is
determined partly by the differences which do exist, and partly by the function of the
receptor bearing cell. Table 4 (overleaf) outlines the major characteristics and cellular
distribution of these complement receptors. All can bind iC3b, emphasising the overlap in
ligand binding amongst these majorCRs. Therefore, given adequate ligand concentration,
a neutrophil could bind via CR1, CR3 and CR4 simultaneously. Similarly, lymphocytes
may bind iC3b via CR1 and/or CR2 (B and some T cells) or via CR3 (NK cells).
However, there is evidence that differing ligand affinity may result in quantitative
modulation of binding. For example, with sheep E bearing 10,000 iC3b molecules,
resettingwith neutrophils is mediated by CR3. In the presence of 10,000-40,000 iC3B/E,
rosetting via both CR1 and CR3 occurs, while >45,000 iC3b molecules are required to
recruit CR4 in these rosetting reactions [101].
1.41 Erythrocyte complement receptor type 1
Erythrocyte CR1 is the principal receptor involved in the physiological disposal ofCIC in
primates. I will therefore describe this molecule in detail and give an outline of the other
major complement receptois (CRs).
The biology ofCR1 has been the subject of recent reviews [102,103] Research leading to
















































































































Early observations ofcomplement dependent cellular interaction with micro-organisms
were followed by formal description of the phenomenon of immune adherence (IA) and
finally by detailed understanding of the molecular biology and functions ofCR1. The
binding ofmicroorganisms to platelets was described by Bull in 1915 [104]. The
involvement ofantibody and complement in these reactions was inferred byRieckenbeig,
Kritschewsky and Tscherikower (reviewed byWalport [102]). In 1930, Duke andWallace
[ 105] associated similar binding reactivitywith primate erythrocytes and in 1938, Brown
and Broom described polymorphism of human erythrocyte binding with opsonised
trypanosomes [ 106]. The term "immune adherence"was used by Nelson in 1953 when he
re-described antibody dependent binding of treponemes and pneumococci to human
erythrocytes, along with the observation that these microorganisms were also opsonised for
phagocytosis [107].
Recently, Fearon and his co-workers have contributed to the detailed biochemical and
molecular biological characterisation of the receptor responsible for IA reactions. A
glycoprotein ofMr 205,000 (gp 205) was initially released from erythrocyte cell
membranes by treatment with detergent (Nonidet P40) and subsequently purified by
extensive chromatographic procedures including affinity separation on sepharose-C3 [108].
This protein was inhibitory in the alternative pathway ofcomplement activation as a result
of its ability to displace Bb from C3b in C3bBbP, the properdin (P) stabilised alternate
pathway C3 convertase. Additional actions in the catabolism ofC3 were noted and CR1 is
now known to be an alternative co-factor to H in the initial Factor I-mediated hydrolytic
cleavage of C3b to iC3b, and to be the sole cofactor to I in the subsequent hydrolytic
degradation to C3c (released) and cell bound C3dg [ 109- 111]. Fearon also demonstrated
that the C3b receptor function ofhuman erythrocytes, polymorphonuclear leucocytes
(PMN), B lymphocytes and monocytes was inhibitable by the F(ab')2 fraction of
monospecific murine anti-gp205 [112]. CR1 is also known to be present on the surface of
glomerular podocytes [113] and on follicular dendritic cells [114]. Receptor numbers differ
amongst these cell types. Fearon's calculations based on these studies with anti-gp205 (a
polyclonal antibody) suggest mean numbers of 950 CR1/E, 21,000 sites/B cell,
57,000/PMN and48,000/monocyte.
1.42 CR1 ligand binding
CR1 Ligand bindingmay involve both hydrophobic and charge interactions [108]. The
binding site ofCR1 to C3 (and C4) appears to be in the C3c (C4c) region [115,116] and
CR1 binding is lost when iC3b (iC4b) is degraded to C3dg (C4d) by the liberation of the c
fragment. C3b is the principal CR1 ligand, and affinity falls in the series iC3b, C4b and
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iC4b. CR1 binding to C3b requires the availability ofat least divalent ligand sites [117]
and is not inhibited by the presence ofmonomelic fluid phase C3b. CR1 binding is most
efficientwith clustered ligands and resetting is dependent on the density ofC3b deposition
(reviewed in [ 103]). Moreover, when C3b is deposited by the classical pathway, CR1
dependent resetting is increased by the proximity ofC4b, suggesting that an important
function of low affinity C4b binding may be to enhance CR1 binding to C activating
immune complexes. Fixed iC3b is a functionally important CR1 ligand and the importance
of clustering and co-operation with C4b seems to be greater when the lower affinity
interaction between this ligand-receptorpair is considered [ 118].
1.43 Molecular biology of CR1
(A) Structure
Themajority of the coding sequence ofCR1 has now been mapped by overlapping cDNA
clones [119,120]. A model of CR1 structure has been constructed [101] and is
characterised by the presence of4 repeated sections of 450 amino acids sharing 70-95%
identity and described as long homologous repeats (LHRs). Each LHR is comprised of 7
repeated sequences of60-65 amino acids, termed short consensus repeats (SCRs). Each
SCR possesses a highly conserved core of 10-15 amino acids which is also found in other
C3 and C4 binding proteins and probably represents common genetic ancestry. The genes
encoding a group ofC3 binding proteins (CR1 ,CR2, C4bp, DAF and FactorH) have been
mapped to band q32 ofchromosome 1 and are described as the regulation ofcomplement
activation (RCA) locus [121]. The genes encoding CR1, CR2, DAF and C4bp are closely
associated on an 800kb section ofDNA within the RCA, while Factor H is separated from
these genes by an unknown stretch ofDNA [121]. The conserved SCRmotif is also found
in other C3/C4 binding proteins such as Factor B and C2, and in somewhich do not have
complement binding activity such as IL-2 receptor and 62-glycoprotein I.
(B) CR1 molecular polymorphism:
CR1 shows 2 molecular polymorphisms, one structural and one (on erythrocytes)
numerical. The commonest structural alleles, designated F and S byWong and colleagues
[122,123] are found in 70% and 3% of individuals and encode proteins of 190Kd and
220Kd, respectively. Heterozygotes accounted for 27% of those studied and show the
interesting phenomenon that the proportion ofallele expressed by the erythrocytes of
different individuals is markedly variable, while leucocytes express greater quantities ofthe
highermolecular weight species. The basis of this polymorphism seems to be differences
in the numbers ofLHR regions encoded by the allele [123], and at least two otherminor
variants of 160Kd and 250Kd have also been recorded [ 124]
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Differing cell types express markedly different numbers ofCR1 (see above). Whereas
expression on leucocytes does not vary significantly between individuals, ECR1 numbers
may vary as much as 10-fold due to polymorphism in the genes controlling ECR
expression. The early observations ofBrown and Broom may be taken to suggest the
existence ofECR1 numerical polymorphism in that E drawn from Brown consistently
failed to mediate immune adherence reactionswith opsonised trypanosomes. Using Hind
HI digestion and a 0.75cDNA CR1 probe, the presence of 2 RFLP alleles corresponding
with numerical expression has been demonstrated [ 125]. All individuals studied possessed
one or both of these RFLP bands, consistent with allelic inheritance. Homozygous
expression ofa 7.4kb band was associated with high CR1 numbers (611+/-33, mean and
SEM), while the rarer homozygous 6.9kb phenotype was associated with lower receptor
numbers (156+/-13). Mean receptor numbers associated with the heterozygous state were
455+/-52 and overlapped extensivelywith the high, but not low, receptor number groups.
Correlation ofcDNA probe mapping to the q32 band of chromosome 1 with structural
alleles in family studies demonstrated that the regulatory region is associated with the
structural gene, is cis-acting and is likely to be a transcription enhancing element [125].
Furthermore, other factors can modulate the regulatory effect of the 7.4kb high expression
allele on receptor numbers. Evidence for this includes the observation that 7.4kb
homozygotes show a wide spread of receptor phenotype, while 6.9kb homozygotes do
not, and also that low expression ofstructural alleles associated with the 7.4kb regulatory
element is seen in certain individuals. The action of these proposed regulatory element is
tissue specific, in that B Cells and neutrophils showed no phenotypic differences associated
with their inheritance.
1.44 CR1 function
The role ofECR1 in immune complex handling is discussed in chapter 1, section 5, while I
will here consider other ECR1 functions and CR1 ligand binding in other cell types.
Erythrocyte CR1 function
The co-factor activity ofCR1 in the degradation ofsurface bound C3 (and C4) has been
discussed. Unlike DAF [8], the unusual structure ofCR1 may allow it to extend its C3
catabolic role beyond the confines of the erythrocyte (or other cell) surface and thereby to
protect nearby cells or biological surfaces from the phlogistic effects of complement
deposition. Fixed iC3b is able to interact with receptors of a variety of other
immunologically competent or phagocytic cells (Table 4) including neutrophils, monocytes,
natural killer cells, follicular dendritic cells and platelets. Degradation to C3d restricts
cellular interaction to cells bearing CR2 (B lymphocytes), thus reducing or altering the
potential biological sequelae. ^ -
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Phagocytic cell CR1 function
In broad terms, the presence ofCR1 on phagocytic cells allows binding, endocytosis and
phagocytosis ofopsonised particles, though the relationship between receptor binding and
cellular activation in the mediation of these functions is complex. Neutrophils are able to
bind and ingest opsonised particles via CR1, but it probably requires interaction of the
particle with other receptors such a IgG Fc receptors (FcR) before a respiratory burst can
occur. Alternatively, activatedmonocytes and macrophageswill phagocytose particles after
CR1 ligand binding alone.
The CR1 ofunstimulated phagocytes resides in two pools; 20% (approximately 3000
CRl/cell) is expressed in clusters on the cell surface, while the remainder is intracellular
[ 126,127]. Activation ofchemotactic receptors (eg C5a), ormechanical stimulation of the
cell results in a rapid surface mobilisation of CR1 (and CR3) from the intracellular pool
[127]. Limited cross-linking ofCR1 viamonoclonal antibodies or dimeric C3b induces
attachment ofthe receptor to the cellular cytoskeleton, myosin dependent redistribution into
caps and patches and is associated with the co-localisation ofCR3 and FcR [ 128,129].
More extensive cross-linking with polyclonal antibodies, orwith C3b and polyclonal anti
C3, results in endocytosis of the receptoi/ligand complex but no respiratory burst
[126,130]. Induction ofa respiratory burst and phagocytosis seems to require activation of
the cell andmay be achieved inmonocytes by treatmentwith PMA [ 131 ] orby contactwith
the extracellular proteins fibronectin [132], laminin [ 133] and serum amyloid P [134].
These conditions also induce phagocytic activation ofCR3, while treatment ofmonocytes
with a T cell lymphokine results only in activation ofCR1[131]. Treatment ofphagocytic
cells (PMN, monocytes and eosinophils) with PMA and a chemotactic peptide plus
fibronectin [135] resulted in phosphorylation ofCR1 and may suggest a role for protein
kinase C.
Soluble CR1
Using 125I labelled Fab MAb anti-CR 1 (YZ-1), Yoon and Fearon [136] have demonstrated
that human serum contains soluble CR1 (sCRl) with functional and structural properties
identical to host ECR1. Levels ofsCRl correlated closelywith ECR1 in normal donors,
and represented about 7% oftheir numerical value. The origin ofsCRl is unclear. The fact
that plasma levels did not rise, while ECR1 numbers fall, with duration of incubation ofE
in vitro in this study suggests that it is not released from E. However, it was also noted
that the correlation between sCRl and ECR1 was lost in SLE sera, and that the sCRl levels
were generally higher in pathological sera which may be taken to suggest the opposite
conclusion . To date, no specific function has been found for sCRl.
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Glomerular CR1
Binding ofEC3b and EC3bi to to renal podocytes was recognised by Carlo et al in 1979
[137]. Kazatchkine and colleagues [138] used anti-gp205 in immunofluorescent studies of
glomerular tissue from 75 patients with a variety ofglomerular pathologies. CR1 was
localised exclusively to the glomerular podocyte and was homogeneously distributed along
the plasmamembrane of this cell. Segmental loss ofCR1 was found in a varietyof renal
conditions. The findings in SLE were variable and included normal staining inmesangial
proliferative and membranous lesions, while the diffuse proliferative nephritis ofSLE (but
not other conditions) was associated with complete loss of staining. Renal CR1 does
appear to have Fl-cofactor activity (reviewed in [103]) and so may serve to limit
complement activationwithin the glomerulus, but its exact role remains poorly understood
and receptor loss is not directly correlated with glomerular C3 deposition [ 139].
1.45 Complement receptor type 2 (CR2)
CR2, the B lymphocyte C3d receptor, is a 140Kd single glycoprotein chain [ 140] andwas
first isolated from Raji lymphoblastoid cells (which express large amounts ofsurface CR2
and no other CRs) [141 ]. The developement of an anti C3d monoclonal with affinity
similar to CR2 [ 142] allowed the demonstration ofCR2 binding specificity to the C3d
region of iC3b, C3dg, C3d and the presence of lower (100 fold) affinity for C3b. The
function ofCR2 as the B lymphocyte Epstein-Barr virus (EBV) receptorwas demonstrated
by the acquisition ofEBV binding activity by S. aureusafter linkage to CR2 [143]. The
biological consequences of interaction between CR2 and its ligands are not fully
understood but may be involved in the regulation ofB cell proliferation. Cross linked
C3dg can stimulate the transition ofpreviously activated, synchronisedmurine B cells from
G1 into S phase [ 144]. Treatment ofB cell populations with polyclonal anti CR2 enhances
certain proliferative responses [ 145], while CR2 becomes phosphoiylated after treatment of
B cells with phorbol myristate acetate (PMA) [135], suggesting the possibility ofa role in
trans-membrane signalling.
1.46 Complement receptor type 3 (CR3)
CR3 is an iC3b receptor on phagocytic cells and the lymphocytes that function in natural or
antibody independent cytotoxicity (NK cells). CR3 is a heterodimer ofCD 1 la and CD 18
and shares an identical B chain (CD 18)with two other heterodimeric complement receptors,
pl50,95 (CD1 lc/CD18) and LFA-1 (CD1 la/CD 18)[ 146]. Genetically determined
deficiency of this group ofmolecules has been found in a small number of individuals who
suffer from recurrent infections, persistent leucocytosis, progressive periodontitis,
ulcerating skin lesions and delayed umbilical cord separation [ 147]. Neutrophils from
these patients show deficiencies in phagocytosis of iC3b bearing particles and a more
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general defect in adhesion-dependent functions such as margination andmigration. CR3
appears to have a complex lectin-like, calcium andmagnesium dependent, binding site and
may have specificity for sugar moieties in addition to complement binding (see [103] for
review). This explains the affinity ofCR3 for such diverse substrates as baker's yeast (5.
cervisiae), rabbit erythrocytes and S.aureus.
1.47 Complement receptor type 4 (CR4)
The phagocytic cell C3dg receptorp150,95 is the third member ofthe CD 18 heterodimeric
membrane glycoprotein family (CD 1 lc/CD 18) [ 146] and has similar binding properties to
CR2. Designated CR4, pl50,95 has affinity for C3dg and, to a lesser extent, iC3b and
C3d [148]. Already described on neutrophils and macrophages, CR4 has also been
recognised as a C3dg receptor on platelets [149].
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Section 5
Complement, Erythrocyte CR1 and Immune Complex Processing in
Primates
Introduction
The appearance of immunoglobulin and complement at the sites of inflammatoiy tissue
damage has fostered the view that the role of the complement cascade in immune mediated
diseases iswholly deleterious. However there is abundant evidence that complement has a
number of protective functions, including the physiological processing of ICs.
Complement thus plays a dual role in IC mediated tissue injury, it favours IC and antigen
removal but if this fails, antigen persistence may lead to C-mediated tissue damage, further
release of autoantigen and continued stimulation of the autoimmune process. The
relationship between the phlogistic capacity ofICs in vivo and in vitromay not be direct,
but the theoretical prediction would be that large, insoluble immune complexes are most
likely to induce tissue damage if their formation and tissue deposition is uncontrolled. In
general larger complexes activate complement more effectively and form at antibody
equivalence, or at slight antibody excess. Complexes containing IgM may be strongly
complement activating since IgM is itselfpolyvalent Further aggregation ofthe complexed
immunoglobulin may be induced by Fc interactions, rheumatoid factors or idiotype-
antiidiotype binding. Complexes of antibodies with high affinity are more resistant to
solubilisation by complement (see below), while larger polyvalent antigens also tend to
promote larger complexes.
1.51 The interaction of complement with ICs
1.51A. Alteration of the physiochemical properties of the IC lattice
Classical and alternative pathway activation produces differing effects on the IC lattice
depending in part on the phase of IC formation in which the interaction occurs. These
effects are: inhibition of IC precipitation (HP) and solubilisation ofpre-formed ICs.
Inhibition of IC precipitation (IIP)
HP was studied by Schifferli and co-workers [ 150-152] and ismainly dependent on early
classical pathway components. Whereas complexes of soluble antigens remained in
solution in the presence of normal serum, ICs formed in Clq deficient or EDTA-treated
serum rapidly precipitated from solution [150]. Precipitation did not occur in Properdin
deficient serum indicating that the alternative pathwaywas not involved in this complement
function, but a secondary increase in the solubility ofprecipitated IC was attributed to
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alternative pathway activity. The role ofthe CI molecular complex was emphasised by the
increased speed and degree ofprecipitation in the absence of this activity compared to
deficiencies ofC2 and C3. In addition, purified CI is itselfable to inhibit precipitation
[151]. Clq binds to the Cy2 domain of the IgG Fc and is thought to sterically interfere with
Ig aggregation. Loss of this direct antiaggregational effect of the C1 molecular complex
may contribute to the finding that nearly all individualswith deficiency of these components
have an immune complex-like disease, compared with the lower incidence in C2 deficiency
[153]. In contrast, Hong and colleagues [154] placed greater emphasis on the quantitative
contribution of the covalent attachment ofC3 to IIP. They also noted that the apparent
molecular radius ofcomplexes was dependent not only on the ratio ofantibody to antigen
(equivalence), but also on the absolute concentrations.
Solubilisation of preformed immune complexes
The alternative pathwaymay be activated by immune complexes. Thismay result from the
presence ofan activating antigen, or from alteration in the antigen surface which renders it
so. Also, C3b can bind directly to the F(ab')2 region ofpolymerised IgG whichmay form
a protected alternative pathway convertase site. The result of the interposition ofC3b
molecules in the IC lattice is probably to reduce Fc-Fc interactions which would lead to
further complex aggregation. The effect of the alternative pathway in solubilising ICs was
described byMiller and Nusssenzweig [ 155]. In addition to the presence ofC3, B, D and
P, optimal solubilisation also requires the presence ofFactors H and I [156] since the
absence of these regulatory proteins allows fluid phase consumption ofC3. Solubilisation
is inhibited by the presence ofrheumatoid factors [157].
1.51B.Opsonisation for erythrocyte processing and phagocytic catabolism
The cascade nature of classical pathway activation and the concurrent catabolism of
activated complement components results in a dynamic process in which sequential
complement fragments, with differing biological activities, are successively exposed on the
IC surface. This "rolling" process probably allows optimal scope for complement mediated
interactions between the IC and the variety of receptors on cells involved in IC transport
and in antigen catabolism. ICs injected experimentally in vivo are rapidly taken up by
erythrocytes via CR1 (see below). CR1 co-factor activity results in obligatory catabolism
ofIC-bound C4 and C3 to fully degraded particles. Deposited C4bwill thus sequentially
form a C3 convertase enzyme followed by catabolism to iC4b and bound C4d, while
deposited C3b will in turn form iC3b and bound C3dg (some C3b may also remain
unchanged in protected sites). Thus at any one time there may be a complexmixture of
potential ligands on the IC surface though there will tend to be a predominant C3 fraction
which is likely to determine the major receptor interaction.
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The presence of C3b will mediate interaction with a wide range of CR1 bearing
phagocytes, leucocytes and antigen presenting cells. Further catabolism to iC3b will cause
release of the IC from the erythrocyte surface and direct binding towards CR3 bearing
PMNs andmonocytes. Finally, release of the C3cmoiety leaves only surface bound C3dg
(C4d) for which no major circulatory cell receptor exists, and ICs bearing only this
complement fragment (such as erythrocytes in some cases ofauto-immune haemolytic
anaemia) may persist in the circulation for prolonged periods. However, stimulatory
interaction with CR2 on B lymphocytes is still possible andmay give these fully processed
ICs a role in modulating the immune response. Moreover, at any point in this process,
Clq and IgG may be bound via their cellular receptors, facilitated in activated phagocytic
cells by co-capping ofFc and complement receptors.
1.52 The erythrocyte and immune complex processing
Immune adherence underlies a number ofexperimental methods for the recognition ofIC.
However, the potential relevance of this phenomenon to in vivo IC clearance has only
recently been recognised. Medofand Oger [110] originally observed that serum treated ICs
of 125I-BSA/polyclonal rabbit or guinea pig anti-BSA would adhere to both erythrocytes
and leucocytes in unfractionated mixtures ofblood cells. Themajority of ICs (80%) bound
to erythrocytes due to their greater numbers, though the binding per cell was higher to
leucocytes. This was followed by in vivo studies mounted by Cornacoffand co-workers
[158] involving the constant rate infusion of large (10-288S) 125I-BSA/anti-BSA
complexes into the descending aortae ofBaboons (and Rhesusmonkeys). Cannulae placed
in the hepatic, renal and portal veins and at other sites were aspirated to determine the
distribution of ICs and their metabolism in various vascular beds. The complexes
employed here are typical ofthose used inmany in vitro studies. They were formed in
vitro, at known equivalence, in the absence ofcomplement and allowed to aggregate over
48 hrs prior to centrifugation and resuspension of the precipitate. They are probably
optimal for complement activation and erythrocyte binding, but may not be representative
of complexes formed in vivo. Interestingly, in two subsidiary experiments [158], no
erythrocyte binding was achieved when these immune reactants were injected in vivoprior
to IC formation. However, the findings of this study do in many ways represent the
paradigm oferythrocyte IC processing and will be discussed in depth.
Maximal erythrocyte binding of an average of 61.2% (range 85.3-17.7%) of injected
complexes was found to occurwithin 3 minutes of infusion. Remaining ICs remained
associated with leucocytes and platelets in the "bufiy coat'' ofthe centrifiiged haematocyte
preparations. Removal of73.1% of ICs from erythrocytes occurred within 5 minutes of
infusion and was maximal in the hepatic circulation (69.3%). Levels of this early phase
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removal from the splanchnic circulation (mainly splenic) were 26.3% and from the kidney
were negligible (4.3%). Quantitation of tissue IC deposition was maximal in the liver,
followed by spleen and lung. Those ICs bound to buffy coat cells were not significantly
cleared in the time course of the experiment (30 mins). There was no evidence of
erythrocyte loss occurring along with IC removal. Isokinetic sucrose density gradient
ultracentrifugation (SDGU) ofopsonised ICs remaining in supernatant after reactionwith
simian erythrocytes showed an almost linear relationship between size and erythrocyte
binding. These experiments demonstrate clearly the potential efficiency oferythrocyte
immune complex clearance mechanisms, though, as discussed above, maywell represent
the "best case" analysis.
In a second series of experiments of similar design [159], it was found that depletion of
complement function by cobra venom factor (CVF, which stabilises the alternative pathway
C3 convertase and depletes serum C3) and by heparin, resulted in failure of IC binding to
erythrocytes in vivo, the ICs appearing to remain in solution in plasma. The clearance of
these unbound ICs from the circulation was more rapid than control, erythrocyte bound
complexes. In the complement depleted state the proportion ofextra-hepatic clearance rose
markedly. The inference from studies ofthis nature is that the rapid clearance of ICs to sites
outside the liver and spleen represents pathological deposition at sites of tissue damage,
though in these experiments, no direct evidence of renal deposition occured. In contrast
[160], this group subsequently studied BSA/anti-BSA ICs formed with monoclonal
antibodies ofdiffering Ig class (IgG 1 and IgA) and differing ability to fix complement and
bind to ECR1. These antibodies were of comparable affinity, though the IgA was more
anionic and the complexes formed were smaller. IgA IC bound less well to E and were
cleared more rapidly from the circulation than the efficient E-binding/complement fixing
IgG complexes. In these experiments, more careful anatomical examination did reveal
increased deposition of the IgA complexes in the lungs and glomeruli, suggesting that
reduced efficiency ofprimate erythrocyte IC clearance mechanisms may have pathological
sequelae in vivo.
The first demonstration of similar IC erythrocyte binding of in vivo formed immune
complexes in primates is the report by Edberg and colleagues [161]. Using polyclonal anti-
dsDNA purified from pathological human sera, and radiolabelled high molecular weight
DNA (ca 9000bp), these authors studied the behavior ofDNA/anti-DNA IC formed in
vivo in a primate (rhesus monkey) and non-primate (rabbit) model. Quantities of
immuno-reactants used represented antibody excess, presumed to approximate to in vivo
conditions. Purified y globulin from normal donor serum was used as control. Injection of
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antibody to give an experimental in vivo litre equivalent to 1/20 of the original patient's
serum titre was followed by rapid infusion of the radiolabeled antigen. Considering the
primate experiments. Under these conditions >90% of the infused DNA formed complexes
and was precipitatable by excess anti-human immunoglobulin. Maximum binding ofthese
in vivo formed ICs to erythrocytes was 45% and occured within 90 seconds of infusion.
In addition, in the rabbit experiments, it was found that this quantity of antibody was
sufficient to mediate complexing ofa second infusion ofDNA 1 hr after the first. The
authors consider that this fact demonstrates the lack of cross-reactivity of these high
binding dsDNA autoantibodies in vivo, as opposed to their behaviour in certain in vitro
studies.
Paccaud, Schifferli and co-workers have studied the behaviour of tetanus toxoid-anti-
tetanus toxoid immune complexes (TT/anti-TT IC) in vitroand in vivo including human
studies. Initial studies [162] have clarified the properties ofthis model immune complex.
ICs formed in 25x antibody excess, and centrifuged to remove aggregates, are
predominantly 45s in size. When incubated in semm theMrofthese complexes increased,
a change which was abolished by EDTA and was probably due to the binding ofC3.
Abrogation ofbinding to E treated with tiypsin (which hydrolyticaly cleaves CR1) orwith
anti-CRl antibodies confirmed the specificity of the LA reaction. The binding of these
complexes to human E in vitro was rapid, nearmaximal binding occurred within 1-5
minutes and minimal further binding took place over the succeeding 30 minutes.
Approximately 45% ofadministered complexeswere bound, and SDGU ofsubsequently
released complexes showed these to have increased in size suggestive of complement
binding as above.
Studies with experimentally depleted sera and in C4 deficient guinea pigs in vivo
demonstrated the classical pathway dependence of these LA reactions. Sera depleted of
Clq, C2 and C4 were unable to promote erythrocyte IC binding, while replenishment of
the deficient factor restored both binding and the kinetics of the reaction. It is of interest to
note that reconstitution of 10% normalClq and 1% normal C4 was sufficient to normalise
IC binding. As with other experiments, clearance ofpre-formed CICs in vivowas more
rapid in the absence of classical pathway activity (in the C4 deficient guinea pig), while
CR1 mediated binding (to platelets in this species) and slower clearance resulted from the
infusion ofC4.
The choice ofTT as antigen has allowed its use in human studies. Tetanus toxoid is a
denatured protein which has been extensively used in vivo and can be considered to have
no toxicity. Anti-TT antibodies, purified from the serum ofhyperimmune subjects is
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commercially available and suitable for in vivo use and, lastly, no clinical effects were
noted as a result of infusion of these complexes in the animal experiments described above.
Schifferli and others have reported the use of these complexes in vivo in 3 normal human
volunteers and in 3 patients with SLE [163]. TT/anti-TT complexes were injected
intravenously either free (in amixture with 99mTC erythrocytes, series 1), or after in vitro
binding to autologous 99mTC erythrocytes (series 2), in separate experiments on
successive days. Analysis ofsamples withdrawn at intervals between 1 and 60 minutes
allowed computermodeling ofclearance kinetics of IC from the circulation. Separation of
complexes into fractions by SDGU prior to incubation with E corroborated the close
correlation of IC size with erythrocyte binding in vitro and rapid binding of large
complexes within 1 minute was noted.
In normal controls, the clearance of IC was saturated during the first minute, while in the 3
subjects with SLE, 25.3, 19.5 and 22% of injected complexes were lost from the
circulation within the first minute. This early removal from the circulation is referred to as
IC "trapping". After the first minute, clearance of IC can be described by a
monoexponential model in both groups and showed a mean clearance of 11.2%/min in the
normal controls. Whereas rapid binding of IC to E was noted in the first series of
experiments, the opposite, release of IC, was noted in the 2nd series where in vitro
binding to E had taken place prior to injection. Both the levels ofuptake and release from
erythrocytes in the first minute after injection showed a relationship to number of
ECRl/cell, which varied in each subject. No significant loss of99mTc labelled E occured
during the period of these experiments, implying that alterations in IC levels were
independent ofRES removal ofE. It is of interest that the rate ofclearance of ICs noted in
this study were similar to those observed for DNA/anti-DNA complexes in the baboon,
described above, and that once bound to erythrocytes, clearance of IC was similar in both
SLE and control subjects. These data appear to support the conclusion that alterations in
the initial, rapid binding ofIC to E may be the one of the most fundamental differences in
immune complex handling in SLE, in so far as these large, soluble, complement fixing ICs
are representative ofthose formed in vivo.
Davies and co-workers have had the opportunity to study the in vivo formation of immune
complexes in patients receiving immunoradiotherapy for ovarianmalignancy [ 164]. On
day 1, patients received intraperitoneal injection of131I mouse anti-tumour antibody at the
therapeutic activity of lOmCi/mg. In order to increase the clearance of these therapeutic
antibodies and to reduce marrow toxicity, patients are then administered human anti-mouse
IgG on day 2 and 3. Infusion of 125I labelled second antibody allowed the kinetics of in
vivo IC formation and clearance to be studied. Many ofthe observed sequelae were those
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predicted from the pre-formed complex models, though the quantitative importance of
erythrocyte related mechanisms was less in this model. Immune complexes of 19-40S (by
SDGU) were formed within 5 minutes of the injection of the second antibody and were
cleared to the liverwith a half life ofapproximately 11 minutes. Circulating complexes
were measured by 4% polyethylene glycol (PEG) precipitation and by solid phase C3d and
C1q binding assay. Between 8 and 11% of the total complexed material was found to bind
to E (via CR1), though the maximal fractional erythrocyte complex binding was higher at
25% ofthe complexed material in the circulation at a point soon after the peak ofcomplex
formation. Coincident with immune complex formation and clearance, a 47% fall in serum
C4, C3 and CH50 occured and at the same time a rise in erythrocyte surface C4 and C3 (to
1230 and 2590 molecules/cell respectively) was found. In the 20 minutes after IC
formation a 32% fall in E CR1 numbers was measured. These changes resemble the
abnormalities seen in SLE erythrocytes which include raised cell surface complement
deposition and low CR1 (see Chapter 1 section 6) and suggest that such abnormalities may
arise, in part, as a result oferythrocyte participation in immune complex transport.
The localisation of exogenous ICs to the liver (and to lesser extent the spleen) has
repeatedly been shown, and the original experiments ofComacoffdemonstrated removal of
IC from erythrocytes in the hepatic circulation presumably by the fixed phagocytic cells of
the RES. Recent data has demonstrated that E-CR1 bindingofICs increases the efficiency
ofphagocytosis in vitro [165]. Phagocytic uptake by the human monocyte cell line U937
was compared between opsonised test ICs (heat aggregated IgG) in solution and bound to
E-CR1. The transfer ofE bound ICs occured within 2 minutes, whereas removal from
solution required up to 1 hour to reach the same steady state reduction. The erythrocytes
themselves did not bind to U937, and eiythrophagocytosis did not occur.
1.53 Erythrocyte CR1 IC binding and release
CR1 binds opsonised ICs via C fragments, and is also involved in the catabolism of these
fragments to particles for which it has no affinity. The process of IC binding must
therefore be followed by release ofthe complexwith subsequent rebinding to other E-CR1
molecules either because of the persistence ofC3b fractions, or as a result of fresh C
activation. The net result ofthis ongoing binding and catabolic release is two-fold. Firstly,
it may allow release of the complex from the erythrocyte surface to facilitate other cell
receptor interactions, such as phagocytosis by hepatic Kupffer cells. Secondly, the reactive
complement species, mainly C3b, iC3b and C4b which opsonise the complex are fully
catabolised by CR1 (and FI, FH, DAF and C4bp) to C3dg (and C4d), which has no
further potential to provoke inflammatory interactions, and will therefore be of lower
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pathogenicity if the complex escapes phagocytosis and is deposited in tissue. This model
has been supported by direct observations [166] and analysis of the kinetics of the
interaction of3H DNA/anti-DNA ICs with SLE erythrocytes [167]. This last study also
demonstrated that low CR1 number and not any alteration in binding function was the
prime determinant ofreduced IC binding by SLE erythrocytes.
Summary
A model ofprimate IC processing has now emerged. Immune complexes form in vivo in
the presence ofcomplement inducing C activation and deposition in the evolving IC lattice.
This modulates the IC lattice to maintain solubility and to reduce lattice extension. C3b
(and C4b) bearing IC are bound by ECR1 to the E surface. Fluid phase Factors I and H,
with CR1 as co-factor catabolise the C fractions allowing release of the IC. Once released,
the IC bearing catabolised Cmay bind to B cells orphagocytes depending on the dominant
C fraction (and other ligands) present, or further C deposition may occur allowing
rebinding ofthe IC to E. The erythrocyte thus acts as a "shuttle" for ICs in the circulation
and takes part in the catabolism ofcell surface opsonic C molecules. In the proximity of
the RES of the liver and spleen, release of the IC will allow its uptake by phagocytes,
which may be activated by the presence of a variety of IC borne C fragments or
Immunoglobulin. This leads to the safe catabolism and disposal ofantigen. During this
process E suffer bystander C3 and C4 surface deposition Further, it is proposed that




Reduction ofErythrocyte CR1 in SLE
Introduction
Patients with SLE have reduced expression of erythrocyte CR1 numbers which is
hypothesised to contribute to disease susceptibility by reducing the efficiency ofE-CR1
dependent IC clearance. Both acquired and inherited factors have been postulated to
explain this finding, though the bulk ofevidence appears to point to acquired deficiency as
the dominant process in themajority of cases. The mechanisms ofCR1 reduction are
partially understood. Loss ofCR1 is also seen in other diseases characterised by the
presence of immune complexes, and one mechanism ofE-CR1 reduction is likely to be
hydrolytic cleavage of the receptor during the phagocytic removal ofbound ICs in the
hepatic RES. In this thesis, I will present data which suggests that direct erythrocyte
binding ofanticardiolipin or related autoantibodies may be an additional pathogenetic
mechanism.
1.61 Reduction of CR1 in SLE: evidence for inherited factors
Reduced erythrocyte CR1 numbers in patients with SLE have been detected by a variety of
different methods including reduced immune adherence haemagglutination activity (IAHA)
[168] and direct enumeration ofE-CR1 by radioimmunometric assay [169].
The possibility that this reduction was inherited was examined byWilson and colleagues
[ 170] in a study ofCR1 numbers amongst 38 patients with SLE, 47 of their 1st and 2nd
degree relatives (in 6 pedigrees), and 113 normal controls in Boston. Monospecific
F(ab')2 anti-C3b were used in radioligand binding assays ofE-CR1 numbers, alongwith
assessment ofdimeric C3b binding sites and serological data. Linear regression ofanti-
CR1 and dimeric C3b binding site numbers with high correlation, suggested that 9
antigenic sites existed for each functional C3b site in both patients and controls. This
polyvalent binding contributes to the high overall estimates ofCR1 numbers which are
systematically greater than those seen in these patients using monoclonal antibodies (see
below). Alternatively, it is not clear in what way background (non-specific) binding of
antibody, or decay of label were corrected for in the assaymethod. Each of these factors
would contribute to raised estimates ofCR1 numbers but would probably not otherwise
deform the data presented. Mean CR1 numbers were were 5014 +/- 15/E in normal
controls and were significantly lower (2804+/-241) in subjects with SLE. Analysis of the
frequency distribution ofCR1 numbers in the control population showed a trimodal
distribution, and family studies suggested co-dominant expression ofalleles for High (H)
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and Low (L) giving 3 haplotypes (HH), (HL) and (LL) with associated ranges ofCR1
numbers. Evidence for a genetic basis of CR1 reduction in SLE patients comes from
analysis ofmean E-CR1 numbers in 47 relatives of 6 probands. These clinically normal
individuals had 3167+/-196 CR1/cell and were statisticaly different from both unrelated
normals and the 6 probands (2049+/-94 CR1/E). By comparison, the spouses ofSLE
patients were lower than, but statistically inseparable from, the normal rangewith 4528+/-
484 CR1/E.
There is little doubt that this study describes the gene linked distribution ofECR1 numbers
(numerical polymorphism ofCR1, see below). It is also apparent that the relatives of
certain patients with low CR1 numbers also have low CR1 numbers, and that this is
suggestive of an association of the proposed LL orHL genotype with the disease state.
However, the ranges of CR1 numbers seen in each group and within each part of the
proposed trimodal (gene associated) frequency distribution overlap so extensively that the
accurate ascription ofgenotype from phenotype in any individual is not possible. It is
notable that the SLE probands whose families were studied show CR1 numbers at the
lowest end of the normal range and it is therefore possible that an unrepresentative sample
ofhomozygous low CR1 (LL) SLE patients were inadvertently studied.
However, these same subjects were studied a second time 4 years later [171] and on this
occasion, direct analysis ofgenotype and measurement ofCR1 number by monoclonal
antibody (Yz-1) were performed. It was observed that CR1 numbers estimated by Yz-1
correlated with those previously observed in the subjects retested and thus appeared to be a
stable trait. This has been interpreted as evidence for the predominance of inherited control
in the determination ofCR1 expression (see [101]). CR1 numbers in patients, relatives
and normal controls were 281 (+/-34, SEM), 457 (+/-21) and 553 (+/-21) respectively.
The 6.9 (low expression) and 7.4kb (high expression) Hind III RFLP fragments associated
with CR1 numerical polymorphism have already been described. The 0.75-kb cDNA
probe CR1.1 was used for Southern blot analysis ofgenomic DNA in a proportion ofthe
patients, relatives and controls analysed in this 2nd study. Themajor findings were that the
frequency of the allelic polymorphisms were not equal amongst the experimental groups.
Figure 9 (overleaf) is redrawn from the original data and shows that the homozygous 7.4-
kb (HH) haplotype is underrepresented in the patients and their relatives. Mean CR1
numbers associated with each genotype was lower in bothpatients and relatives than in
controls sharing the same genotype and CR1 numbers in family members showed a
statistically significant regression correlationwith the CR1 numbers ofdisease probands
[101]. The conclusion reached is that the data support an important genetic contribution to
reduced CR1 in SLE.
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However, certain aspects of the datamay not be fully consistent with this hypothesis. The
homozygous low condition was infrequent in all groups, but was less frequent in the
patients than in the control groups. This may suggest that the LL genotype is lethal in the
presence ofSLE, but is otherwise not easy to explain if the allele is a disease susceptibility
gene. Moreover, the reduction of the HH genotype was more marked in the patients'
relatives than in the disease group (see figure 9). Lastly, the occurence of reduced CR1 in
the genotype matched relativeswhen compared with controls argues for the existence ofan
associated second genetic (oracquired) abnormality in these individuals. No such second
locus has been described. However, there is further evidence of a genetic influence in




Figure 9. Frequency ofRFLP alleles for high (7.4kb) and low (6.9kb) ECR1 numbers in










By comparison, a family study and further genetic analysis ofpatients in Cambridge did
not support the conclusion that reduced CR1 numbers are inherited in SLE, nor did
analysis ofCR 1 numbers from SLE families in Athens [101]. Walport and colleagues
[172] employed El 1 [173], amurine monoclonal anti CR1, to enumerate erythrocyte CR1
sites in 48 SLE patients and 48 consanguineous relatives from 17 families. The measured
range ofCR1 numbers in these normal relatives was 145-1,214 CR1/E and a reduction of
CR1 in SLE probands was seen. An attempt was made to fit family data to aMendelian
model of inheritance, as proposed byWilson, but proved impossible due to difficulty in
determining the ranges ofCR1 number appropriate to each genotype. In addition, certain
families are described in which the SLE propositus has phenotypically low CR1 in families
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who seem to be genotypically high. These data are taken to exclude genetic factors as the
"sole" source ofphenotypic variation in SLE patients, though they do not exclude a
superimposed acquired CR1 loss, whichmay have obscured other effects.
Data derived from direct observation ofgene frequency, however, seems compelling and
appears to exclude inherited reduction ofCR1 as a general disease mechanism in SLE
[174]. The 6.9 (low expression) and 7.4kb (high expression) Hind HI RFLP and the
CR1.1 partial cDNA ligand were used to probe genomic DNA in a family study ofSLE
patients, their consanguineous relatives and unrelated normal controls. Moldenhauer's data
demonstrate that the inheritance of these 2 alleles is co-dominant with gene frequencies of
0.73 for the 7.4kb (H) band and 0.27 for the 6.9kb (L) band. Mean CR1 numbers were
725 CR1/E (95% CI; 652-801) in 29 normal subjects with the HH haplotype, 463 (410-
520) in 27 with the HL bands and 260 (160-383) in 4 control subjects with the
homozygous low genotype. The gene frequencies found in SLE patients were not
significantly different to those in normals, but within each genotype, CR1 numbers for
patients were lower than both relatives and controls, while relatives were not significantly
different from controls. In this study only 4 subjects with the homozygous low genotype
were detected and none had SLE. The authors conclude that the inherited variation in CR1
numbers does not play a role in causing susceptibility to SLE. To date, it has not been
resolved whether these mutually exclusive conclusions reflect true differences in disease
mechanisms amongst different populations.
1.62 Acquired reduction of ECR1 and associated erythrocyte C deposition
While the role ofgenetic factors remains controversial, there is abundant evidence that loss
ofCRl may be acquired in patientswith SLE [175-178]. CR1 numbers have been found
to fluctuate with disease activity [175-177] and transfusion ofE with high CR1 numbers
into SLE patients has allowed direct observation ofacquired CR1 reduction in vivo[209].
In these experiments, groupA Rh(D) +ve patients were transfused with type O Rh(D) +ve
cells while O Rh(D) +ve patients received O Rh(D) -ve blood. Differential agglutination
allowed retrieval oftransfused cells which had acquired a reduction in CR1 numbers in two
patientswith SLE and onewith cold agglutinin disease [ 179].
A number ofstudies associate ECR1 reduction with cell surface C3 deposition and suggest
that C-bindingmay result from erythrocyte IC binding. Inada et al [178] found that the
presence of IC activity in serum correlated with defective C3b receptor function ofSLE E.
Ross and colleagues [175] observed an inverse relationship between E-CR1 and
erythrocyte bound C3dg which varied with disease activity while in vitro experiments
demonstrated that approximately 250 C3dg moleculesT* were deposited subsequent to the
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binding and release ofsoluble DNA/anti-DNA immune complexes to E in whole blood. In
the transfusion experiments conducted by Walport and colleagues [179], there was
concomitant deposition ofC3dg on E as CR1 loss occured. CR1 reduction and E C3dg
deposition was also noted in patients with other diseases associated with C activation such
as auto-immune haemolytic anaemia (AIHA), mycoplasma pneumonia, PNH and chronic
cold agglutinin disease (see [175]), and the experiments ofDavies and colleagues [164]
confirm the association of in vivo IC formation with E surface complement deposition and
CR1 reduction. The mechanism which links E-surface complement deposition and CR1
loss seems likely to be related to binding to phagocytic C3b receptors with subsequent
release ofproteolytic enzymes (see below).
1.63 Functional correlates of ECR1 reduction and abnormalities of
C-mediated IC clearance in SLE
The importance ofCR1 reduction in immune complex disease lies in the possibility that this
may result in reduced efficiency of the primate erythrocyte IC clearance mechanism. Taylor
et al [ 180], demonstrated reduced C-mediated binding of3 HDNA/anti-DNA ICs to SLE
erythrocytes in vitro, though no alternative enumeration ofCR1 on these E was obtained.
Further kinetic studies comparing the binding and release of these complexes to normal E
and those from SLE patientswith low C-mediated bindingwere undertaken [181]. Normal
E bound these ICs within 4 minutes at 37°C, while SLE erythrocytes both bound less IC
and reached equilibrium after 30 minutes. Confirmation ofdefective CR1/C-mediated IC
clearance in SLE patients in vivo-was obtained by Schifferli and colleagues using the
TT/anti-TT IC model described above [182]. Briefly, nine controls and 15 patients with
conditions characterised by IC formation or hypocomplementaemia, including 2 with
hereditary C deficiency were studied. Radiolabeled IC were injected free or, in a second
series ofexperiments, after binding to E in the presence ofnormal serum in vitro. Two
phases ofIC clearance were identified with free IC, an initial rapid phase occurringwithin
the first minute, prior to circulation of the IC to the hepatic MPS [163] was referred to as
"trapping". Thereafter, a slower phase of IC removal with monoexponential kinetics
occured. Trappingwas thought to take place before the IC could have been exposed to the
hepatic RES and may thus represent pathological deposition of IC in target sites. Itwas
seen predominantly in the patient group (and 1 control subject) and correlated with low
CR1 number and low binding of IC to E within the 1st minute of infusion. The
monoexponential clearance of IC occured at a mean rate of 14.1%/min, was faster in the
patients than controls and showed an inverse correlation with CR1 numbers and the
retention of IC by E after 1 minute. The second series ofexperiments showed that up to
81.4% of IC were released from E within 1 minute in vivo and that release was inversely
correlated with CR1 number. A small proportion of released ICs showed trapping in
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patients with low CR1 and a high percentage release of IC. The complement deficient
patients were unable to opsonise ICs for E binding in vivoand showed trapping and rapid
second phase clearance. However, in these, as in the other patients, infusion of IC bound
to E in vitroabolished these abnormalities and led to only slightlymore rapid second phase
clearance than was observed in normal controls. In one patient with inherited Clq
deficiency infusion of300ml of fresh frozen plasma restored 29.8% of IC binding to E and
5% haemolytic CH50 (personal observation).
These experiments demonstrate the potentially pathogenic role ofhypocomplementaemia
and reduced CR1 in patientswith IC mediated diseases, but can be criticised on the basis of
the size and antigenic composition of the model IC used which may be unlike those found
in vivo. Certainly, the characteristics of the IC model appears to affect the abnormalities
found. Lobatto et al defined the clearance kinetics of soluble HAGG ICs [ 183] in SLE
and control subjects. The patients showed slower clearance of IC in the presence of
reduced E binding and complement activation. This was attributed to reduced splenic
uptake of these ICs by external scintigraphy, and was thought to represent splenic Fc
receptor dysfunction previously characterised in relation to E-IgG complexes [ 184,185].
Inhibitor proteins may further reduce C-mediated IC clearance mechanisms in certain
diseases. Ng and colleagues [186] found a heat-labile protein with lysine-binding
properties which inhibits CR1 binding of opsonised ICs in the sera ofa percentage of
patients with SLE. The inhibitor was not endogenous ICs, RFs, serum protease enzymes
or plasminogen. A second inhibitor, which interferes with IC opsonisation and C-mediated
inhibition ofprecipitation by displacing Clq from its Fc binding site, has recently been
identified in RA and in normal control sera and is a 60-kd glycoprotein [187]. The role of
these, or other, inhibitors in the pathophysiology of IC related diseases has not been
defined.
1.64 Mechanisms of ECR1 loss: proteolysis and association with positive
Coombs' test
A number ofmechanisms may underlie the acquired reduction ofCR1 in SLE. CR1 is
susceptible to cleavage by tiyptic enzymes [188] which may be produced by peripheral
blood leucocytes (PBL) or the phagocytes of the fixed mononuclear phagocytic system
[179]. The deposition ofC3dgwhich was induced in vitro by DNA^anti-DNA IC [ 167]
was not associated with CR1 reduction despite the presence ofhigh numbers ofPBLs.
Alternatively, immune complexes are removed from the E surface during transport through
the circulation ofthe liver and spleen [158]. Endocytosis of IC receptor by hepatic Rupffer
cells (reviewed in [102] and [179]), or "bystander" tryptic cleavage due to release of
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proteolytic enzymes, could occur during this process. Cell-surface complement, in the
absence ofbound ICs would promote similar effects. Blockade of receptor by ICs or fixed
C3 fragments have been discounted as possible mechanisms, as have the effects of
erythrocyte aging [175,189] during which CR1 numbers gradually decline [188].
Autoantibodies to CR1 have been defined in the sera ofpatientwith SLE. The presence of
anti-CRl was associated with a fall in measurable E-CR1 sites and a flare in disease
activity, all ofwhich reversed with treatment [190]. However, such antibodies appear to
be rare, occurring in 1% of 179 SLE sera tested [191].
An association between reduced CR1 activity (IAHA assay) and a positive Coombs' test
has been noted [192]. This was attributed to receptor occupancy by C3c molecules or
immune complexes, although this seems an unlikely explanation in view of the evidence for
IC binding and release, or the known co-factor activity ofCR1. A subsequent report links
the presence of antiphospholipid antibodies (aPL), detected as anticardiolipin (aCL)
binding, with hypocomplementaemia and a positive Coombs' test [ 193]. Both serum C3
and C4 levels were correlated with aCL, but no association was found with laboratory
(DNA binding, mean CIC levels), or clinical, indicators of disease activity. Moreover,
aCL binding activity could be eluted from the erythrocytes ofone Coombs' positive patient,
suggesting that amechanism explaining the association may be direct binding ofaCL to E,
with subsequent classical pathway activation. Deleze and colleagues [ 194] have reported
an association between the rare syndrome of combined AIHA and thrombocytopaenic
purpura (Evan's syndrome) and aCL in patientswith SLE, underlining the potential role of
these autoantibodies in the haemocytopaenias of immune disease. In this thesis I will
present data which suggest that aCL (or related specificity) may also be associated with
reduced CR1 numbers [ 195] and that aPL maybe common anti-erythrocyte autoantibodies
[196]. I will also present data which suggest direct binding of polyclonal aCL to
erythrocytes and that aPL in Coombs' positive subjects show increased binding to neutral
PLs.
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Chapter 2. General Methods
2.1 Buffers
The following standard buffers were used. All chemicals were supplied by BDH
Chemicals Ltd, (Chadwell Heath, Dagenham, Essex) and were ANALAR grade unless
otherwise stated.
Phosphate buffered saline (PBS), pH 7.4
potassium dihydrogen phosphate 0.1M (38.6mls),
dipotassium hydrogen phosphate 0.1M (160mls),
NaCl 16.35g made up to 21ts in double distilled H2O (ddFLO)
Complement fixation test diluent (CFD)
Oxoid, Unipath Ltd, Wade Rd, Basingstoke, Hants.
Ethylenediaminetetraacetic acid (EDTA) 0.2M:
500mls 0.2M Na2 EDTA (37.22g)
0.2M Na4EDTA(4H20) (41.62g) made up to lltr in ddlLO
2.2 Purification and Preparation ofMonoclonal Antibodies
Monoclonal and other antibodies were the kind gift of a number ofworkers and were
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Antibody Ligand Species Source/Medium
Anti-human C4 C4 Sheep Serotec laboratories, Oxford. Polyclonal
antisenim
Anti-DAF[8] DAF Murine DrEMedof, NewYork. Polyclonal
immunoglobulin
MabBHl[199] Phospholipids Human DrC. Mackworth-Young, RPMS,
(-ve charge) monoclonal London andDr K.Thompson, Mi l l,
Cambridge. Cell culture supernatant
Table 5. List ofantibodies employed.
A number ofprocedures, as follows, were used to prepare the these reagents prior to use:
2.3" Cell culture ofMAb Anti-Rodgers: 1 hybridoma cells
Murine hybridoma cells were provided by Dr C.Giles andMs T. Robson, stored in liquid
nitrogen with DMSO preservative. Conventional cell culture techniques were used
throughout to grow these cells and to harvest supernatant. All procedures were performed
in a laminar flow sterile hood using no-touch sterile technique.
Media: Full RPMI1640: (Sigma)
Cell culture medium: to 170mls ddFLO add: 20 mis 10 xRPMI, 2mls
penicillin/streptomycin (10,000IU/ml), 2mls LGlutamine (0.2M), 2.5mls Na
Pyruvate (1 lmg/ml), 6.5mls Nal lCO ? (7.5%), 20mls heat inactivated foetal calf
serum (FCS)
Method
Briefly, the following steps were followed.
1. Mouse splenic macrophages were harvested from a recently sacrificed Balt/c mouse
(kindly provided byMs J. Roberts, Dept Immunology, RPMS) and cultured for 48hrs in
full RPMI medium in a 25 ml flat-walled cell culture flask to provide amacrophage lawn.
These were examined for morphological evidence of infection and viability prior to
proceeding.
2. Frozen hybridoma cells were thawed rapidly in a 37°C water bath and 5mls ofFCS
added dropwise with agitation prior to placing in a sterile 25 ml flask with macrophage
"feeder" cells as above.
3. Cells were washed twice in 20 mis cold culture medium by centrifugation at 1200 RPM
for 5 minutes, resuspended in 20mls fresh culture medium and added to the macrophage
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lawn in 25ml culture flasks at 2.5xl05 cells/ml culture medium.
4. Cells in culture were incubated at 37°C in a sterile incubator in air and 5% CO2.
5. Medium was changed and harvested after 1 week of growth and at 48hr interval
thereafter or sooner if the indicator colour altered.
6. Supematants for IgG purification were obtained after 12 days ofculture and aliquots of
growing cells were taken and stored in liquid nitrogen in DMSO for future use.
2.4 Affinity Purification ofmonoclonal anti-C4A, anti-C4B and anti-C4d
Purification ofMab anti-Rodgers: 1 (anti-C4A) culture supernatant, Mab 1228 (anti-C4B)
andMab T2. C5.12 (anti-C4d) ascites was by acid elution from proteinA affinity column
after binding in the presence ofhigh salt concentration at alkaline pH. These conditions
have been shown to be optimal for the purification of IgG murine monoclonal antibodies
[200]. All antibody purification was carried out at 4°C in a cold room.
Materials
Affinity column: A 1cm x 5cms column (bed volume approx 4mls) ofproteinA-
conjugated Sepharose C1-4B (Pharmacia,Midsummer
Boulevard,Milton Keynes) was kindly donated by Dr. R.
Harrison, Mm, Cambridge and kept in storage buffer at 4°C
prior to use
Peristaltic pump and tubing
Amicon (Amicon LTD, UpperMill, Stonehouse, Glos) ultrafiltration apparatus and
pressurised nitrogen gas cylinder
Buffers
1. Column storage buffer PBS, 0.5% Na CI, lOmM NaN3, pH 8.0
2. Regeneration buffer 0.2M Glycine HC1, pH 2.7
3. Binding buffer 1.5M glycine, 3.0M NaCl, adjusted to pH 8.9 with 5M NaOH
4. Elution buffer lOOmM Citric acid, adjusted to pH 3.0 with 5M NaOH
5. Dialysis buffer PBS, lOmM NaN3, pH 7.4
Method
1. Samples were first equilibrated with loading buffer, small volumes of ascites were
diluted to 50% (by volume) in 2 x loading buffer (anti-C4B and anti-C4d), while larger
volumes (anti-C4A cell culture supernatant) were equilibrated by the direct addition ofNaCl
and glycine. pH was assessed by pH meter or by paper pH strips depending on the sample
volume.
2. The column was washed extensively first with PBS pH 7.4, then with acid glycine
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regeneration buffer until the optical density at 280nM (OD280) ofeluate was zero.
3. The column was then adjusted to pH 8.9 by washing in loading buffer and the sample
loaded by continuous, recycled perfusion using a peristaltic pump at 4°C for 18hrs.
4. The column was then washed in PBS, pH 7.4 till the OD280was zero.
5. Aliquots ofeach sample and the column exclusion fractions were retained.
6. Bound material was then eluted by perfusion of the column with elution buffer. The
pHand OD280 and of 1ml fractions was recorded and collected until the OD280 had
returned almost to zero.
7. Fractions were then assayed for IgG byOuchterlony gel immunoprecipitation.
8. Resulting IgG containing fractions were pooled and dialysed against 10 litres ofPBS,
NaN3 lOmM at 4°C for 24 hrs prior to concentration using an Amicon filter at 201bs4nch2
ofNitrogen followed by final estimation ofOD280.
9. In the case ofanti-C4A purification: pre-loading, column exclusion fractions, pooled
1st protein peak and a sample from the elution tail were tested for anti C4A, C4B and C4d
activity by agglutination ofC4 coated erythrocytes (kindly performed by Dr C. Giles,
RPMS).
For anti-C4d, radiolabelled purified IgG was tested by co-precipitation with commercial
anti-human C4. Briefly, whole serum was placed in 3 wells cut in 0.7% agarose
(lOplAvell) and subjected to electrophoretic separation. Two troughs were then cut in the
gel between the wells. One was filled with mixed 125I anti-C4d and cold anti-C4, the
other with cold anti-whole serum. The presence of specific anti-C4 activity in the
radiolabelled antibodywas confirmed by comparison of immunoprecipitation in stained gel
and autoradiography of the labelled antibodyprecipitation.
Results
Active antibody was eluted in the first protein peak in fractions 4-8 and appeared as the pH
of the eluate fell from 8.9-3.0. The representative acid elution profile ofanti-C4d is shown
overleaf in figure 10, while representative profiles for the purification ofanti-C4A and anti-





Figure 10. Acid elution profile for the affinity purification ofanti-C4d ascites.
Fraction number
Figure 11. Representative acid elution profiles for the affinity purification ofanti-C4A cell
culture supernatant and anti-C4B ascites.
The presence of IgG the first peak in column fractions was confirmed byOuchterlony gel
precipitation for each antibody. For anti-C4A, binding activity and specificity of cell
culture supernatants, column void volume, pooled 1st peak IgG and post affinity column
supernatant were tested in a semiquantitative fashion by their ability to agglutinate
erythrocytes coated with C4 from donor serum ofknown Chido and Rodgers serotypes.
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Agglutinating activity was present in cell culture supernatant (1+) and was highest in
pooled IgG fraction (+++). No agglutination was found in supernatant after affinity
absorption and no agglutination was found in any fraction in the presence ofC4B (Ch: 1
+ve, Rg: 1 -ve) bearing erythrocytes. For anti-C4d, co-precipitation ofC4 from whole
serum by radiolabelled purified protein and commercial anti-human C4 confirmed the
activityof the antibody preparation.
Lack of cross-reactivity of each anti-C4 antibody was demonstrated in sensitive
radioimmunoassay by reaction of each with genetically deficient serum, ie anti-C4A
recognised C4B deficient serum but not C4A deficient, while the opposite was true ofanti-
C4B. Anti-C4d recognised both C4A and C4B deficient sera but not C4d deficient serum
(this rare serum was kindly donated by Dr C.Giles, RPMS). No cross-reactivity was
found with serum at 1:100 dilution (approx 2.4pg/ml), while the assay was capable of
recognising C4 at a dilution of 1:6400 (approx 37.5ng/ml). Typical yields for anti-C4Mab
affinity purification procedures were:
Mab anti-Rodgers: 1 (Anti-C4A) 150mls cell culture supernatant = 1.5mg
Mab 1228 (anti-C4B) 1.0ml ascites = 4.0mg
MabT2. C5.12 1.5mls ascites = 4.84mg
2.5 Affinity purification ofR 340 Rabbit polyclonal anti-mouse IgG
Purification of this antibodywas achieved by acid elution from a mouse IgG-conjugated
Sepharose C4B column loaded in alkaline, high salt conditions.
Conjugation ofMouse IgG to Sepharose C4B
Materials
Cyanogen Bromide activated Sepharose C4B (600pg) (Pharmacia)
Mouse IgG, 7.5mgbil (courtesy ofDrMJWalport)
2ml syringe barrel and glass wool baffle
Amicon ultrafiltration apparatus and pressurised Nitrogen gas cylinder
Buffers
Coupling buffer NaHC03 lOOmM, NaCl 500mM adjusted to pH 8.3 with 5.0M
NaOH
Blocking buffer TRISHCLpH8.2
Washing buffer NaAcetate lOOmM, NaCl 0.5M adjusted to pH 4.0 with 5.0M
NAOH
PBS, NaNs lOmM, pH 7.2
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Method
5.0mg protein/ml of sepharose C4B is recommended as the optimal ligand concentration
[201 ]. The following procedure was therefore followed:
1. 600pg Sepharose C4B dry powder was added to 20mls of ImM HCL for 20 minutes
prior to washingwith a further 200mls of the same solution in through a glass sinter filter
under suction.
2. This was then washed with 5mls ofcoupling buffer, removed from the filter paper
immediately as awet gel and transferred with washing into a 5ml stoppered plain glass tube
containing 3.25 mgmouse IgG in 2mls ofcoupling buffer.
3. The mixture was turned end on end for 2hrs at room temperature and allowed to settle
for 30 minutes.
4. The supernatant was removed and the OD280measured to estimate coupling efficiency
(87%).
5. The coupled gel was blocked by turning end to end for 2hrs at room temperature in
4mls ofblocking buffer.
6. The blocked gel was then washed alternately in 1mM HC1 and Acetate washing buffer
by filtration under suction prior to washing with PBS, lOmM NaN3, pH 7.2 prior to
packing into the column with briefpacking by high buffer flow rates to form an affinity
column of lml bed volume at 3.0mg/ml Mouse IgG.
2.6 Affinity purification ofR 340 rabbit anti-mouse IgG
Materials
R 340 Rabbit anti-mouse IgG, 36mg/ml (courtesy ofDrM. J. Walport)
Mouse IgG-coupled Sepharose C4B affinity column as above
Buffers
Washing buffer TRISHCL 1M, pH 8.3
Loading buffer TRIS HC11M, NAC1140mM, pH 8.3
Elution buffer TRIS HC11M, NAC1500mM, pH 8.3
Method
1. The affinity column was washed extensively with washing buffer then sample
equilibrated with loading buffer.
2. The sample was mixedwith an equal volume of2x loading buffer and loaded twice
undergravity and for 2 hrs thereafter by peristaltic pumping.
3. Elution was then undertakenwith the high salt elution buffer, 1ml fractions collected
and OD280measured.
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4. The presence ofmurine IgG binding activity in elution fractions was confirmed by
Ouchterlony gel immunoprecipitation usingMouse IgG (as above) as antigen and the IgM
containing peak pooled and dialysed against 6 ltrs ofPBS, 10mMNaN3at4°C for24hrs.
5. The resulting pool was concentrated by ultrafiltration in an Amikon filterat 201bsdnch2
ofNitrogen prior to final estimation ofOD280.
Result
The OD280 elution profile ofR 340 from mouse IgG affinity chromatography is shown
below in figure 12. The yield was 1.5mg.
0 4 8 12 16
Fraction number
Figure 12. Affinity purification ofR 340 rabbit anti-mouse IgG from mouse IgG-
conjugated Sepharose C4B.
2.7 Affinity purification of Sheep polyclonal anti-C4
This procedure involved salt and acid elution of commercial polyclonal anti-C4 from a
human C4-conjugated Sepharose C4B affinity column. The method and results are very
similar to the foregoing but acid elution was required to release specifically bound material.
Materials
Affinity column: Human C4-conjugated Sepharose C4B, 2.5ml bed volume was
kindly donated byDr R. Harrison,Mi l l, Cambridge.
Anti-C4: Sheep anti-human C4 was obtained from Serotec (Serotec,
Station Rd, Blackthorn, Bicester, Oxon).
Peristaltic pumps and Amicon ultracentrifiigation apparatuswere used as before
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Buffers and eluates
Loading buffer TRIS lm, NaCL 0.14M, ph 8.3
Salt elution buffer TRIS lm, NaCL 0.5M, ph 8.3
Acid elution: Glycine lOOmM, pH 2.3
Method
1. 5ml ofantibodywas equilibrated with 5mls of2 x loading buffer.
2. After equilibration with buffer, the column was loaded with antibody by continuous
cyclical perfusion using a peristaltic pump at 5mMir for 24his at 4°C.
3. The columnwas then eluted with salt elution buffer to remove weakly bound material
and washed until the eluate OD280 returned to baseline.
4. Antibodywas then eluted with glycine lOOmM, pH 2.3 and 1ml fractions collected into
test tubes containing an equal volume ofwashing buffer to partially neutralise the eluate.
5. Pooled fractions were immediately dialysed against 3 ltrs ofPBS, lOmM NaN3, pH
7.3 for 24 hrs at 4°C to reduce acid damage.
Result
A broad elution peak was obtained and 8 1 ml fractions were pooled for dialysis and
concentration. The final yield was 6.9mg.
2.8 Purification of BH1 human hybridoma monoclonal aCL
BH1 is a human hybridoma IgM antibody obtained from the peripheral blood lymphocytes
ofa patientwith the primary antiphospholipid syndrome. This antibodywas purified by
euglobulin precipitation followed bygel chromatography on Sephacryl S-300.
Materials
A 2.5x150 cms pre-packed gel filtration column (Bio-Rad Laboratories, Caxton
Way,Watford, Herts) containing Sephacryl S-300 (Pharmacia) was kindly
provided byDrC. Winearls, Renal Unit, RPMS.
A variable rate peristaltic pump and tubing
Amicon ultrafiltration apparatus and pressurisedNitrogen gas cylinder
Sorval RC5B refrigerated ultracentrifuge and UB4 rotor
(Du Pont Co UK,WedgewoodWay, Stevenage, Herts)
Buffers
Euglobulin precipitation buffer 2mM Phosphate buffer, pH 6.0
Gel filtration buffer lOmM TRISHCL, 150mM NaCL, pH 7.3, Conductivity




1. 500mls of cell culture supernatant was concentrated 10 fold by ultrafiltration under
501bsfinch2 pressure using an Amicon filter and pressurised Nitrogen cylinder.
2. This was dialysed against 6 ltrs ofeuglobulin precipitation buffer at 4°C for 24 hrs.
3. The precipitate was harvested and washed in 3 changes ofbuffer by centrifugation at
2500ipm and redissolved in 1ml running buffer.
Gel filtration: all procedures were carried out at 4°C in a cold room
1. The column was equilibrated until the conductivity equalled running buffer and the
resolving capacity of the gel estimated by filtration ofamixture ofknown human IgG and
IgM. Human IgM appeared between 40 and 64 mis elution volume, while IgG was eluted
between 80 and lOOmls.
2. The redissolved euglobulin precipitate was then carefully loaded onto the top of the
column by injection via a 3-way tap and the column pumped at 20mls/hr. All air was
excluded from the column.
3. 4ml fractions were collected and the OD280measured.
4. Column fractions were assayed for IgG and IgM byOuchterlony immunodiffusion.
IgG was not found while IgM bearing fractions were pooled and dialysed against 3 ltrs of
PBS, NaN3 lOmM prior to final concentration and estimation ofprotein concentration.
Results
The elution profile for Sephaciyl S-300 gel filtration of euglobulin precipitate ofhuman
monoclonal aCL (anti-negatively charged phospholipid) BH1 is shown below (figure 13).
The elution profile of test human IgG is also shown for comparison, though not to the
same scale. While there was a suggestive peak at the IgG position on the BH1 elution, no
IgG was detected by gel immunoprecipitation. The final yield from this procedure was
6.0mg of IgM.
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Figure 13. Gel filtration ofMab BH1 anti-phospholipid antibody euglobulin precipitate.
2.9 Radiolabelling Procedure for Monoclonal Antibodies
Radiolabelling was carried out by the "Iodogen" method [202]. In general, 1 -2.5pCi of
fresh Na125I (Amersham International Ltd, Lincoln Place, Greenend, Aylesbuiy, Bucks)
was used to radiolabel lOOpg ofantibody and all procedures were carried out in a fume
cupboard in a designated "hot" laboratory. Latex gloves were worn at all times when
handling radioactive materials and all surfacesmonitored by hand held Geiger-counterafter
procedures.
Materials
1.5ml conical, capped polypropylene tubes (EppendorfGerateban, Hamburg 63, W
Germany) coatedwith Iodogen (1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril)
by evaporation from a volume of 1ml dichloiomethane.
Na125I ofknown specific activity (Amersham)
Sephadex-G25 'TD 10"Gel filtration column (Pharmacia)
Buffers
PBS and PBS, 1% bovine serum albumin (BSA)
Method
1. One pi ofNa125I at lmCi/ml was added to lOOpg ofantibody in PBS/lOmM NaN3
(lOOpl approximate volume) and agitated for 15 minutes at room temperature.
2. A 2.5pl aliqout ofthis reaction mixture (pre-separation) was retained.
3. A pre-packed PD10 (Pharmacia) column (10 ml bed volume) was blocked with PBS
80
1% BSA, washed with 50mls ofPBS and the top just allowed to dry by gravity elution of
the buffer.
4. The bulk of the reaction mixture was then carefully pipetted, with a small volume of
washing, onto the centre of the column bed and eluted with 500pl aliquots of PBS,
allowing each aliquot to enter the gel prior to addition ofthe next.
5. The activity ofeach fraction was monitored and the peak ofprotein bound radioactivity
was routinely found in the 5th and 6th of these 500pl fractions which were then pooled,
free radioiodine appearing in subsequent fractions was discarded.
6. A 2.5pl aliquot ofpooled labelled antibody (post-separation) was also retained prior to
addition of 0.1ml 30% BSA solution (approximately 3% final concentration) as stabilising
protein.
The efficiency of radiolabelling and the specific activity of labelled antibody was then
calculated by precipitation ofall protein in the pre- and post-separation aliquots with 10%
(w/v) Tri-Carboxylic Acid (TCA) in the followingmanner
1. Fifty pi ofnormal serum was added to each retained (pre- and post-labelling) 2.5pl
aliquot to act as excess (carrier) protein followed by 500pl TCA and the precipitated protein
separated by centrifugation at 10,000 G.
2 In each case, a lOOpl aliquot ofsupernatant (S) was removed and counted separately
from the remainder containing the protein pellet (P). The protein-bound counts are thus
given by subtracting (S x 5.5) from the total counts (S + P).
3. The percentage ofprotein-bound counts in the pre-separation specimen indicates the
efficiency of radio-iodine incorporation and was routinely > 90%.
4. Since the concentration ofprotein (X) and the radioactivity in the 2.5pl pre-separation
specimen are known, the concentration in the post-separation specimen (Y) and the specific
activity (cpnVjag antibody)may be calculated in the followingmanner.
cpm (P) pre-separation x 400
= cpm/jig (specific activity)
X pg/ml
cpm (P) post-separation x 400
= Yjug/ml (of labelled antibody)
cpm/jig (specific activity)
Specific activities of 1-2 x 106 cpm/jig and recovery of60-80% of labelled protein
were routinely achieved and this method was used unless otherwise stated.
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2.10 Radioligand enumeration of cell surface antigens
These assays were performed by application ofthe method previously described [175].
Preparation of test erythrocytes
Buffer: PBS containing 1% bovine serum albumin (BSA), 10 mM NaN3 (PBS/BSA) was
used throughout
Washing erythrocytes
In all experiments, unless otherwise stated, eiythrocytes were separated, washed and
packed by centrifugation at 2500 rpm in anMSE "Mistral" 3000 centrifuge (MSE Ltd,
Scientific Instruments, Bishop Meadow Rd, Loughborough, Leics.) and all blood samples
were processed within 4 hrs ofvenesection. After packing, plasma and buffy coat cells
were removed by suction aspiration and the erythrocytes washed 3 times in 5 volumes of
cold (4°C) PBS/BSA bufferby centrifugation and aspiration.
Cell counting
Packed cells were then resuspended in an equal volume of cold PBS/BSA buffer and
counted by a semi-automated technique. Cells were first diluted to 1/20,000 in "Isoton"
(CoulterElectronics, Northwell Drive, Luton, Beds) routine haematological diluent in two
steps using a Dual Dilutor II (Coulter) automated dilutor. Erythrocyte concentration was
then measured by using a mark II semi-automated "Coulter"-counter (Coulter) after
adjustment of the aperture current to the appropriate setting for the measurement of red
cells. Routine automated haematological analysis was performed on 10 samples by the
department ofhaematology, Hammersmith Hospital, to exclude the presence ofexcessive
numbers ofwhite blood cells and to calibrate the Coulter-counter used. A mean of
1.87xl09 white blood cells/1 and 15.57xl09 platelets/1 were present after washing and
linear regression analysis of measurement by Coulter-counter and by the routine
haematology laboratory gave a slope of 1.05 and a regression coefficient of 0.982.
Duplicate analysis of20 specimens gave a coefficient ofvariation for the measurement of
erythrocyte concentration of 2.75%. Washed erythrocytes were then adjusted to a
concentration of5.0xl012/ml in PBS/BSA buffer and stored at 4°C prior to analysis. Initial
observations showed that ligand numbers were stable for up to 1 week under these




1 ml LP3 test tubes (Elkay Lab Products Ltd, Unit 5, The Ridgeway Centre,
Basingstoke)
250jil polypropylene microfiige tubes (Elkay)
Dibutylpthalate and dinonylpthalate (BDH)
Benchtop ultracentrifuge (Beckman Instruments Ltd, Sands Industrial Estate, High
Wycombe, Bucks)
Gamma counter. LKB "1260 multigamma" gamma counter and printer (LKB-
Pharmacia, Midsummer Boulevard, Milton Keynes)
Method
1. Aliquots of radiolabeled antibodies of known specific activity were adjusted to a
concentration of 30pg/ml (the concentration of antibody prior to admixture with
erythrocytes will be referred to as the initial concentration) in PBSBSA buffer.
2. Erythrocytes were adjusted to 5.0xl08/ml buffer and a 75]il aliquot ofantibody was
added to 375pi erythrocytes at in a Beckman LP3 polypropylene test tube, capped and
incubated for 30 minutes in a 37°C water bath with regular agitation. The reaction
concentrations ofantibody and cellswere therefore 5\ig/m\ and 3.33xl08/ml respectively.
3. The reaction was then stopped by cooling the tubes in amelting ice water bath.
4. Duplicate 150pl aliquots of reaction mixture (5xl07 cells) were then carefully layered
onto 75pl aliquots of a mixture of4:1 dibutylpthalate and dinonylpthalate in a 250pl
polypropylene microfuge tube and bound counts (pellet) separated from free (supernatant)
by ultracentrifiigation at 10,000G for 5 minutes in a bench-top ultracentrifuge.
5. After freezing at -70°C for 1 hr, unbound label in the aqueous phase was separated
from bound counts in the erythrocyte pellet by cutting the polypropylene ultracentrifuge
tube through the solidified oil layerwith wire cutters. The radioactive disintegrations of
duplicate pellet and supernatants were then measured and expressed as mean counts per
minute (cpm).
Correction for background binding
A certain proportion of the radioactive counts in the erythrocyte pellet (the background) are
carried there by non-specific trapping amongst the cells during centrifugation. An initial
approach to correction for non-specific background binding was to perform each incubation
in the presence of 250% excess unlabelled (cold) blocking antibody. However, this
blocking concentration proved to be inadequate and the mean binding of 5 monoclonal
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antibodies (anti-C4A, C4B, C4d, C3d, C3dg) in the presence ofcompeting cold antibody
was 12.5%. There were insufficient reagents to pursue this method of background
correction furtherwith higher cold antibody concentrations in each reaction. I therefore
analysed the percentage of radiolabelled antibody appearing in the erythrocyte pellet in
reactions where no specific binding was expected.
Method
A total of 12 assays were performed under standard conditions with antibodies and cellular
substrates where no specific binding was expected.
1. Anti-C4A was incubated with eiythrocytes from a C4A deficient donor.
2. Anti-C4B was incubated with erythrocytes from aC4B deficient donor
3. Mab clone 4 [ 198] was incubated with normal eiythrocytes. (Clone 4 recognises C3c
which is released from the erythrocyte surface in the presence ofFactor I and CR1 in whole
blood, and is therefore a negative control antibody). Assays were conducted in duplicate.
Result
The mean percentage non specific binding in the erythrocyte pellet in these experimentswas
0.217% of the total cpm offered in the reaction and this figure was used for background
correction in radioligand binding studies. I also noted that antibody background rose with
the "age" of the label, ie the time since the radiolabelling reaction, .and therefore adopted
the procedure of replacing all labelled antibodies with a fresh aliquot after a period of45
days and omitted all measurements madewith older labels from further analysis.
2.11 Standardisation for variation in specific activity between aliquots of
radiolabelled antibody
Alterations in the radiolabelling reaction conditions, notably in the duration of the
iodogenation reaction or the quantity ofNa 125I addedmay lead to variation in the specific
activity of the radiolabelled monoclonal probe and therefore of results obtained from
successive labelled aliquots of the same antibody. To standardise for this effect, duplicate
measurements ofat least 6 samples were made with "old" and "new" labels as each
successive labelled aliquot ofeach antibodywas introduced. The resultswere compared by
linear regression, plotting results obtained with the "old" label on the Y axis. The slope of
the regression thus represents a cumulative correction factor and was used to standardise
the quantification ofantigens to the equivalent measurement by the first labeled antibody
preparation. This method does not improve the "veracity" of the quantification since the
first labelled preparation may not be optimal. In practice, themajority of labelling reactions
were quite closely equivalent and the cumulative correction factor applied remained near
unity, with the exception ofone labelling ofanti-C4A and the second labelling ofanti-DAF.
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2.12 Calculation of ligand binding sites per erythrocyte
Mean pellet counts were corrected for non-specific binding, as described above, to give
erythrocyte-bound cpm. After labelling and calculation of the labelled antibody
concentration, triplicate 1 OOng aliquots ofantibody were placed in separate LP3 test tubes
and counted. The median sample was preserved by covering with melted candlewax and
used as a standard to correct for decay of the label activitywith time. Given the numberof
cells in the pellet (150|jl at 3.33xl08/ml: 5xl07 cells), the number ofmolecules in lOOng (4
x 101'), it is possible to calculate the number ofantibody molecules bound/cell using the
formula:
cpm-bound/reaction x 4.0x 10"
cpm lOOng 5.0 xlO7
This can be simplified to:
cpm-bound/reaction x 8000
cpm lOOng
The number ofmolecuWcell calculated in this way was then standardised for differences
in labelled antibody activity to give the final enumeration.
2.13 Low ionic strength method for coating erythrocytes with C4
Erythrocytes may be coated with C4 by incubation with serum at low ionic strength [203].
Incubation ofpacked erythrocytes and serum at concentrations ofapproximately 5 and 10%
respectively in 10% sucrose solution produce a strong coating ofcovalently bound C4 on
the cell surface. These conditions may be varied to produce the optimal density of cell
coating.
Method
1. Type O erythrocytes from a healthy volunteer were washed 3 times in cold PBS/BSA
buffer and packed by centrifugation as described above.
2. 20pl packed cells, 40pl donor serum (self) and 400pl 10% sucrose were incubated at
37°C for 30 minutes with regular agitation prior to washing in cold PBS/BSA buffer as
described above.
3. Control cells incubated with serum, lOmM EDTAwere prepared in the same fashion.
4. 200 mis of packed cells were incubated with radiolabelled anti-C4d and Protein A at
approximately 250jig/ml (5 x 105 cpm) for 30 minutes at 37°C in a final volume of0.5ml
PBS prior to separation ofbound from free antibody by centrifugation ofduplicate 50jul
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aliquots through oil mixture as before.
5. Radioactivity bound to erythrocytes (pellet) and free label (supernatant) were then
separated by centrifugation and the eiythrocyte-bound cpm measured as before.
Result
Binding ofantibody expressed as % cpm offered is shown below in table 6 and
demonstrates that C4 is deposited on erythrocytes by the classical pathway, in a calcium
dependentmanner. Protein A acts as a negative control and also demonstrates that
deposition ofautologous IgG does not occur.
Table 6. Calcium dependent deposition ofC4d to human erythrocyte by incubation at low
ionic strength.
While this experiment is semiquantitative (erythrocyteswere not enumerated) experiments
under standard radioligand binding assay conditions demonstrated deposition ofup to 4 x
105 C4 moleculesfcell.
2.14 Radioimmunometric assay of C4 isotypes in serum
A two armed immunoradiometric assay was devised for the measurement of serum C4
isotype concentrations. Briefly, C4 was captured from serum by polyclonal sheep anti-C4
immobilised in removable microtitre wells. Duplicate aliquots of each sample were
incubated on each of three identical plates for the parallel estimation ofC4A, C4B and C4d.
After washing, captured C4 was probed withmurine monoclonal antibody and bound
antibody revealed with radiolabelled rabbit anti-mouse IgG. C4 bound was quantified by
comparisonwith serial dilution ofpool normal human serum and results calculated by
computer spread-sheet specificallywritten for the purpose.
96 well removablemicrotitrewells, "Imulon 2 Removawells"
(Dynatech laboratories Ltd, DauxRd, Billingshurst, Sussex)
Single chamberand multi-barrel "pipetteman" pipettes
(Gilson SA, BP No 45-95400, Villiers le Bel, France)









Affinity purified: sheep polyclonal anti-C4, murinemonoclonal anti-C4A, C4B and
C4d, 125I rabbit polyclonal anti-Mouse IgG (see above)
Buffers
Washing and blocking buffer PBS, 0.2% BSA, 0.05% Tween 20, NaN3 lOmM, pH 7.4
Method
Washing and blocking bufferwas used for incubation ofsamples, washing ofunbound
material and blocking ofnon-specific binding. 50jj1 aliquotswere used at each step.
1. Polyclonal anti-C4 was bound to 96 well microtitre assay plates by incubation at 4°C
for 18 hrs at lOpg/ml PBS, pH 7.4. Assay plates consisted ofstrips of separable wells
located in 96-well holders and were easily removed for the final measurement of
radioactivity bound in each individual well.
2. After washing and blocking of non-specific binding with 6 changes of buffer,
duplicate 29.76nl aliquots of test serum (50 pi semm at 1:1680 dilution) was incubated on
each of three identical plates for 18 hrs at 4°C. A standardised technique was employed to
improve assay reproducibility. lOgl aliquotswere obtained using a 5-20pl variable volume
pipette, previously calibrated byweighing dispensed distilled water. Samples were diluted
in 2 steps by the addition of lOgl neat serum serially to buffer. The pipette-tip was
carefully wiped with tissue to remove adherent semm and was changed at each step. Each
well was individually aspirated to dryness by suction between each change ofwashing
buffer, taking care not to disturb the bound material in the base ofthe well.
3. Unbound material was removed by 6 washes of buffer, the plate covered with
laboratory clingfilm to reduce evaporation and incubated with 2.0pg/ml ofanti-C4A, C4B
and C4d for 4hrs at 37°C
4. Afterwashing and blocking as before, 100, 000 cpm/well (approximately 2pg/ml) of
radiolabelled rabbit anti-mouse IgG was incubated for 4hr at 37°C and the plate finally
washed and dried prior to separation of the wells and individual measurement ofbound
radioactivity in the gamma-counter. The mean disintegrations of 125I-labelled anti-mouse
IgG specifically bound in each duplicate pair ofwells are expressed as counts perminute
(cpm).
Standard samples, calculation of results and assay variability
Pool semm was donated by 20 normal volunteer laboratory and hospital staff (10 female
and 10 male), median age 23.5yrs. Semm was separated and stored in aliquots at -70°C
within 4hrs ofvenesection. Pool semm was serially diluted 8-fold from 1:100 in blocking
buffer and 50pl aliquots incubated in duplicate in the same manner as test samples.
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Standard sampleswere incubated on each assay plate. Sera from healthy donors deficient
in C4A, C4B and C4d were included to provide a value for non-specific, background
binding which was subtracted from each test result. Two further normal sera expressing
both C4 isotypes were included in each assay as standard samples to allow inter-assay
comparisons.
Calculation of results
The assay was linear in the range 125 - 15.6nl ofserum added, and allowed quantification
in the range 250 - 7.8nl serum added. Typical assay standard curves are shown below in
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Figure 14. Standard curves ofdilutions ofpool serum measured as C4A, C4B and C4d
for the quantification ofserum C4 levels. The dilution of test samples is indicated by the
arrow.
Assay results were calculated with a Macintosh, SE 20 desk-top computer (Apple
Computers Inc) utilising an Excel 1.53 spreadsheet programme (Microsoft Software Ltd)
written byme for the purpose. Themean cpm ofeach standard dilution was calculated and
corrected for background binding in the presence ofC4 deficient serum as above. A
linearised standard curve was then constructed in the followingmanner. CPM associated
with each dilution ofpool serum was expressed as the percentage ofthemaximum binding
associated with the top dilution ofpool serum (1:100) and transformed by the equation
Logn (100-%maxV%max
This is equivalent to the logit transformation [204] (Ln p/(l-p)) and improves
responsiveness of the assay at the extremes (the sigmoid portion of the response curves)
extending the range ofvalues which can easily be mathematically modelled. In practice this
improved themeasurement ofvalues between 250 - 125nl ofserum added (dilutions 2 and
3 ofpool serum) and 15.625 - 7.8 lnl ofserum added (dilutions 6 and 7). These values
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were then plotted on the X axis and regressed against the log of the quantity of serum
added in nanolitres using Cricket Graph 1.31 software (Cricket Software). This
programme allows a number of line models to be constructed and I found that a second
order polynomial expression (Y= A+Bx+Cx2) fitted the datamost closely, frequently with
a correlation coefficient ofunity. The regression coefficients were then be used in the
spreadsheet described above to calculate the equivalent quantity ofpool serum (nl pool
serum) represented by the mean cpm binding from the incubation ofstandard dilutions of
test serum. To illustrate the accuracy of this method, figure 15 shows the same standard
curves as in figure 14 recalculated as nl ofserum from the experimentallymeasured cpm at
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Figure 15. Data for the same standard curves as in figure 14 treated as unknown samples
and computed as nl of serum, with the actual quantity in each dilution shown for
comparison.
Calibration of C4 assay
Having calculated the quantity ofC4 in test samples as the equivalent volume ofpool semm
(nl pool semm), results were initially calculated as the percentage of the volume at test
dilution (50jil/1680 = 29.76nl) and expressed as % pool normal human serum (%
pool serum). These values were then calibrated by comparison with total C4 in mg/1
measured in 11 test samples (including the assay standards) by laser nephelometry.
Nephelometry was kindly performed by Dr B P Morgan, Department of Chemical
Pathology, University Hospital ofWales, Cardiff. Figure 16, overleaf shows that the
regression ofC4d measured by RIA (expressed as % pool semm) with C4 total measured
by nephelometry (also expressed as % of the C4 in mg/1 in samples ofpool semm assayed
by nephelometry) approaches a slope of 1.0, implying that there is no systematic variation
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in eithermeasurement. Figure 17.below demonstrates the calibration of the assay by linear
regression ofC4d (RIA, % pool serum) with nephelometric C4 total expressed as mg/1.
The slope of regression is 2.4 Values ofC4d (% pool serum) were therefore adjusted by
2.4, while values ofC4A and C4B were adjusted by 1.25, on the assumption that pool
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Figure 16. Correlation ofC4 total measured by RAI with C4 measured by nephelometry.
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Figure 17. Calibration ofC4 RIA in mg/1.
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Inter-assay variability
The 4 standard samples (C4AQ0, C4BQ0, normal 1 and normal 2) weremeasured in each
assay. Eight sets of assays were performed to measure C4 in patients with SLE (for
comparison with erythrocyte andHAGG C4 deposition) and in genotyped normal sera for
the analysis ofC4 genotype and phenotype relationships. The mean and SD of the 8
measurements ofC4A, C4B and C4d available for each of these 4 samples (excluding the
deficient alleles) was taken and the the coefficient ofvariability found. The average value
of these coefficients, the inter-assay variability ofC4 measurements was 13.74%.
Intra-assay variability
In the analysis ofC4 genotype and phenotype, a total of45 measurements amongst 16
individuals were made in duplicate in the same assay run (for the purposes of this analysis
the measurement ofC4A, C4B and C4d in each sample are considered to be independent
variables and referred to as measurements ofC4). Figure 18 shows the regression analysis
of the first and second measurements of these samples, the correlation coefficient (R) is
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Figure 18. Regression analysis ofduplicate measurements ofC4 in serum. The correlation
coefficient (R) is 0.70 and regression coefficient is 0.963.
This method ofassessing variability between two measurement has been criticised [205],
and figure 19 (overleaf) shows the result of the analysis suggested by these authors for the
repeatability ofclinical measurements. Briefly, the differences between the 1st and 2nd
recordings are plotted against the average ofthe 2 measurements. The mean (-0.323) and
the standard deviation (SD) of the differences (39.47) is then calculated. To comply with
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the British Standards Institution definition ofacceptable repeatability (the repeatability
coefficient) 95% of differences should lie within 2 SDs of their mean. For this assay,
88.9% ofdifferences lie within this range.
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Figure 19. Plot of the differences of repeated C4 measurements from the average of the 2
values (Y) and the average ofthe measurements (X). The mean of the differences (—X)
and mean plus or minus 2 standard deviations (— X+2SD, X-2SD) are also shown.
The mean of these differences expressed as a percentage of the average of the
measurement, the coefficient of variation, is 19.9%. However, as may be seen from
figures 18 and 19, a small number ofmeasurements (7) appear to show extreme variability
and the median percentage intra-assay coefficient ofvariation is 7.0%.
2.15 Quantification of immune complex C4 deposition by ELISA
A modification of the serum C4 RIA was developed to quantify the deposition of C4
isotypes on test immune complexes in vitro. In view of the importance ofDNA-antiDNA
ICs in the pathogenesis ofSLE, attempts were made to quantify C4 deposition in this IC
system. Briefly, purified IgG with high DNA binding activity (measured by Farr assay)
was prepared from SLE serum by saturated ammonium sulphate precipitation and ion
exchange chromatography using Sephadex DE52 gel. DNA ofknown molecularweight
was purified from salmon sperm DNA by phenol/chloroform extraction, Hind III DNAse
digestion, gel electrophoresis and electro-elution from gel fragments. This was
radiolabeled with 32P CTP by the Klenow fragment end filling method. Immune
complexes were prepared by incubation with purified anti-DNA using serum, EDTA and
DNAse digested DNA complexes as controls. Despite employing a number ofsolid phase
ligands and probes (including protein A, polyclonal and monoclonal anti-C4, monoclonal
anti-C3d, C3dg, C3c and C3 neoantigen) it was not possible to produce a quantitative
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assay system. This was in part due to difficulties in reducing background, non-specific
binding ofDNA. Successful quantification was achieved using heat aggregated IgG
(HAGG) as the test immune complex.
Preparation of HAGG
Heat aggregates were prepared by the internationally standardisedmethod [206],
1. "Sandoglobulin" sterile human IgG was obtained from Sandoz Pharmaceuticals
(Frimley, Surrey ), dialysed extensively with PBS and stored at -70°C without
preservatives (Sodium Azide inactivates the peroxidase colour reaction).
2. Stock IgG was adjusted to 20mg/ml PBS buffer and aggregated by heating at 63°C
(internal temperature of test tube) for 30 minutes in a thermostatically controlledwater bath.
3. After aggregation, the reagent was centrifuged at 10,000 G for 30 minutes and
subaliquoted for storage at -70°C prior to use.
Elisa assay
Buffers
Washing buffer PBS, Tween 20 0.05%
Blocking buffer PBS, 0.05% Tween 20, 0.2% BSA, lOmM EDTA
Complement Fixation test diluent (CFD), (Oxoid)
Method
50pl aliquots of all reagents were used and unbound reagents were removed with 6
changes ofwashing buffer and non-specific binding blocked by incubationwith blocking
buffer for lhr at 37°C between each step.
1. Sterile human C lqwas obtained (Sigma) and incubated in flat bottomed 96 well ELISA
plates (Nunc A/S, DK-4000 Roskilde, Denmark) at lOpg/ml in PBS buffer pH7.4 for
18hrsat4°C.
2. Test sera were stored at -70°C prior to use, thawed rapidly in a 37°C water bath and
kept on ice during sample preparation. Stock 200mM EDTA was used to prepare a control
aliquot (lOmM EDTA final) ofeach sample.
3. HAGG was diluted 1:40 in CFD and a lOpl aliquot added to 90jil of test and EDTA
control serum (final concentration 50pg HAGG/ml serum) in a 2ml test tube and
incubated in awater bath at 37°C for 30 minuteswith frequent agitation.
4. The reaction was stopped by the addition of400pl of iced blocking buffer, 1 OmM
EDTA and duplicate aliquots pipetted onto each of 3 identical ELISA plates for the parallel
assay ofC4A, GIB and C4d. These were incubated at 37°C for4hrs prior to washing and
blocking as above.
5. Plates were then serially incubated with 2pg4nl purified monoclonal anti-C4A, anti-
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C4B and anti-C4d in blocking buffer, followed by peroxidase-conjugated polyclonal sheep
anti-mouse IgG (Dako Ltd, 22 The Arcade, The Octagon, HighWycombe, Bucks)
6. Bound peroxidase-conjugated antibody was revealed with 5mg OPD (o-
phenylenediamine dihydrochloride, Sigma) in 50mls lOOmM Citric acid buffer pH 3.0,
activated by the addition of20pl hydrogen peroxide. The reaction was stopped after 10
minutes at room temperature with H2SO4 1M and the optical density at 482nM read in an
MR 710 automated ELISA plate reader (Dynatech).
Standard samples, the calculation of results and assay variability
Pool serum was derived from 20 normal volunteer laboratory and hospital staff (15 female
and 5 male), average age 23.5yrs. Serum was separated and stored in aliquots at -70°C
within 4hrs ofvenesection. Eight serial dilutions ofHAGG in CFD were made from a
starting concentration of4mg4nl. Aliquots ofeach dilution (lOjul) were added to 90pls of
pool normal human serum and to pool serum, lOmM EDTA as control followed by
incubation on each plate, in parallel with samples, as described above. In addition HAGG
at 50jig/ml (equivalent to test samples) was incubated in C4A, C4B and C4d deficient
serum (and EDTA controls) and added to each plate as standard and negative control
samples. The reference range was thus 400 - 3.125pgHAGG4nl pool serum and the assay
was linear in the range 400- approximately 6.25pgHAGG/ml pool serum. Typical
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Figure 20. Standard curves for the quantification ofC4A, C4B and C4d deposited on test
immune complexes (HAGG) in vitro. Test samples are incubated with 50jjg/mlHAGG as
indicated. Mean ODU in unknown samples is converted to the quantity of HAGG
producing equivalent binding in pool serum and then expressed as the % of 50pg/ml to
give% HAGG pool equivalent.
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Calculation of results
Test results were calculated by the same computer programme used for the C4 serum RIA
from the 2nd order polynomial regression of the transformed meanODU of the standard
curves with the log concentration ofHAGG in serum. The background non-specific
binding (usually 0.17-0.22 ODU) relevant to each assay (eg C4A null serum, lOmM EDTA
for C4A measurements) was subtracted from meanODU readings in the calculation of
specific C4 bound. The control value ofbackground corrected binding in the presence of
EDTA, which represents immune complexes, or other Clq bindingmaterial [206,207] in
serum at the time ofsample collection, was then subtracted from each measurement. For
simplicity, the calculated quantity (pgHAGG equivalent/ml pool serum) was expressed as
the percentage of the quantity ofHAGG offered/reaction (50pg/ml serum), as above.
Intra-assay variability
Intra-assay variability was estimated by repeated assay of 12 test samples on the same
assay plates, a total of 31 measurements. The mean of the differences between each
measurement expressed as a percentage of the average of the 2 measurements, the
coefficient ofvariation, is 13.75%. The result of linear regression analysis of the first
with the second of these measurements is shown below in figure 21. The slope of
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Figure 21. Linear regression analysis of the repeatability of the measurementofHAGG C4
deposition by ELISA assay amongst 31 measurements.
Variability has been analysed further by the method ofAltman and Bland as described
above. The mean ofdifferences was -2.247 and the standard deviation of the differences
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was 20.01. As explained, to comply with the British Standards Institution definition of
acceptable repeatability (the repeatability coefficient) 95% ofdifferences should liewithin 2
standard deviations of theirmean. For this assay, 90.33% of the differences shown in
figure 22 arewithin 2 SDs ofthe mean.
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Figure 22. Repeatability ofHAGG C4 measurements analysed by the method ofAltman
and Bland.
Estimation of intra-assay variabilitymay be made by comparing the value ofC4 total and
C4A or C4B deposited on HAGG from standard null sera. Only sixmeasurementswere





Studies of the relationship between C4 genotype and phenotype
The extensive inherited polymorphisms of the two isotypes ofC4, C4A and C4B,
includes null alleles, associated with no expressed protein, and homoduplicated genes,
encoding increased levels ofC4 has been described in detail above. Identification of
null alleles and homoduplications has posed considerable technical difficulties due to
the great variation in C4 levels in normal subjects. Two advances have simplified this
task. Firstly, the identification ofDNA polymorphisms correlating with the presence of
certain C4 null alleles, and, secondly, the availability ofmonoclonal antibodies which
distinguish the two isotypic variants ofC4. Nevertheless, even with the use ofsuch
monoclonal antibodies to assay separately C4A and C4B concentrations, it has been
difficult to ascertain accurately genotype from phenotype in order to detect single C4
null alleles [97,209]. In addition, certain C4 alleles express the antigenic activity of the
opposite isotype, a factor which may further obscure the relationship between
phenotype and genotype.
The physiological significance ofthe extensive inherited polymorphism at the C4A and
C4B loci is uncertain. The association ofcomplement deficiencies and C4A null alleles
with SLE has been described above. Many other associations between particular
allotypic variants ofC4 and diseases have been found, but these may be ofno direct
physiological significance and secondary to linked "disease susceptibility genes"
encoded elsewhere in the major histocompatibility complex (MHC). For example,
Felly's syndrome has been associated with the presence ofC4B null alleles [210],
though in this case C4B null alleles may be markers ofparticular haplotypes containing
other, linked, disease susceptibility genes.
In order to study aspects of the relationship between C4 genotype and phenotype I have
measured the serum concentrations ofC4A and C4B and correlated these with C4
genotype amongst a cohort of normal relatives ofpatients with rheumatoid arthritis,
who had participated in a family study of the major histocompatibility complex in this
disease [211]. Results obtained confirmed extreme phenotypic overlap between
different C4 genotypes. The factors contributing to this degree of overlap are not
known but I have here studied the variation associated with gender, age and acute phase
response, the influence of the presence ofa null allele on the expression ofassociated
genes and the effects ofC4 alleles with abnormal antigenic reactivity.
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Patients
Sera from 129 normal individuals were fully genotyped for HLA and complement
genes as part of a family study of the HLA region in rheumatoid arthritis [211]. In
order to ascertain the possible influence of gender on C4A and C4B expression, 32
haplo-identical sibling-pairs of opposite sex were identified from this cohort of
subjects. Setawere stored in liquid nitrogen prior to use. C4 is an acute phase protein
and I considered the possibility that family members of patients with RA might
themselves have subclinical disease. I therefore measured levels of the acute phase
reactant, C-reactive protein, in all samples and excluded from further analysis 1 sample
from a subject with C-reactive protein concentrations ofgreater than 1Omg/1. The acute
phase response ofC4d was studied amongst patients undergoing breast surgery and
these are described further below.
Methods
Serum C4 isotype levels weremeasured by isotype specific RIA as described in general
methods, chapter 2. Serum CRP was measured by Mancini radial immunodiffusion
and I am grateful to Dr P.N. Hawkins, RPMS for the provision ofpurified CRP and
polyclonal anti-CRP used for this assay.
Statistical analysis
Linear regression was used to measure the correlation between total C4 concentration
and the sum ofC4A and C4B concentrations. Otherwise non-parametric statistical tests
were used throughout the study.
Results
3.1 Validation ofC4 radioimmunoassay
The validity the assay was shown by the demonstration ofa close correlation between
total C4 given by the sum of the independent measurements ofC4A and C4B with C4
total estimated as C4d. Linear regression analysis gives a correlation coefficient (R) of
0.917 and slope of 1.014 (figure 23). This compares with a recently reported ELISA
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Figure 23. Correlation of total C4, measured as C4d, with the sum of the isotypes
C4A and C4B measured individually.
3.2 Effect of number of C4 genes on serum C4 concentration
The levels of C4A found in individuals with 0 (homozygous C4AQ0), 1 (single
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Figure 24. Concentration ofC4A (mg/1) associated with 0,1,2 and 3 C4A genes in 63
normal siblings ofpatients with rheumatoid arthritis. 7 subjects with the haplotype
HLA-B44,C4A3, C4BQ0, DR4 are represented by unfilled circles o .
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C4A was not detected in subjects with homozygous C4AQ0 alleles. The median
concentration ofC4A in subjects with 1 gene was 65.69mg/l (range 34.0 - 179.5mg/l;
n= 18), 2 C4A genes was 134.88mg4 (range 44.8 - 246.5mg/l; n=22) and 3 C4A genes
was 241.12 mg/1 (range 91.5- 444. lmg/1; n= 10). Therewere significant differences in
C4A concentrations between the different groups of subjects (Kruskal-Wallis
H=23.20, P<0.001), but a wide overlap in phenotypic expression of C4A
concentrationswas seen between the different genotypes.
The haplotype HLA-B44, C4A3, C4BQO, DR4 is associated with Felty's syndrome
and has been demonstrated to contain two C4A alleles [210]. The expression ofboth
of these genes was confirmed by the finding ofC4A concentrations of 174.12mg/l
(range 45.1 - 295.2mg/l) in 7 subjects bearing this haplotype. The concentration of
C4B was 62.12mg/l (range 8.9 - 98.0mg/l) and of total C4, 237.5mg/l (range 65.5 -
356.5mg/l), in these 7 subjects (Fig 24). One individual was homozygous for this
haplotype, repossessed 4 C4A genes, and showed a C4A concentration of339.12mg/l
with absent C4B.
No duplicated C4B genes were present in our population. The ranges of C4B


















Figure 25. Concentration ofC4B (mg/1) associated with 0 (homozygous deficiency), 1
or 2 C4B genes in 63 normal siblings ofpatients with rheumatoid arthritis.
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As with C4A, levels ofC4B associatedwith 1 C4B gene (median 62.75mgd; range 8.9
- 157.6mg/l; n=18) or2 C4B genes (124.56mgd; range 67.0 - 375.0mgd; n=42) were
statistically different (Mann-Whitney U= 112, P<0.001) and there was a relationship
between gene number and C4B concentration, however there was againmarked overlap
ofphenotypic expression between the different genotypes (Fig 25).
The overlap between phenotypes wasmostmarkedwhen total C4 concentrations (C4d)
were related to the number ofC4A and C4B genes (Fig 26: C4d: 2 genes= 128.75mgd,
range 60 - 150mg/l, n=7; 3 genes = 210.62mgd, range 105.2 - 512.8mgd, n=26; 4
genes=246.38mg/l, range 65.5 - 541.0mg/l, n=30). The differences between these












Figure 26. Concentration of total C4, measured as C4d, associated with 2,3 or 4 C4
genes in 63 normal siblings ofpatientswith rheumatoid arthritis.
3.3 Factors potentially contributing to variability of C4 gene expression
Gender
In mice the C4 homologue, Sip, is under androgenic control. I therefore looked for
evidence that the expression ofC4A or C4B in humans might be similarly controlled.
Thirty two haplo-identical sibling-pairs ofopposite sex were available for study. These
individuals showed no clinical or laboratory evidence of rheumatoid disease, and all
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sera were negative for CRP. The results of this analysis are shown in Figure 27,
below. Statistical comparison by Wilcoxon Signed Rank Pairs test showed no
differences in C4A or C4B levels between males and females (for C4A, z=0.334,
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Figure 27. Concentration ofC4A and C4B (mgd) in 32 haplo-identical opposite sex
sibling pairs. No statistical differences exist between the levels ofC4A or C4B found
in correspondingmale-female sibling pairs.
The effect ofnull alleles on the expression ofthe other C4 isotype
There is some evidence for "feedback" control of synthesis of C4 in vitro [68]. I
therefore tested the hypothesis that reduced C4 production due to a null allele of one
isotype might be accompanied by increased synthesis ofC4 of the other isotype. No
such increase in synthesis was found. Subjects were identified with 2 C4B genes,
accompanied by 0 (n = 7), 1 (n = 18) and 2 (n = 17) C4A genes. C4B expression was
103.5mg/l (range = 67.0 - 132.0mgd) in subjectswith homozygous deficiency ofC4A
compared with 123.4mg/l (range = 69.5 - 425.0mg/l) in those with 1 functional C4A
gene and 141.9mg/l (range = 71.9 - 194.6mg/l) in those with 2 functional C4A genes
(Kruskal-Wallis H=5.28, P=NS). In subjects with 1 C4B gene the concentration of
C4B found in 4 individuals with 2 C4A genes was 74.5mg/l (range = 27.1 -
157.5mg/l) and in 14 individuals with 3 C4A genes was 60.38mg/l (range = 8.9 -
102
106. lmg/1). These are not significantly different (Mann-Whitney U=34, P=NS).
Similarly, in subjects with 2 C4A genes, C4A egression was 120.2mg4 (range = 80.6
- 246.5mg/l) in 4 subjects with 1 C4B gene compared with 135.0mgd (range = 44.8 -
200.9mg/l) in 17 individuals with 2 functional C4B genes (Mann-Whitney U=31,
P=NS).
Age
Holme and colleagues [97] have reported that C4B levels rise with age by 12% per
decade, while for C4A the increase is 3%. The effect of age was much less marked
amongst the subjects studied here. The effect ofage upon C4A levels in 31 subjects
bearing 2 C4A genes is shown in figure 28A, while the relationship ofC4B with age
amongst 45 individuals with 2 C4B alleles is shown in figure 28B. Both show a rise
with age but the effect is weak and is only significant in the case ofC4B (C4B: rs =
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Figure 28B. The effect ofage on C4B levels amongst 45 subjects with 2 C4B alleles.
Acute phase response
C4 is known to be an acute phase reactant [212]. It is not known whether C4A and
C4B show differential responses to acute phase stimuli. I attempted to study this
possibility bymeasuring C4 responses amongst 28 women (median age 59yrs) referred
to the surgical unit ofSt Bartholomew's hospital for "lumpectomy" ofbreast lesions.
All were subsequently shown to have benign disease. These subjects were chosen
since they seemed unlikely to have a stimulus to complement consumption, reducing
the confounding effect ofcombined alterations in C4 production and turnover and I am
indebted toMrMWoods and Dr C. Ingham-Clark for the collection of specimens and
to Mr.C.Gilmore for allowing us to study his patients. Informed consent was
obtained. Samples were taken on the day ofadmission, lhr post-operatively, and at 24
and 48hrs post-operatively andwere separated within 2 hrs ofvenesection and stored at
-70°C prior to C4 estimation. For samples other than 1 hr post-operative, each patient
was venesected at 1 lam after lhrs bed rest. No clinical evidence of chest or post¬
operative wound infections was noted. CRP was kindly measured by the clinical
chemistry department, St Bartholomew's hospital.
Twenty five patients showed a rise in CRP, the median levels at 0, 1, 24, and 48hrs
being 5.0, 2.5, 47.0, 39.5 mg/1 respectively. Serum C4d levels did not rise in the
time-scale of these observations. Mean C4d was 190.7mg/l (+/-84.25 1SD) at time 0,
165.7mg/l (+/-76.5)at lhr, 183.4mgd (+/-89.4) at 24 hrs and 189.1mg/l (+/-92.6)at
48 hrs. There were no significant differences between these C4 levels and no
correlation ofC4d with CRP levels was found.
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3.4 Measurement of C4 levels in individuals with haplotypes with
anomalous antigenic expression
The apparent expression ofC4A and C4B in 6 members ofa family known to possess
a C4B5 allele (Rodgers 1, Chido-1) (Dr C.Giles, personal communication) is shown in
Table 7. In the family members with theMHC haplotype containing C4A4, B5,DR4
the C4 phenotypic levels are compatible with recognition ofthe C4B5 allele by the anti-
Rodgers 1 antibody used in this study.
C4 alleles C4A mg/1 C4B mg/1
A4, B5/A3,BQ0 155.0 0.0
A4, B5/A3,B1 201.60 65.87
A4, B5/A3, B1 167.25 67.75
A4, B5/A3,B1 129.87 55.87
Table 7. The apparent concentration ofC4A and C4B associated with the complotype
C4A4, C4B5 in 4 members ofa family in whom the C4B5 allele was known to express
the rare Rodgers 1 +ve, Chido 1 -ve serotype. Protein expressed by this C4B allele is
recognised as C4A by the anti-Rodgers 1 monoclonal used to measure C4A in this
study. For comparison, median C4 concentrations associated with 2 C4A and 2 C4B
genes in this study were 134.8 and 124.5mgd respectively.
Discussion
The immunogenetics ofC4, and the relationship between C4 genotype and phenotype are
complex. C4AQ0 are associated with SLE and a number ofother diseases. Itwould be of
use in epidemiological studies, and potentially in clinical practice, to be able to identify
heterozygous deficiency of C4A by simple serum assays without the need for more
complex genetic or complement allotyping procedures. I have therefore used the
availability of isotype specific monoclonal antibodies to study the relationships between C4
genotype and phenotype, and factors affecting the expression of C4 alleles. Initial
approaches to quantification ofC4 isotypes depended on measurement of the ratio ofC4A
to C4B by densitometry, a method later refined by enzyme digestion of C4 which
simplifies the banding pattern ofC4 on gel electrophoresis [24]. Previous studies have
shown a reduction of total C4 associated with the presence ofnull alleles [213]. Reference
ranges for the identification of genetic deficiency have been suggested [214] and
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densitometry ofelectrophoretic bands has been used to quantify C4 isotype levels and to
estimate the presence ofhomoduplicated C4 loci [215]. Scanning densitometrymayallow
probable assignment of single null alleles [216], but will not detect the presence of null
alleles at both loci. Accurate quantitation ofC4A and C4B is now possible using
monoclonal antibodies which are virtually specific for each isotype. However, results
obtained by application of these reagents to sensitive ELISA assays [97,209] still showed
overlap between phenotype and genotype, a findingwhich I have confirmed here. While
an obvious dose effect ofC4 gene number on mean C4 levels was seen when each isotype
was considered separately (figures 24 and 25), the range ofoverlap between each group
did not allow accurate assignment ofgenotype from the phenotypic data. Furthermore,
when total C4 levels were measured, the distinction between groups was even less distinct
(figure 26) and I have concluded that it is notpossible to determine the presence ofa single
null allele from measurement of total C4.
The factors contributing to this phenotypic variability are not known, and it is not clear
whether there is a quantitative polymorphism ofC4 allele expression analogous to the
erythrocyte complement receptor, CR1. Differential regulation ofmouse C4 and Sip
expression by tissue specific trans acting (non H-2-linked) genetic influences has been
demonstrated [65,66], and variable expression of C4 in individuals known to have
identical extended haplotypes may suggest similar mechanisms in humans [68]. The
observation that the total C4 measured in individuals with 3 orwith 4 C4 genes was similar
suggested the possibility that there may have been partial compensation for the presence of
a null allele by increased expression ofthe associated opposite isotype. However, I could
find no evidence to support this hypothesis when I considered the effect of the presence of
null alleles on levels of the opposite isotype.
Other physiological factors whichmay affect C4 expression include age, sex and the acute
phase response. I could detect no effect ofgender on C4 levels in haplo-identical brothers
and sisters (figure 27), suggesting that human C4 levels are not influenced by sexhormone
production. Holme and colleagues [97] have reported that C4B levels rise with age by
12% per decade, while for C4A the increase is 3%. The effect of age was much less
marked inmy data. Levels ofC4A and C4B both tended to rise with age (figure 28A and
28B) but these correlations were weak and, in the case ofC4A, did not reach statistical
significance. C4 does respond as an acute phase protein and, in the mouse, C4 isotypes
show differential responses to inflammatory stimuli [71 ]. Normal CRP levels in these sera
make an acute phase response an unlikely cause ofvariation in this study. My attempt to
study the acute phase responses ofC4 isotypes directly was unsuccessful due to failure of
C4 levels to rise within 48hrs of an adequate surgical stimulus. Little complement
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consumption was anticipated amongst these patients undergoing relativelyminor surgery
with no evidence ofsepsis. A statistically insignificant post-operative fall in C4 levels was
noted andmay suggest that complement consumption occured. Major trauma reduced C4
levels [217] and surgery involving cardiopulmonary bypass results in a transient fall in C4
levels with evidence ofcomplement turnover [218], levels returning to normal after 48hrs.
While I had not anticipated high levels ofC-consumption in these patients undergoingmore
minor surgery, the similarity of the time scale of changes in C4 levels suggests that this
might have occured. Alternatively, the time scale of these observations may have been
inadequate since the progressive rise in C4 seen after acute myocardial infarction was
maximal (140%) after 80 hrs [212].
Knowledge of the extended haplotype which is inherited in linkage with individual C4
molecules is of assistance in interpreting phenotypic and other data. RFLP analysis
coupled with pulsed field gel electrophoresis [219] has shown that the C4BQ0 in the
extended haplotype encoding B44, C4A3, C4BQO, DR4 is associated with the presence of
a duplicated C4A gene in locus 2 (the C4B locus). The findings here (figure 24) confirm
the observations [220] that this duplicated gene is expressed. This haplotype may be a
further source ofvariability in studies inwhich extended haplotypes are not analysed. It is
ofparticular interest that the B44, C4A3, C4BQO, DR4 haplotype is found at increased
prevalence amongst patients with Felly's syndrome [210] and it has been suggested that the
mechanism underlying the association in related to the role ofcomplement in IC processing
[210]. The case for an important physiological effect of the C4B deficiency encoded by
this haplotype is weakened by the finding that this haplotype is associated with increased
production of C4A, which would be expected to partially compensate for the C4B
deficiency, especially with regard to immune complex opsonisation.
C4A and C4B are highly homologous proteinswith less than 1% variation in total amino
acid sequence between the two isotypes. Isotypic identity is conferred by substitutions
amongst a group of4 amino acids which lie in the C4d region ofthe a chain. As explained
in chapter 1, the relationship between isotypic identity and serological activity is complex
and a further 3 groups ofamino acid substitutions involving 6 residues are also involved in
determining antigenic reactivity (see figures 4, 5 and 6). Most C4A molecules express the
Rodgers 1 antigenic determinants while most C4B molecules are recognised by antibodies
to Chido 1. Monoclonal antibodies to these determinants allows the accurate measurement
of immunological reactivity in serum which equates almost exactly with the presence of
C4A and C4B. However, the correspondence between serological reactivity and isotypic
identity is not absolute and rare alleles which express reversed antigenicity such as a
Rodgers+1, Chido -ve C4B5 molecule have been recognised. In the observations reported
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above (table 7), one family was known to posses this allele. The apparently anomolous
levels ofC4 found in 7 members of this family (table 7) illustrates the subtle difference
between isotypic and serotypic identity and points to one source ofspurious variability in
studies of this type. Similar findings were made by Holme and colleagues in a family
carrying a C4B5 allele and the opposite effect was noted with aC4A1 molecule [97].
To summarise these studies, I have found a high degree ofvariability in the expression of
C4 genes in normal individuals, confirming previous observations and suggesting that
there may be considerable difficulties in the accurate determination ofC4 genotype from
phenotypic data. Of the physiological variables considered, gender does not affect C4
expression, while age has only a small effect. I found no compensatory increase in the
production of the opposite isotype in the presence of a null allele. The problems of
reversed antigenic expression have been demonstrated and I have shown that the
homoduplicated C4A gene in the Felty's syndrome associated haplotype A44, C4A3,




Experiments related to the radioligand binding enumeration of
erythrocyte surface C4A, C4B, C4d and DAF
The conditions used here for radioligand binding experiments are the same as those used in
previous studies oferythrocyte surface C3 deposition [175] and are known to produce 95%
saturation ofmonoclonal anti-C3d (clone 3) and anti-CRl (El 1) in cell surface ligand
binding sites. The experimental conditions and method employed are described above.
However, the radioligand binding characteristics ofMab anti-Rg 1 (anti-C4A), Mab 1228
(anti-C4B), Mab T2. C5.12 (anti-C4d) and ofanti-DAF have not previously been studied
and a series ofpreparatory experiments were therefore performed.
4.1 Maximal binding of radiolabelled antibodies by excess erythrocytes
To determine the proportion of immunoreactive material in radiolabelled antibody
preparations, the binding of anti-C4A, anti-C4B and anti-C4d with erythrocytes at a
concentration 25 x the experimental radioligand binding conditions, was measured.
Erythrocytes bearing high numbers ofC4 molecules were prepared by incubation with pool
serum at low ionic strength as described above. Controls were prepared by opsonising
normal erythrocytes with low C4 surface deposition with serum, lOmM EDTA (for anti
C4d binding), or with normal serum deficient in the C4 isotype to be measured (for C4A
and C4B). Cells were washed 3 times in PBS, 1% BSA buffer, packed and used at the
maximal concentration of 1.25 x 10I0/ml. Antibody and cells were incubated at 37°C for
30 minutes in duplicate and erythrocyte bound label separated from free by spinning
duplicate 150jul aliquots through oil as described for radioligand binding assays.
Results
Maximal specific binding are shown below in table 8. The non-specific binding in each
control sample has been subtracted.
Table 8. maximal specific binding of radiolabelled anti C4 antibodies to excess EC4A,
EC4B and EC4.
Method








These values are a slight underestimate ofmaximal binding achievable, since a small
number ofboth C4 isotypes are present on the control erythrocytes (approximately 1% of
the measurable C4 surface molecules recognised on the test cells). The background count
in radioligand binding studies is primarily due to non-specific trapping of label amongst the
erythrocytes during centrifugation and rises with the density of cells in the reaction.
Measurement ofbackground at high cell concentrations in this way may thus lead to an
overestimation of the non-specific binding present under experimental conditions.
However, a second experiment with anti-C4B at 4% of the above cell concentrations
(equivalent to the relative concentrations in radioligand binding assays) showed similar
results with 20.79% specific binding despite 20-fold reduction in background These
results demonstrate the total percentage of functional antibody binding activity in the
radiolabelled preparations used in these studies though the exact proportion in successive
aliquots ofantibody would be likely to vary depending on radiation damage during the
radiolabelling reactions and, potentially, with the homogeneity achieved by separate
antibody purification procedures.
4.2 Saturation of ligand sites in radioligand binding studies
It is important to use saturating quantities of antibody in order to achieve accurate
quantification of cell surface ligand sites. The concentration ofantibody in the reaction
mixture in these ligand binding experiments was 5jig/ml, as previously described [ 175].
Figure 29, overleaf, shows the effect ofalterations in the concentration ofanti-C4A, anti-
C4B and anti-C4d under standard reaction conditions with normal control erythrocytes
from an individual HB known to have serum concentrations of 25.0mg/l ofC4A and
70.31mg/l of C4B and low numbers of erythrocyte C4A and C4B (35 and 39
molecule^cell respectively).
Method
Serial dilutions ofeach antibody in PBS-BSA bufferwere prepared starting from 50jig/ml.
75jul aliquots were incubated with 375jj1 of erythrocyte suspension (at 4xl08/ml) giving
maximal reaction concentration ofantibody of 8.3mg/ml. After incubation, E-bound




The results of this experiment expressed as ng ofantibody specifically bound in each




















i 1 . 1 . 1 1 1—




Figure 29. The relationship between the reaction concentration ofanti-C4A, Anti-C4B and
anti-C4d and the quantity ofantibody (in ng) specifically bound to erythrocyte surface
ligands. Saturated binding is found at a reaction concentration of0.5jig/ml for anti-C4A
and Anti-C4B and approximately lpg/ml for anti-C4d. The reaction concentration used in
radioligand binding assays was 5pg/ml.
Discussion
It can be seen that specific erythrocyte antibody binding is saturated in the range from
10pg/ml to approximately 0.5jig/ml (1 jig/ml for anti-C4d). At the reaction concentration
used (5jjg/ml) the quantification of ligands is unlikely to be significantly affected by the
differences in % total binding activity of radiolabelled antibody preparations noted above,
or by small variations in the quantity of antibody offered in each reaction due to
experimental error.
4.3 The specificity of C4 isotype recognition by Mab anti-Rg: 1
(anti-C4A) and Mab 1228 (anti-C4B) in radioligand binding assays
The specificity of recognition of C4A an C4B by Mab Anti-Rg: 1 and Mab 1228
respectively, is of critical importance in the accuracy of the results reported here. The
binding specificity of these antibodies have been independently verified. In addition, the
aliquots ofantibody donated for these experiments were tested by the semi-quantitative
differential agglutination method (kindly performed by Dr C. Giles). However, it was
important to exclude the possibility that veiy low levels ofcross recognition ofC4 isotypes
could affect quantification in sensitive radioligand binding assays.
Ill
Method
Normal blood group O erythrocytes bearing approximately 100 C4A and 400 C4B
molecules/cell were coated with C4A or C4B by incubation at low ionic strengthwith
normal serum deficient in the isotype to be measured. 75pl aliquots of 8 serial dilutions of
antibody giving an initial reaction concentration of lOpg/ml were incubated with 375pl
aliquots ofwashed erythrocytes at a reaction concentration of 7.5xl08/ml, then bound
antibody separated from free and non-specific background subtracted as before. Both cell


































Figure 30. Comparison ofanti-C4A and anti-C4B binding to EC4A. Reaction
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Figure 31. Comparison ofanti-C4A and Anti-C4B binding to EC4B. Reaction
concentration ofantibody in the first serial dilution is 10pg/ml.
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Discussion
It can be seen from figures 30 and 31 that there is little evidence of cross recognition of
opposite isotypes by the C4A and C4B monoclonal antibodies used. A low level of
specific binding of the opposite isotype was seen and was appropriate to the numbers of
molecules of that isotype present on normal erythrocytes used to prepare EC4A andEC4B.
There may, however, be a measurable recognition ofC4A by mab 1228 at the highest
concentration ofantibody used (figure 30). Given the conditions ofthis experiment which
employed cells with very high C4A numbers and higher concentrations ofall reagents than
in standard assays (equivalent to 10 - 16,000 molecules/cell), these low levels ofcross-
reactivity are unlikely to be ofsignificance under routine conditions.
4.4 Scatchard analysis of anti-C4A, anti-C4B, and anti-C4d binding to
erythrocytes
Since the use of these monoclonal antibodies has not previously been described in
radioligand binding assays, analysis ofantibody affinity by Scatchard binding plots [221 ]
was undertaken. In general, I felt that the most accurate measurement ofaffinitywas likely
to be obtained by assay ofanti-C4A and anti-C4B binding in the absence ofthe opposite
isotype on the erythrocyte surface. It was also important to the validity ofC4 quantification
that the anti-C4d monoclonal used here recognised C4A and C4B with the same affinity. I
therefore prepared EC4A and EC4B cell substrates, in addition to EC4 and normal cells in
the Scatchard experiments performed. Lastly, there was the potential problem ofvariation
in binding affinity due to radiolabelling damage ofany individual aliquot ofantibody
unduly influencing the results obtained in any single experiment. Therefore, Scatchard
binding experiments were repeated under slightly different experimental conditions and
using aliquots ofantibody from at least 2 separate radiolabelled batches (3 foranti-C4B and
anti-C4d) to obtain mean estimates ofantibody affinity.
Method
Cell substrate and control cells varied according to the relevant conditions for each
experiment and are summarised along with results in table 9:A, and B (pi 15, 116) and
Scatchard plots are shown in figure 32: Al-3, Bl-4 and dl-4 (ppl 17-119). C4A bearing
erythrocytes (EC4A) used in experiments B4, and d4 were preparedwith cells from aC4A
deficient normal donor opsonised with C4B deficient serum. The control was anti-C4A
binding, and C4B binding was adjusted for this value after allowing for differences in
specific activity of the antibodies. Experiments A1, B1 and d 1 were performed with E
from a normal donor bearing 102 C4A and 329 C4B molecules cell and had no formal
internal control. In experiments A2 and d2 these erythrocytes were coated with C4A from
donor deficient serum by incubation at low ionic strength, while in experiments B2 and d3
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these erythrocytes were coated with C4B and control values in the presence of excess
(20|ig/ml) "blocking" unlabelled anti-C4B was subtracted.
In each instance a 75pl aliquot of serial dilution of radiolabelled antibodywas incubated
with erythrocytes and controls at the concentrations indicated, prior to separation ofbound
from free as before. Results were expressed as bound/free cpm and as moles ofantibody
specifically bound/L of reaction volume. Binding affinity constant was calculated as the
negative slope of regression. Experimental results are summarised in table 10, below.
Results.
Themean affinities calculated in thisway are shown below in table 10
Table 10. Mean binding affinity constants ofmonoclonal anti-C4 antibodies.
Discussion
A number of these experiments employ erythrocytes substrates bearing both isotypes. The
demonstration (see above) that there is negligible cross recognition ofC4A and C4B by the
monoclonal antibodies used here implies that an accurate estimate ofantibodyaffinitymay
be obtained despite the presence ofsmall numbers ofmolecules of the opposite isotype.
The erythrocytes used in experiment B1 bear more C4A than C4B and a high relative
concentration ofantibody (17pg/ml) was employed. In addition this experiment returned
the highest value for C4B antibody affinity (6.07xl08M1)- Some cross recognition of
C4A may therefore have been measured. Omission of this result produces a small
reduction of the calculated mean affinity ofMab 1228 to 3.41xl08 M"1. A variety of
controls were used in these experiments. In the absence ofsignificant cross-reactivity
between Mab anti-Rgl andMab 1228, themain effect ofbackground subtraction is to shift
the position of the line in the Scatchard plot, but not to alter the slope. Validation of the C4
measurementsmade in these (and other) experiments depends on the correlation oftotal C4
measured as the sum of individual isotypes with total C4 measured by Mab T2. C5.12,
anti-C4d. Experiments d2, d3 and d4 were performed with EC4A (d2) and EC4B (d3, d4)
substrates and show no significant difference in the affinity ofanti-C4d for each isotype.
The affinity ofanti-C4d with EC4A was 1.197xl09M1 and the meanaffinity for EC4B in
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4.5 Correction ofC4B enumeration
During the course of the experiments above (and others), it became apparent that Mab
1228, anti-C4B appeared to systematically under-read the number ofC4B molecules
present on test erythrocytes. For example, EC4A used in experiments A2 and d2 showed
equivalent numbers ofC4 molecules when probed for C4A and for C4d (quantified as
5212 molecules ofC4A/cell by Mab anti-Rg: 1 and 4439 molecules ofC4d/cell byMab T2.
C5.12). By comparison, EC4B (bearing approximately 300 C4A/cell) used in experiments
B2 and d3 were measured as 1301 C4B and 3181 C4d by MAbs 1228 and T2. C5.12
respectively. Experiments were therefore performed to quantify this effect.
Method
A series oferythrocytes with increasing numbers ofC4 molecules/cell were prepared by
incubating with Blood group O normal erythrocytes with C4A and C4B from serial
dilutions ofdonor deficient serum in low ionic strength buffer. A 375jil aliquot of cell
suspension was then incubated with 75pi ofantibody ofknown specific activity followed
by separation ofbound from free in the usual way. The binding ofanti-C4A with EC4A
was measured concurrently by two separately radiolabelled aliquots ofanti-C4A [anti-C4A
(9) and anti-C4A (10), respectively], and with one aliquot anti-C4d [anti-C4d (9)], while
EC4B were measured with two preparations ofanti-C4B [anti-C4B (8) and anti-C4B (9)],
respectively] and with the same preparation ofanti-C4d. Counts specifically bound were
corrected for background binding as described in general methods. Specific binding is
expressed as jug ofantibody bound/reaction. Cell numbers in each reaction were checked
prior to incubation and did not show significant variation.
Results




Figure 33 A. Regression analysis of specific binding of 2 radiolabeled aliquots ofanti-
C4A [anti-C4A (9) and anti-C4A (10)] with one radiolabelled aliquot ofanti-C4d [anti-C4d
(9)] with EC4A expressed as pg bouncFml reaction mixture.
Anti-C4B bound pg/ml
Figure 33 B. Regression analysis of specific binding of 2 radiolabelled aliquots ofanti-
C4B [anti-C4B (8) and anti-C4B (9)] with one radiolabelled aliquot ofanti-C4d [anti-C4d
(9)] with EC4B. Expressed as pg bound/ml reaction mixture.
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The regression slopes are shown below in table 11.









Table 11. Slopes of linear regression analysis of 2 aliquots ofanti-C4A [anti-C4A(9) and
A( 10)] and 2 aliquots ofanti-C4B (anti-C4B(8) and B(9)] with 1 aliquot ofanti-C4d
[anti-C4d(9)].
Discussion
Itwill be seen that while the regression ofC4A with Old is near unity the regression of
both aliquots ofanti-OlB demonstrates a systematic reduction in the quantification ofcell
surface GIB molecules by this antibody (discussed below). These and a number ofother
experiments (data not shown) confirmed that Mab 1228 recognised only a proportion ofthe
C4B molecules present on the cell surface. A correction factor of2.5 (the mean regression
ofanti-C4B in these experiments was 2.48) was therefore applied to the numbers ofG4B
molecules measured on experimental samples. This figuremay be slightly high since the
EC4B used in the experiments described here bore a small number ofC4A molecules
(100/cell) which would be recognised by anti-C4d but notMab 1228 and therefore tend to
increase the regression slope. However the number ofC4B molecules on each cell was
such that this effect is small, and has not been considered further.
4.6 Validation of cell surface C4B correction factor
Evidence that this correction is validmay be obtained by considering alterations in the linear
regression analysis of the sum ofG4A and C4B with C4d molecules^cell measured on
erythrocytes before and after the application of the correction for reducedGib recognition.
Erythrocytes were obtained from 68 individuals in order to study differences between
erythrocyte surface G1A and C4B deposition in vivo. Figure 34, overleaf shows the
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Figure 34. Linear regression analysis of total numbers ofC4 molecules/cell measured as
the sum of individual C4A and C4B measurements and C4 total measured as Old before
(pre-correction) and after (post-correction) the application ofthe calculated correction factor
of2.5 to the estimates ofG4B. Correlation coefficients are 0.931 and 0.967 pre and post-
correction respectively. Regression slopes are 0.69 and 1.29 pre and post-correction
respectively.
Discussion
Figure 34 demonstrates improvement in the accuracy of the regression ofsum C4A and
C4B with C4d after correction ofC4B enumeration in this wayand all experimental results
are reported after application of this correction factor. This analysis also confirms the
internal consistency of the measurement oferythrocyte surface C4 sites in that total C4
measured as the sum of the two isotypes correlates closely with total C4 measured as C4d
across the whole range ofC4 numbers measured.
4.7 Studies with Anti-DAF: Scatchard analysis of binding affinity
Initial experiments demonstrated that a starting concentration of6.667 x 107E/ml (reaction
concentration 3.333 x 107/ml; 1 x 107 cells/aliquot counted) was optimal for DAF
enumeration. This is equivalent to 20% of the standard cell concentration employed for the
other radioligands. Scatchard binding was performed in the conventional manner by
incubating 75pl aliquots ofserial dilutions of 125I anti-DAF, initial concentration 15jig/ml,
with 375pl aliquots of test normal erythrocytes bearing 1420 measured DAF sites/cell at




Results were expressed as bound/free cpm and specific bound antibody in mole&^L of
reaction mixture and the binding affinity constant derived from the negative regression
slope of the Scatchard plot as illustrated below in figure 35.
Anti-DAF BoundM/L
Figure 35. Scatchard binding plot ofmonoclonal anti-DAF.
The binding affinity constant ofmonoclonal anti-DAF was
8.105 x 109 m-1
4.8 Saturation of cell surface ligand sites by mab anti-DAF
An experiment was performed to ensure that cell surface ligand binding was saturated at
the concentration ofantibody offered in the reaction mixture.
Method
Serial dilutions ofanti-DAF were incubated with test eiythrocytes from a normal control
subject under standard conditions. The numbers oferythrocytes in each reaction tubewere
counted prior to incubation and did not vary significantly.
Results





















Figure 36. Binding of anti-DAF from serial dilution with normal erythrocytes after
incubation under standard conditions expressed as apparent numbers ofmoleculesfcell.
Discussion
It can be seen from figure 36 that the enumeration ofDAF molecules was constant in the
range ofanti-DAF antibody concentrations 8.0 - 0.5jig/ml antibody offered. Experiments
were therefore conducted with anti-DAF at 2pg/ml starting concentration (0.333jjg/ml
reaction concentration).
General Discussion
These experiments have explored the application ofmonoclonal antibodies (anti-C4A, anti-
C4B, anti-C4d and anti-DAF) to radioligand binding enumeration of these cell surface
antigens in preparation for their use in studies of the pathophysiology ofC4 isotypes in
SLE. Optimal assay conditions and the binding affinity constants of these monoclonals
have been defined. One major problem was encountered, that Mab 1228 appears to
systematically undercount the number ofeiythrocyte surface C4B molecules. The principal
evidence for this was derived from comparison of the concurrent enumeration of
erythrocyte-bound C4A (on C4B deficientEC4A) by anti-C4A and anti-C4d, with similar
measurements ofEC4B made concurrently by anti-C4B and anti-C4d. Measurement of
C4A and C4d were equivalent while Mab 1228 showed a systematic reduction ofC4B
enumeration across awide range ofantigen concentrations (figure 33A and B, table 11).
The explanation for this is not clear. Damage to the monoclonal during radiolabelling is
possible, though if so, the effect was consistent throughout a number of repeated
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radiolabelling procedures. The affinity constant ofMab 1228 (4.07xl08M'') was lower
than the C4A and Old monoclonals (8.17xl08and 1.058xl09M '' respectively), though
this was not a verymarked difference. Nor was any difference in binding affinity ofanti-
Old towards OlA orG4B found in Scatchard binding studies (table 9A and B), excluding
the possibility that the problem was due primarily to variation in the affinities of the other
anti-Ol monoclonal antibodies employed. Iodination of the antibodymay have affected
antigen recognition, or there may exist more than one antigenic population ofC4B on
erythrocytes, though this seems unlikely. Mab 1228 was purified from ascites and may
therefore have been contaminated by light chain or irrelevant immunoglobulin. The low
maximal binding acheived with this antibody (20.56%, table 8) may suggest that this was
so, though moab anti-C4d was also purified from ascites by the same procedures and
showed much higher maximal erythrocyte binding (68.26%, table 8). The use ofantibody
at non-saturating concentrations could contribute to undercounting, though initial
experiments seem to have excluded this possibility (figure 29). Whatever the cause,
application of the correction factor derived from a number ofexperiments including those
shown in figures 33: A and B correct the undercounting and improve the correlation oftotal
C4 measured as C4A and C4B with total C4 measured as Old (figure 34) and I have
therefore felt it justified to correct the experimental erythrocyte C4B measurements by




Erythrocyte C4, C3 and DAF deposition in patients with SLE and the
primary antiphospholipid (1° APL) syndrome in vivo and
Immune Complex C4 deposition in vitro
Efficient disposal of immune complexes in vivo requires classical pathway activation.
Patients with SLE are at risk of functional C4 depletion due to genetic deficiency ofC4
alleles, especiallyC4A. Functional differences between C4A and C4B may therefore be of
importance in the pathophysiology ofSLE. C4A binds preferentially to amino groups and
thus to protein antigens, while C4B binds preferentially to carbohydrate moieties and thus
to erythrocytes. Detailed understanding of these functional differences has arisen
primarily from studies ofa small number ofpurified C4 isotypes, individually ormixed, in
serum free conditions in vitro [37-43]. I therefore studied the immune complex binding
activity ofC4A and C4B in two contrasting models: binding to SLE erythrocytes in vivo
(erythrocyte surface antigens are primarily carbohydrate) and binding to test immune
complexes ofprotein antigen (heat aggregated IgG) from complexmixtures ofwhole SLE
sera in vitro.
5.1 Studies with SLE erythrocytes in vivo
Erythrocyte complement deposition is a common abnormality in patents with SLE.
Mechanisms contributing to this in vivo are likely to include complement fixation
secondary to direct autoantibody binding and bystander deposition during erythrocyte-
mediated CIC processing. Similarmechanisms are likely to affect patients with the 1° APL
syndrome. The greater affinity of the C4B intrachain thiolester for hydroxyl moieties is the
principal determinant of increased sheep E surface deposition and haemolytic activity in
vitro. However, C4A and C4B binding with human erythrocytes in vivo may be
modulated by the presence ofregulatory proteins such as DAF.
The demonstration that an excess ofC4B overC4A is found on SLE erythrocytes would
suggest that these physiological differences between C4 isotypes are of importance in vivo
as well as in vitro. I therefore studied Erythrocyte surface C4A, C4B, (C4d) C3d and
DAF numbers and compared thesewith the concurrent serum C4A and C4B (and C4d)




Pathological samples were obtained from 49 subjects including 45 (1 male) conforming to
ARA criteria for definite SLE and 4 (1 male) with findings suggestive of the primary
anticardiolipin syndrome (for simplicity these are referred to as SLE sera in figure legends).
19 normal control specimenswere obtained from clinically healthy laboratory staff(8 males
and 11 females). Erythrocyte surface DAF numberswere measured in 27 of these patients
and in 18 ofthe healthy controls.
Samples
In each case, two 10 ml samples ofblood were taken. Serum and erythrocytes were
prepared as described in general methods (chapter 2). In all cases, serum samples were
refrigerated at -70°C within 4hrs ofvenesection. Erythrocytes were separated, washed and
stored at 4°C in bufferwithin 4 hrs ofvenesection and were retained at 4°C forup to 72hrs
prior to analysis.
Methods
Radioligand binding assays for the enumeration oferythrocyte surface C4A, C4B, C4d
and C3d and RIA of serum C4A, C4B (and C4d) levels were performed as described in
general methods (chapter 2). Non parametric methods were used for all statistical
comparisons and results are quoted asmedian and range where appropriate.
Results
5.11 Serum and erythrocyte C4A and C4B
Results of the measurement ofC4A and C4B in these sera are shown overleaf in figure 37
Amongst control subjects, median serum C4A concentration was 91.2mg/l (range: 0.0-
286.25mg4), while C4B concentration was 100.0 mgd (0.0-251.25mg/l). In subjects with
SLE median serum C4A concentration was 48.8mg/l (0.0-185.Omg/I), while C4B was
66.2mgd (6.2-251.2mg4).
Erythrocyte C4A and C4B levels in these subjects are shown in figure 38: A and B.
Amongst control subjects, the median number of C4A molecules/erythrocyte was
62.0mols/cell (range: 5.0-236.0mols/cell), while the median number of C4B
moleculeyerythrocyte was 198.4mols/cell (0.0-568.9mols/cell). Amongst subjects with
SLE, the median number of C4A molecules/erythrocyte was 297.0mols/cell (1.0-




















































Figure 37. Serum C4A, C4B concentrations (mg/1) amongst 49 patientswith SLE and the














































Figure 38: A and B.. Erythrocyte cell surface C4A and C4B (molecules/cell) amongst 19
normal control subjects (figure 38: A) and 49 subjects with SLE and the primaryAPL
syndrome (figure 38: B). For legend, see above
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Statistical differences amongst these datawere sought by the Mann-Whitney U test. Table
12, below, shows the results.
Comparison Control (n=19) SLE (n=49)
U P U P
Serum C4A/C4B 201 <0.274 1348 <0.0002
Erythrocyte C4A/C4B 318 <0.108 1790 <0.0001
Table 12. Mann-Whitney U comparison ofserum and erythrocyte levels ofC4A and C4B
amongst 19 control subjects and 49 subjects with SLE and the 1° APL syndrome.
Discussion
A Statistically significant excess ofC4B was found on SLE erythrocytes in these studies
(C4B 749-lmoVcell: range 54.9-4382.2 ,C4A 297mols/cell: range 1.0-1796.0).However,
a significant reduction ofserum C4A concentration was also present in SLE sera (C4A
46.8mg/l: range 0.0-185.0, C4B 63.6mg/l: range 6.2-241.2) and could have been
responsible for the erythrocyte findings. I therefore sought correlations between serum and
erythrocyte C4A and C4B levels to investigate this possibility.
5.12 Correlation of serum and erythrocyte C4A and C4B levels
Results of the correlation ofserum and erythrocyte C4A levels amongst control subjects are
are shown overleafin figure 39 and the same analysis forC4B in figure 40. Correlation of
serum and erythrocyte C4A and C4B levels amongst STE subjects are shown in figures 41
and 42 (p132). Results ofSpearman correlation analysis are shown below in table 13.
Correlation Control SLE
is P is P
serum/eiythrocyte C4A 0.595 < 0.007 0.276 <0.055
serunvferythrocyte C4B 0.451 <0.053 -0.039 <0.079
Table 13. Correlation ofserum and erythrocyte C4A and C4B amongst 19 normal control
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Figure 39. Correlation ofserum C4A concentration with erythrocyte C4A levels amongst
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Figure 40. Correlation of serum C4B concentrationwith erythrocyte C4B levels amongst


























Figure 41. Correlation ofserum C4A concentration with erythrocyte C4A levels amongst
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Figure 42. Correlation ofserum C4B concentrationwith erythrocyte C4B levels amongst




Amongst normal subjects there existed a strong correlation ofserum C4A and C4B
concentrationwith erythrocyte surface deposition (figures 39 and 40), though the
correlation forC4B did not reach statistical significance amongst the small number of
control subjects in this study. However, no correlations were found between serum and
erythrocyte C4A and C4B levels in SLE subjects (figures 41 and 42). For C4B, a weak
negative correlation (-0.039) was found (figure 42). These data suggest that reduction of
serum C4A concentration is not responsible for the observed excess ofC4B on SLE
erythrocytes.
5.13 Studies of cell surface DAF
The cell surface regulatorymolecule DAF could be important in determining differences in
cell surface C4 deposition. I therefore measured erythrocyte surface DAF numbers were in
27 subjects with SLE and the primary APL syndrome and 18 normal control subjects by
radioligand binding assay as described above.
Results
Numbers (median and range) ofDAFmolecules/erythrocyte amongst 27 subjects with SLE
and the primary APL syndrome were 1369.0 (range 751.0-2109.0) and amongst 18
normal control subjects were 1324.5 (range 625.0-1780.0). These results are shown






























Figure 43. Numbers oferythrocyte cell surface DAF molecules amongst 27 patientswith
SLE (and 1° APL syndrome) and 18 normal control subjects.
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5.14 Correlation of C4A and C4B with erythrocyte C3d deposition
Differences between C4A and C4B in their efficiency as mediators of classical pathway
activation were sought by correlation ofC4 isotype deposition with C3d on erythrocytes
from patients with SLE and the primary antiphospholipid syndrome. Cell surface C4B
shows a strong correlation with C3d deposition (figure 44: rs = 0.710, P = <0.001) and
approached a linear relationship (R = 0.849). However, the correlation ofC4A deposition
with C3d, though statistically significant, is less marked, (figure 45: rs = 0.380, P =

















Figure 44. Correlation oferythrocyte surface C4B and C3d deposition amongst 49 patients

















Figure 45. Correlation oferythrocyte surface C4A and C3d deposition amongst 49 patients
with SLE and the primary antiphospholipid syndrome (rs = 0.380, P = 0.007).
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5.2 Quantification of C4 deposition on HAGG immune complexes
in vitro
Erythrocyte surface antigens are predominantly carbohydrate in composition. Having
studied differences between C4A and C4B in binding to erythrocytes in vivo, I then
tested the binding ofC4 isotypes to test immune complexes ofprotein antigen. The
theoretical prediction from consideration of the differential ligand binding affinity of
C4A and C4B is that C4A would show increased binding to ICs ofprotein antigens,
themirror image of the situationwith eiythrocytes. Studies utilising individual purified
C4 isotypes in vitro [42,43] have tended to confirm this prediction, suggesting a ratio
of 1.5-2.0/1 for the excess C4A binding. However, it is unclearwhether the same
relationships would be found when complement activation occurs in the presence of
both isotypes and regulatory proteins in vivo. The fluid phase opsonisation of test
immune complexes (heat aggregated IgG) byC4 isotypes in complexmixtures inwhole
serum was used as amodel of the physiological situation and the relationship between
serum C4 isotype levels and their deposition on test immune complexes was
investigated using the assays for fluid phase (RIA) and IC-bound (ELISA) C4
described in chapter 2.
Patients and materials
Forty four subjects with SLE were studied. Serawere subjected to centrifugation at
10,000G twice after separation to remove pre-formed ICs and subaliquoted within 4hrs
for storage at -70°C. Control opsonisation ofHAGG was measured in the presence of
lOmM EDTA, to exclude those samples with high levels ofpre-formed circulating ICs.
Five patients showed high levels ofcontrol binding (> 10% pool serum equivalent) and
were omitted from further analysis. Control binding was subtracted from all
measurements prior to further analysis. A further 5 samples with C4AQ0 were
excluded from analysis since this experiment was aimed at testing IC opsonisation in
the presence ofboth isotypes, and also because the presence ofzero values in both
semm and IC assays produced spuriously high statistical correlations amongst C4A
measurements. Spearman rank order correlation analysis was employed to test the
strength ofassociation between serum and IC C4 levels amongst the 34 samples
remaining. For the purposes ofcomparison, both quantities were expressed as relative
values, serum C4 as % pool semm and HAGG C4 levels as % pool serum equivalent
(the same pool semm was used in both assays).
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Results
5.21 Validation ofHAGG C4 assays
Figure 46, below, shows the regression analysis of total C4 deposited on HAGG
measured as the average ofthe independent measurements ofC4A and C4B with total
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Figure 46. Validation ofimmune complex C4 quantification by linear regression of
total C4 measured as the average of independently measured C4A and C4B with total
C4 measured as C4d amongst 34 subjects with SLE.
5.22 Quantification of serum and IC C4 levels and their correlation
Table 14 (overleaf) shows the levels ofC4 isotypes in serum and deposited onHAGG
from these samples, the ratio ofHAGG to serum levels derived from themedian values
and also the results of Spearman rank order correlation analysis of relationships
between semm and IC C4 levels are also shown. Figure 47 A and B overleaf illustrate
the lack ofcorrelation between serum and IC C4A and C4B levels.
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C4A C4B
Median (Range) Median (Range)
Serum C4 (% pool serum)












Table 14. Quantities ofC4A and C4B in serum and deposited on test immune
complexes (HAGG) in vitroamongst 34 subjectswith SLE, alongwith the results of
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Figure 47: A and B. Correlation ofC4A (figure 47 A) and lack ofcorrelation ofC4B
(figure 47 B) deposition onHAGGwith concomitant semm levels amongst 34 patients
with SLE (see table 14, above for correlation coefficients).
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Discussion
These experiments explored differences between C4A and C4B in erythrocyte and protein
immune complex binding assays. Such differences may be determined primarily by
differences in C4 isotype thiolester binding specificity and are likely to reflect important
aspects ofC4 physiology in vivo.
The first finding of these studies has been confirmation in wVoofthe increased binding of
C4B to erythrocytes (figure 38 A and B). Semm concentrations ofC4 are equal amongst
control subjects, but semm C4A concentrations are significantly lower than C4B amongst
subjects with SLE (figure 37, table 12). That reduction ofserum C4A does not account for
the excess ofC4B seen on SLE erythrocytes is demonstrated by the correlations ofserum
and cell surface C4A and C4B shown in figures 39-42, summarised in table 13. While a
strong correlation of serum and erythrocyte C4A and C4B is seen in normal subjects
(figures 39 and 40, for C4A: rs=0.595, P=<.007, for C4B: rs=0.451, P=<.053), this
correlation is lost amongst subjects with SLE (figures 41 and 42, for C4A: rs=0.276,
P=<.055, for C4B: rs=-0.039, P=<.079) and C4B shows a weak negative correlation.
These data imply that reduced semm concentration ofC4A did not determine the increased
C4B deposition found on SLE erythrocytes The negative correlation of semm C4B with
erythrocyte levelsmay imply that cell surface deposition is an important factor in reduction
of semm C4B concentration in SLE, though this negative correlation did not reach
statistical significance (table 13). Studies ofcell surface DAF numbers show no difference
between SLE and normal control subjects (figure 43), implying that variation in this cell
surface complement regulatory protein was not a factor in determining pathological
erythrocyte C4 deposition in SLE in vivo. In fact, weak negative correlation ofDAF
levels on cell surface deposition ofC4 were found, though these were not statistically
significant (data not shown). These findings confirm and expand those ofprevious in-
vitro studies and are consonantwith the known preferential binding of the C4B intrachain
thiolester to the carbohydrate moieties abundant on the erythrocyte surface.
In addition to increased numbers ofC4B molecules on the erythrocyte surface, my data
may be taken to suggest that C4B forms a more efficient erythrocyte bound C3 convertase.
While cell surface levels ofboth isotypes correlate with C3d deposition, the correlation of
C4B (rs = 0.710, P = <0.001) is stronger than C4A (figure 45, rs = 0.380, P = 0.007),
and approached a linear relationship (R = 0.849, figure 44).
The known increased affinity ofC4A for amino-group ligands is paralleled by the greater
efficiency ofC4A than C4B in the opsonisation ofprotein ICs for CR1 binding in vitro
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[42], and thismay be the functional link which underlies the association ofC4AQ0 with
SLE. The hoped-for corroboration of this difference in the experiments described here,
using mixtures ofvarying proportions ofC4A and C4B in whole SLE semm as amodel of
the in vivo situation, was lacking. I found a weak, though just statistically significant,
correlation ofsemm C4A levels with IC C4A deposition (figure 47A, table 14: for C4A rs
= 0.442, P = 0.01), while semm C4B levels did not appear to be directly correlated to IC
deposition (figure 47B, table 14: for C4B rs = 0.04, P = 0.342). The possibility that
correlations would be apparent at lower semm C4 concentrations was examined in
subgroups of the data, but no consistent effects were found. It may be argued that the
approach taken here is unlikely to demonstrate subtle effects. Schifferli [40] found that
mixing C4A and C4B from single donor deficient seramasked the excess activity ofC4A
in IIP in vitro and that the addition ofeven 1% C4 to semm free systems restored full Hp
activity. In the light of these facts, my datamay be interpreted as tending to support a
more important role for C4A. However, viewing the data displayed graphically in figures
47A and B underlines the weak overall correlation between semm C4 levels and IC isotype
deposition and an alternative conclusion is that factors other than semm C4 levels are of
importance inmodulating the opsonisation oflCs in whole semm.
While these experiments give no information as to the nature ofsuch additional factors, a
number ofpossibilities exist. C4 is a labile protein and even in carefully collected samples
theirmay be artefactual loss ofC4 functionalactivity reducing the sensitivity of the simple
comparative approach employed here. My techniques also specifically removed (in the
preparation ofsemm from plasma) and controlled for, the presence ofnaturally occurring
ICs, which may have had some effect on the levels of functional C4 remaining for
experimental activation. Isenman and Young [38] found no differences between C4A and
C4B in their activation by purified Clq, however, recent studies [222] have found
differences in the levels ofC4 activation products associatedwith the presence ofC4AQ0,
which appeared to be independent of the associated C4 levels. Thus differences in the
semm levels of other complement proteins may be a biological factor contributing to
variability in these experiments. Carefully timed, dynamic studiesmay have demonstrated
subtle differences in the opsonic efficiency ofC4A and C4B. Preliminary experiments of
this kind measuring C4A and C4B binding to HAGG at intervals demonstrated that
opsonisation was complete after 1 minute, but no consistent differences between C4A and




Reduced numbers of CR1 on erythrocytes from patients with
SLE and the antiphospholipid syndrome are associated with
increased levels of anticardiolipin antibodies
CR1 displays a numerical polymorphism on erythrocyteswhich is controlled by both
inherited and acquired factors. Amongst normal humans, the number of CR1
molecules on erythrocytes varies between means of approximately 100 and 1500
molecules per cell [102]. The level ofnumerical expression is stable amongst normal
subjects and is, in part, regulated by a locus encoded in close vicinity to the CR1
structural gene on Chromosome 1 [ 125]. It has been shown that CR1 numbers are
reduced on the erythrocytes ofpatients with several diseases including SLE [ 168-
170,172,175] autoimmune haemolytic anaemias [175], paroxysmal nocturnal
haemoglobinuria [223], AIDS [224], and lepromatous leprosy [225]. There has been
dispute whether the mechanism for this reduction amongst SLE patients is inherited or
acquired. Evidence for the "inherited" hypothesis has come from family studies, both
at the phenotypic and genotypic level. However the majority of the evidence suggests
that the low levels ofCR1 are acquired in patients with SLE. This evidence includes
data from family studies showing discrepancies between numerical phenotype and
genotype; findings of correlations ofCR1 levels with indices ofdisease activity and
measures of complement activation; and experiments showing loss ofCR1 from
erythrocytes transfused into patientswith SLE (discussed in chapter 1).
It has previously been observed that there is an association between the presence of
antibodies to negatively charged phospholipids, anticardiolipin antibodies, and the
presence of positive Coombs' tests in patients with SLE [193]. The finding that
reduction oferythrocyte CR1 was associated with disease activity and correlated with
erythrocyte C3 and C4 deposition in patientswith SLE, autoimmune haemolytic anemia
and other conditions characterised by the presence ofautoantibodies [ 175-177], ledme




Thirty three laboratory personnel and hospital staffwere the control panel for this
study. Fifty three patients had systemic lupus erythematosus classified by the revised
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ARA criteria. Eight patients had the clinical syndrome that has been associated with the
presence ofanticardiolipin antibodies (16). These subjects all had raised ACA with
recurrent spontaneous abortions (n = 3), deep venous thrombosis (n = 3), pulmonary
hypertension (n = 1), haemolytic anaemia (n = 2), bone marrow necrosis (n = 1).
Assays for aCL and DNAb
Anticardiolipin antibodies ofboth IgG and IgM classes were measured on each serum
sample by an ELISA method as previously described [226]. Dr S.Loizou kindly
performed aCLELISA assays for this study. Abnormal results were defined as greater
than 5 standard deviations above the normal mean value defined in 150 normal subjects
(normal IgG < 9.0 aCL ELISA units (AEU), normal IgM <8.0 AEU). Anti-ds DNA
antibodies were measured by Farr assay [227] with abnormal results greater than 5
standard deviations above normal mean value. Farr assays were performed by Ms
G.Angus with my assistance.
Monoclonal antibodies
The preparation/purification ofmonoclonal antibody reagents are described in general
methods, chapter 2. Monoclonal antibody to CR1 was Ell. Antibody to C3d was
Clone 3 and to C4d was T2.C5.12. Monoclonal antibodieswere radio-iodinated using
Iodogen to ameasured specific activity, usually between 1 - 2 pCi/jig, as described.
Enumeration of antigens on erythrocytes
The mean number ofantigen sites on erythrocytes was measured using a radioligand
binding assay as previously described [ 175] and as detailed inmethods: chapter 2.
Assay for C4 in serum
C4 concentration was measured by radioimmunoassay, and are quantified in mg/l by
comparison with pool normal serum, calibrated by laser nephelometric estimation of
total C4, as described in methods: chapter 2.
Statistical methods
Non-parametric comparisons were performed throughout. Differences between
populations were assessed by the Mann-Whitney U test. Correlations were performed
by the Spearman Rank test.
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Results
6.1 Autoantibodies to cardiolipin and to dsDNA
Levels ofaCL were measured amongst the 61 subjects with SLE and with the anti-
phospholipid antibody syndrome by ELISA. Twenty seven of these subjects (44%)
had levels of IgG or of IgM aCL greater than 5 standard deviations above the normal
mean for this assay [226]. DNA binding was greater than 30% in 23 of the 57 (40%)
subjects in whom this measurement was obtained. There was no correlation between
levels ofaCL and ofDNAb (Table 15, p 144).
CR1 levels
The mean number ofCR1 molecules per erythrocyte amongst the 33 normal subjects
was 685 (1 SE = 49), compared with 430 (1 SE = 36) amongst the 34 SLE patients
without aCL, and 305 (1 SE = 25) amongst the 27 SLE patientswith aCL (Figure 48,
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Figure 48. Mean number ofCR1 molecules, expressed as molecules per erythrocyte,
in 33 normal subjects, 34 SLE patients without anticardiolipin antibodies, and 27 SLE
patients with anticardiolipin antibodies. The number ofCR1 molecules per red cell
amongst the aCL-negative SLE patients was significantly lower than amongst the
normal subjects (z = 3.77, p < 0.001). Similarly the mean CR1 number was
significantly lower amongst the aCL-positive SLE patients compared with their aCL-
negative counterparts (z = 2.34, p < 0.02).
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6.2 Levels of C4d and of C3d on erythrocytes
The mean numberofC4d molecules per eiythrocyte amongst the normal subjects was
209 (1 SE = 17), compared with 961 (SE 128) amongst the SLE patientswithout aCL
(z = 6.5, p<0.001), and 1859 (1 SE = 562) amongst the SLE patientswith aCL (aCL-
vs aCL+, z = 1.36, p = 0.09). Similarly the mean number ofC3d molecules amongst
the normal subjects was 92 (1 SE = 10), amongst the SLE patientswithout aCLwas
308(1 SE = 51), and amongst the the SLE patients with aCL was 564 (1 SE = 134)
(Figure 49). The C3d valueswere significantly different between each group.
z = 5.1 z = 2.49 a (3616)
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Figure 49: Mean number ofC3dmolecules, expressed asmolecules per erythrocyte, in
33 normal subjects, 34 SLE patients without anticardiolipin antibodies, and 27 SLE
patients with anticardiolipin antibodies. The number ofC3d molecules per red cell
amongst the aCL-negative SLE patients was significantly higher than amongst the
normal subjects (z = 5.1, p < 0.001). Similarly the mean C3d number was
significantly higher amongst the aCL-positive SLE patients compared with theiraCL-
negative counterparts (z = 2.49, p < 0.012).
6.3 Correlations between aCL levels, CR1 and complement on cells and
in serum
The hypothesis was tested that raised levels ofaCL were associated with reduced
numbers ofCR1 and with increased C3d and Old deposited on erythrocytes. Table 16
(pl45) shows correlations between aCL levels (highest value for IgM and IgG) and
numbers of erythrocyte CR1, Old, and C3d, and serum C4. A highly significant
negative correlation was observed between aCL levels and CR1 numbers and ahighly
significant positive correlation between aCL levels and erythrocyte C3d numbers.
These correlations remain significant even if corrected for the total number of
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correlations performed in this study (n= 19). There were only very weak correlations
observed between CR1 numbers and erythrocyte C3d and C4d levels (Table 15, below)
and these did not alter when the analysis was restricted to those subjects with
abnormally elevated deposition ofC3d and C4d (> 2SD above the normal mean) on
erythrocytes: CR1 versus C4d: RSp = -0.198 (P > 0.05); CR1 versus C3d: RSp = -
0.177 (P> 0.05).











CRl number 57 0.15 0.27
erythrocyte C4d 57 0.08 0.58
eiythrocyte C3d 57 0.16 0.24
serum C4 50 -0.43 0.002
CRl
eiythrocyte C4d 61 -0.22 0.092
erythrocyte C3d 61 -0.20 0.123
DNAb
aCL 57 0.33 0.13
Table 15. Correlations between aCL level (highest reading of IgG or IgM), DNAb,
and levels oferythrocyte CRl, C4d, C3d, and serum C4 levels.
I then asked whether the effects of the IgM or IgG class of the aCL could be
distinguished with respect to CRl and complement levels on erythrocytes. Both IgG
and IgM aCL levels were correlated inversely with CRl numbers, and with each other
(Table 16, overleaf). However, whereas IgG aCL levels showed no correlation with
erythrocyte C4d and C3d numbers, highly significant correlations were found between
IgM aCL levels and these antigens.
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erythrocyte C3d 61 0.73 < 0.001
Table 16. Correlations between IgG and IgM aCL levels and erythrocyte CRl, C4d
and C3d numbers.
6.4 Correlations between DNAb and CRl and complement on cells and
The relationships between levels ofanti-DNA antibodies and erythrocyte CRl, Old and
C3d and serum C4 concentrationwere examined in order to test whether the observed
correlations between aCL levels and these parameters could simply be explained by an
association between the levels ofaCL and disease activity. There was no correlation
between the levels of aCL and of DNAb (Table 15). Similarly there were no
correlations between DNAb and erythrocyte CRl, Old or C3d (Table 15). There was
no correlation between aCL levels and serum C4 levels (Table 15), but in contrast, the
DNAb was highly significantly negatively correlated with serum C4 levels (Table 15).
This correlation remained significant when corrected for the number of tests performed.
Discussion
The role oferythrocyte CRl in the processing ofcirculating ICs and the hypothesis that
reduction ofCRl numbers in SLE may contribute to disease susceptibilityby reducing the
efficiency ofprotective effector functions of the complement system has been discussed in
chapter 1 sections 5 and 6. Observations that CRl numberswere also low in patients with
in serum
145
autoimmune haemolytic anaemias and in patients with paroxysmal nocturnal
haemoglobinuria led to the development of the hypothesis that erythrocytes bearing
autoantibodies or opsonic complement fragments may lose their CR1 by receptor
proteolysis during the interaction of erythrocytes with cells of the fixed mononuclear
phagocytic system [ 175]. Studies showing that CR1 loss could be demonstrated on
erythrocytes transfused into patientswith SLE and/or haemolytic anaemias [ 179] supported
the hypothesis that loss ofCR1 from erythrocytes occurswithin the circulation. Two sets
of observations on SLE patients suggested that antiphospholipid antibodies might be a
factor associated with reduced CR1 levels on the erythrocytes ofpatients with SLE. The
presence ofantiphospholipid antibodies was correlatedwith positive direct antiglobulin
reactions [193]. Low CR1 numbers were similarly associated with positive direct
antiglobulin reactions [192]. The authors of this latter study postulated that the link
between low CR1 and the positive antiglobulin tests was the presence of immune
complexes bound to erythrocyte CR1.
In my studies, a negative correlation (rs = -0.43) was detected between aCL levels and
CR1 numbers on erythrocytes ofSLE patients (table 15). This correlation was highly
significant despite no account being taken of the subjects' CR1 numerical "genotype" and
was not explained by an overall correlation with disease activity since no such relationship
existed between aCL and DNAb or serum C4 levels (table 15). The demonstration of
erythrocyte complement deposition by the classical pathway could suggest that the
relationship between aCL (or a closely related antibody) and low CR1 numbers was the
result ofdirect binding ofaCL to the erythrocyte surface. Such direct binding has not yet
been unequivocally shown. The strongest evidence has been the observation ofaCL
activity in the eluate from erythrocytes ofa single patient with high serum aCL levels and
positive direct antiglobulin reaction [193]. Correlations amongst aCL levels and
erythrocyte C4d and C3d levels were found in my studies (table 16). IgM, but not IgG,
aCL were found to be correlated highly significantly with the number ofC4d and C3d
molecules on the patients' erythrocytes. Both IgG and IgM aCL levels correlated inversely
with erythrocyte CR1 numbers (table 16), and it is hard to disentangle their relative
contributions to the reduction ofCR1. However it is noteworthy that therewas only a very
weak inverse correlation between CR1 numbers and levels oferythrocyte Old and C3d in
the present study. This observation implies that IgG aCL, which were not correlated with
levels of complement deposition on erythrocytes, may be related to loss ofCR1 by a
mechanism independent ofcomplement. An extension of the original hypothesis [ 175] to
incorporate this finding would be that erythrocytes, opsonised with either IgG or
complement, lose their CR1 on interactionwith cells ofthe fixed mononuclear phagocytic
system. The inclusion ofmany subjects with IgG aCL inmy studymay explain the overall
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lack of correlation between CR1 levels and C4d and C3d numbers on erythrocytes,
differing from previous observations [ 175].
In contrast to the studies ofNorbergand colleagues [228] and Hazeltine and coworkers
[ 193], I found no association between aCL and reduced levels of serum C4 (table 15),
although I did find the previously described inverse correlation between levels ofanti-
dsDNA antibodies and serum C4 levels [229]. This may be explained by our studying
different populations. Norbeig and colleagues [228] compared C4 levels between patients
with aCL and recurrent spontaneous abortions and women with recurrent spontaneous
abortions and no antiphospholipid antibodies. The population ofpatientswith aCL studied
here comprised mainly patients with SLE, amongst whom many other autoantibodies
which fix complement were present, eg anti-dsDNA antibodies. However, the strength of
the negative correlation (-0.43) between the level of aCL and mean erythrocyte CR1
numbers suggests that aCLmay be an important acquired factor determining the reduction




Antiphospholipid antibody erythrocyte binding
In patients with SLE [194,230] or the 1°APL syndrome [231], the presence of
antiphospholipid (aPL) antibodies is associated with haemocytopaenia. In addition,
cardiolipin binding reactivity has been eluted from the Coombs' positive erythrocytes of
patients with SLE [ 193]. These observations, along with the evidence presented in the
preceding chapter, suggest that aPL bind directly to erythrocytes in patientswith connective
tissue diseases and raise the possibility that aPL are a common anti-erythrocyte (and anti¬
platelet) antibody. I therefore surveyed the prevalence ofaCL positivity amongst patients
selected on the basis of a positive Coombs' test, and attempted to demonstrate direct
binding ofpolyclonal and monoclonal aCL antibodies to normal, SLE and Coombs'
positive erythrocytes.
Cardiolipin binding antibodies in patients with SLE show cross reactivitywith negatively
charged phospholipids (PLs) such as phosphatidylcholine, but do not commonly binding to
neutral PLs such as phosphatidylserine [232]. The erythrocyte membrane is asymmetric
[233]. The external lipid bilayer consists mainly of neutral moieties and normally
expresses only low levels ofnegatively charged PLs, though there is a degree ofmobility
(flip-flop) of lipids between the two leaflets [233]. I therefore tested the hypotheses that
aPL antibodies in patients with AIHA showed increased binding to neutral PLs and that
manipulation of the erythrocyte surface to expose more negatively charged PLs would alter
aPL binding.
Patients, Materials and Methods
Serum and erythrocyte samples were collected from thirty patients attending the
haematology department, Hammersmith Hospital for the assessment ofa positive Coombs'
test, or in the follow-up of known Coombs' positive haemolytic anaemia. Erythrocytes
were washed 3 times in PBS/BSA buffer and stored at 4°C, while serum samples were
separated and stored at -70°C usually on the day ofvenesection, as described.
Cell surface C3, C4 and CR1 numbers were enumerated by radioligand binding in the
usual manner. Serum cardiolipin binding was kindlymeasured byDr S. Loizou byEliSA
assay as previously described [226]. IgG and IgM antibody binding to a panel of
phospholipid (PL) antigens was measured by an adaptation of this method in which, 5
other negatively charged and 4 neutral PLs were used as the solid phase antigen in place of
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cardiolipin in ELISA assay [232]. 16 of these Coombs' positive subjects were tested for
cross-reactive PL binding in this way. Eight of these were known to have been aCL
positive, and 8 had never shown reactivity to cardiolipin.
Antibodies and radiolabelling
Anti-CRl (El 1), anti-C3d (clone 3) and anti-C4d (T2, C5.12) and Iodogen labelling
techniqueswere used as described above. The IgM monoclonal antibody BH1 was derived
from the lymphocytes ofa patientwith the 1°APL syndrome [199]. The patient, BH has
been reported elsewhere (previously referred to as patient 9 [234]). The complications
suffered by this patient include 4 first or second trimester abortions, 8 episodes ofvisual
loss, mild thrombocytopaenia, livedo reticularis, Raynauds' phenomenon and aortic
regurgitation. The patients' seium and BE11 were known to bind to cardiolipin and to be
positive in the lupus anti-coagulant test, but to be VDRL negative and to show no cross-
reactivitywith dsDNA. BH1 is thus thought to be typical ofaPL antibodies. Furthermore,
BH1 is known to bind to all of the panel of negatively charged PLs used in these
experiments, though not to neutral PLs and is able to inhibit the binding of IgG class aCL
to cardiolipin, implying similar binding specificity. Polyclonal IgG and IgM class aCL
antibodies were purified from high titre cardiolipin binding patient sera by elution from
cardiolipin liposomes andwere kindly donated byDr S.Loizou. Immunoelectrophoresis of
these antibodies confirmed that the IgG preparation was free of IgM and vice-versa.
Radiolabelling ofaCL antibodies proved to be difficult and initial attempts to label
polyclonal aCL by the Iodogen method led to inactivation of cardiolipin binding, though
BH1 could be successfully labelled by this method. Polyclonal IgG and IgM aCL were
therefore labelled by the lactoperoxidase (Sigma Pharmaceuticals) method described by
Thorel and Johansson [235] with minor modifications. Briefly, lactoperoxidase was
incubated with antibody at at 0.8pg/jjg antibody for 5 minutes at 22°C in the presence of
0.88% H2O2 after careful exclusion ofNaN3 from all reagents. Bound label was then
separated from free Na125I and the specific activity and antibody concentration calculated
by TCA precipitation as described. Specific reactivities of2-4 x l()6/jigwere achieved for
BH1, but lower specific activities (2.5 x lO^cpm/pg) were acheived with polyclonal IgG
and IgM aCL. Functional integrity of the labelled antibody was demonstrated by the
finding ofspecific binding of5.4% ofoffered IgG, 2.1% oflgM and 26% of labelledBH1
to ACA in ELISA wells, using aCL blockedwith 2% BSA as control..
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Results
7.1 Erythrocyte C3, C4 and CR1 amongst Coombs' positive subjects
Mean erythrocyte C3d was 886.3 molecules/cell (+/-307.3,1SE) and C4d was 2199.5 (+/-
496.5) amongst 22 of these patients, while mean CR1 numbers were 590.4 (+/-59.2).
For comparison mean C3d, C4d and CR1 amongst 33 normal control subjects were 92 (+/-
10), 209 (+/-17) and 605 (+/- 49), respectively. While C3 and C4 numbers are raised,
CR1 numbers amongst these subjects were not significantly different from the normal
population (U = 277.5, P = 0.07).
7.2 The Prevalence of aCL Antibodies amongst Coombs' positive
subjects
Nine of these 30 AIHA patients (30%) showed positive aCL titles, 8 IgM and 1 IgG. The
clinical details and aCL levels amongst these patients is shown below in table 17. Allowing
that aCL may be primarily associated with SLE in the 2 patients with this diagnosis, the
prevalence ofaCL amongst Coombs' positive patients was at least 25.0%, compared with
the normal population (<2%, Dr S.Loizou, personal communication).
Autoimmune neutropenia (2)
patient 1 female aged 88 IgG ACA 6.4: IgMACA 27.0
patient 2 female aged 66 IgG ACA 1.7: IgM ACA 12.0
kerato-conjunctivitis sicca Coombs' positive for complement only
Haematological malignancy (2)
patient 1 CLL IgGACA 7.0: IgM ACA 22.0
patient 2 T cell lymphoma IgG ACA 6.4: IgM ACA 8.0
(AIHA and autoimmune thrombocytopenia)
Coombs' positive (1)
coincident finding IgG ACA 1.2: IgM ACA 27.0
AIHA (2)
patient 1 severe intractableAIHA
IgG ACA 0.8: IgM ACA 168.0
patient 2 IgGACA 6.5: IgM ACA 64.0
SLE (2)
patient 1 AIHA 8 yrs prior to SLE
IgG ACA 1.0: IgM ACA 62.0
patient 2 IgG ACA 9.0:IgM ACA 34.0
Table 17. Prevalence ofaCL antibodies amongst 30 Coombs' positive patients.
150
7.3 Cross reactivity with negative and neutral phospholipids amongst
Coombs' positive subjects
IgG and IgM cross-reactivity of 16 Coombs' positive sera against a panel ofneutral and
negatively charged PLs was tested by Dr S.Loizou. Negatively charged PLs used were:
cardiolipin (CL), phosphatide acid (PA), phosphatidyl inositol (PI), phosphatidyl glycerol
(PG) and phosphatidyl serine (PS). Neutral PL were phosphatidyl ethanolamine (PE),
phosphatidyl choline (PC), phosphatidyl 1-a phosphatidyl choline, y-acetyl-B-O-alkyl
(platelet activating factor, PAF) and Sphingomyelin (SPH). Halfof these subjects were
known aCL positive, and halfwere aCL negative. A panel of 8 normal control sera were
used. Mean (+/-1 SD) IgM PL binding was 0.384 (+/- 0.593) AEU, while IgG controls
showed 0.436 (+/- 0.685) AEU. Significant binding was defined as > 5 SD above the
mean of 8 normal controls as before [226]. Figure 50: A and B (overleaf) shows the results
of these measurements expressed as SD above the mean ofnormal control binding, the
normal range is shown cross-hatched. Ten individuals were positive in these assays and
extensive cross-reactivitywas noted. For IgM, 10 (62.5%) showed binding to negatively
charged PLs, 8 ofwhom were reactive to cardiolipin and 2 (12.5%) showed -ve PL
reactivity independent ofCL binding. Eight subjects showed IgM binding to neutral PLs
(50%), 7 ofwhom were cross reactivewith CL, the remaining individual was positive for
sphingomyelin binding only. With regard to IgG, 7 subjects (43.8%) were positive and all
bound to -ve PLs. Six (37.5%) showed CL binding and 1 was independent. Four (25%)
individuals showed IgG binding to neutral PLs, 3 cross reactive with CL and 1
independent of this specificity. As indicated, cross reactivity amongst these sera was
extensive. The results ofSpearman rank correlation between levels ofIgG and IgM aCL
antibodies and antibodies to other PLs is shown below in table 18.
Negative Neutral
PA PG PI PS PC PE PAF SPH
IgG rSp 0.65 0.72 0.88 0.69 0.36 0.66 0.54 0.63
aCL P< 0.006 0.002 0.001 0.003 0.166 0.005 0.032 0.009
IgM rSp 0.92 0.79 0.98 0.88 0.65 0.56 0.75 0.86
aCL P< 0.001 0.001 0.001 0.003 0.006 0.025 0.001 0.001
Table 18: Correlation ofIgG and IgM CLbindingwith binding to negative and neutral PLs
amongst 16 Coombs' positive subjects. Non-significant correlations are shown in bold.
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Figure 50A and 50B. Binding of IgM and IgG aPL antibodies to
negatively charged and neutral phospholipids amongst







































































































































Negatively charged Neutral charge
Figure 50A and B. Binding of IgM and IgG aPL antibodies to negatively charged and
neutral phospholipids amongst 16 Coombs' positive subjects. The normal range (<5 SD
above the mean of normal binding) is indicated by the cross-hatched area.
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7.4 Ligand Binding of Purified aPL Antibodies
To investigate the potential cellular pathogenicity ofaPL antibodies an attemptwasmade to
demonstrate the binding ofpurified aPL antibodies to eiythrocytes. The purified IgM
monoclonal antibody BH1 is described above as are patient derived affinity purified
polyclonal IgG and IgM aCL binding antibodies which were kindly donated by Dr
S.Loizou.
7.41 Experiments with BH1
A number of experiments were performed and will be described in outline since no
evidence ofBH1 binding to eiythrocytes could be demonstrated. BH1 was radiolabelled
by Iodogen and by the lactoperoxidase method withminormodifications. The following
experimentswere then performed.
Direct Binding ofBH1 to Erythrocytes
BH1 was incubated with erythrocytes from normal control subjects (n = 6), patientswith
SLE (n = 11) and Coombs' positive, non SLE subjects (n = 5) under the same conditions
as those employed for radioligand binding studies. Mean percentage BH1 bound was
0.63, 0.71, and 0.74 respectively. When serial dilutions of radiolabelled BH1 were
incubated with known numbers oferythrocytes from these 3 study groups, no evidence of
a specific binding effect could be detected. Similarly, when serial dilutions oferythrocytes
were incubated with a potentially saturating concentration of labelled antibody (lSpgtol), a
consistent level of apparent binding suggestive ofnon-specific background only (0.5%)
was found. The same results were obtainedwith incubation at 37, 22 and 4°C regardless
ofduration up to 18hrs.
Indirect Evidence of BH1 Binding to Erythrocytes
The possibility that weak BH1 binding was occurring followed by elution during
experimental procedures was tested by examining normal (n=2) and SLE (n=2)
erythrocytes for evidence of complement deposition subsequent to incubation with
unlabelled BH1 and autologous serum using EDTA and no-antibody controls, at differing
temperatures as above. No evidence ofdeposition ofC3, C4 or reduction ofCR1 could be
found.
Binding of BH1 to Erythrocyte Ghosts
Since the distribution oferythrocyte membrane lipids is asymmetric and negative PLs are
mainly internal, the possibility that BH1 may binding to internal membrane lipids was
tested by incubation of radiolabelled BH1 to erythrocyte ghosts prepared by sonication of
normal erythrocytes. No specific binding could be found.
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7.42 Studies with Affinity Purified polyclonal IgG and IgM aCL
Binding of 125I aCL to Erythrocytes and 125I Protein A probing
Serial dilutions of radiolabelled IgG and IgM antibodies were incubatedwith normal human
erythrocytes using the method described for radioligand binding studies. No evidence of
specific binding could be detected. To exclude the possibility that radiolabelling damage
was affecting the reagents, serial dilutions of lOOjul unlabelled IgG aCL starting
concentration lOOpg/ml were incubated with lOOpl normal human erythrocytes at 1.5 x
108/ml PBS/BSA buffer, using irrelevant human IgG as control. These were then washed
3 times to remove unbound antibody and probedwith 125I Staphylococcal Protein A (ljjg,
105 cpm) prior to separation ofbound antibody by centrifiigation through oil. The results
are shown below in figure 51 and suggest that some specific binding of IgG aCL was
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Figure 51. Binding of 125I labelled Staphylococcal Protein A to normal human
erythrocytes incubatedwith affinity purified IgG aCL and with irrelevant human IgG
control.
Binding of 125I aCL to altered erythrocytes
Sodium Tetrathionate is a cellularmetabolic inhibitor which has been shown to induce a
glucose dependent alteration in erythrocyte cell membrane lipid composition [236].
Incubation of cells with tetrathionate has been shown to increase the exposure of
phosphatidylethanolamine (a negatively charged PL) from 5 to 20% . These changes are
antagonised by pre-incubation with glucose. In view of the failure of 125I IgM aCL, and
the indirect evidence of IgG binding to native erythrocyte membranes, the binding of




Incubation buffer: NaCL 50mM, KC1 lOOmM, Na2HP04/NaH2P04 lOmM, sucrose
44mM. pH 7.4
Method
Tetrathionate treatment of erythrocytes
Washed normal human erythrocytes were incubated in 10 volumes of incubation buffer
with 1 ImM glucose added to control cells for 24 hrs at 37°C with gentle rotation. 5mM
NA tetiathionate was then added, the pH adjusted to 8.0 and incubation continued at 4°C
for 4hrs.
125I aCL probing
Cellswere washed 3 timeswith PBfyBSA buffer, adjusted to at 5 x lO^/ml, incubated with
125I antibody (5pgbil) prior to separation ofbound from free by centrifugation of duplicate
125pl aliquots through oil as before. Conditions were adjusted so that each 125jil aliquot
contained approximately 3.5 x lO^cpm labelled antibody. Cells were probed with 125I:IgG
and IgM aCL and BH1. E11 was used as a control for non-specific, proteolytic removal of
cell surface antigens. Results are shown in figure 52. By comparison, treatment of
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Figure 52. Binding of radiolabeled aPL antibodies and control (mab El 1) to human
erythrocytes treated with Na Tetralhionate in the presence or absence ofglucose (control).
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Discussion
Anticardiolipin antibodies are a commonly occurring member ofa family ofantibodies
which bind principally to the phosphodiester group ofnegatively charged PLs. Clinically,
aCL are associated with prolongation ofcoagulation tests in vitro (the lupus anticoagulant
test) but venous and arterial thromboses in vivo, recurrent abortion, livedo reticularis,
neurological disease and also thrombocytopaenia and Coombs' positivity (see [237] for
review). These antibodiesmay occur as a solitary immunological abnormality (the primary
antiphospholipid syndrome), or as part ofa connective tissue disease such as SLE, where
their presence appears to define a subgroup ofpatients characterised by haemocytopaenias
[ 194]. Deleze and colleagues [238] studied 500 patientswith SLE and concluded that IgG
aCL were associated with thrombocytopaenia, while IgM aCL were associated with
haemolytic anemia and apositive Coombs' test. Direct binding ofaCL to native blood cells
has been difficult to demonstrate and typically has required extensive alteration to the cell
surface [239], though binding to erythrocytes has been inferred [193] and binding to
platelets has been reported [240].
Cardiolipin (diphosphatidylglycerol) is a common antigen, however, its location in the
mitochondrial membrane [241 ] makes it unlikely to be an antigen directly responsible for
erythrocyte cell surface binding. The external bilayer of the erythrocyte membrane
comprisesmainly of the neutral PLs phosphatidylcholine (PC) and sphingomyelin (SPH),
while the internal leaflet contains both phosphatidylethanolamine (PE, neutral) and
phosphatidylserine (PS, negatively chaiged) [242], though a degree ofcrossover (flip-flop)
of internal PS to the exteriorofthe cell does occur [233]. Anti-cardiolipin antibodies show
extensive cross-reactivitywith other negatively charged PLs [232], but little binding to
neutral PLs. It seems likely, therefore, that for significant eiythrocyte binding to occur, the
cell membrane must be abnormal in its lipid composition, as is the case with sickle-cells
[243] or that erythrocyte-binding antibodies are a subset with a high degree of cross-
reactivity to neutral PLs. Cabral and colleagues have recently described the isolation ofan
IgM class aCL antibody from a patientwith HA (but not SLE) which showed binding to
phosphatidylcholine (neutral) and to bromelain treated erythrocytes [244] and that PC
cross-reactivity was more common in aCL positive SLE subjects with haemolytic anemia
than those without this complication. The studies described here show that aCL antibodies
are common in Coombs' positive subjects without connective tissue diseases, being present
in 7 of 28 (25%) subjects, and in a further 2 (making a total of 9 out of 30 subjects
surveyed) with concommitant SLE, giving an overall prevalence of30%. This suggests
that aCL may be a common anti-erythrocyte autoantibody in non connective tissue disease
subjects [196].
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Sixteen ofthese Coombs' positive subjects were then tested for cross-reactivity against a
panel of negative and neutral PLs. Previous studies [232] have demonstrated the
heterogeneity of lipid binding and functional characteristics amongst aCl and aPL
antibodies from patients with SLE and syphilis. The results obtained with these Coombs'
positive non SLE patientsmay suggest further heterogeneity amongst disease groups and
indicate an increase in binding to neutral PLs whichmay be of functional significance. In
the study ofLoizou and colleagues [232] subjects with SLE showed low levels of cross-
reactivitywith neutral PLs (27.3% for IgM and 16.4% for IgG antibodies, Dr S.Loizou,
personal communication), while neutral PL binding was almost as common as negative PL
binding amongst subjects with syphilis. Amongst these Coombs' positive subjects, 50%
showed IgM and 25% IgG binding to neutral PLs. As shown in table 18, both IgG and
IgM neutral PL-binding antibodies showed significant cross-reactivitywith CL as judged
by Spearman correlation analysis. Amongst the patients reported by Loizou et al,
significant correlations with CL amongst IgG antibodies were typical ofsyphilis not SLE
subjects. Moreover the dominant cross-reactive neutral PL target amongst SLE patients in
Loizou's study was PC, while the correlation between PC and CL amongst Coombs'
positive subjects was not significant (table 18). Antiphospholipid antibodies in Coombs'
positive subjects thus seem to resemble those in patientswith syphilis more than SLE, but
differ in being associated with the haemocytopaenias which are typical of the connective
tissue diseases. However, I consider these to be preliminary findings only, since the
number ofCoombs' positive patients were small and the selection ofequal numbers ofaCL
positive and negative patients may have biased the results. Against selection bias
significantly affecting these results is the fact that in the study ofLoizou et al IgG class
neutral PL binding was found in 18.5% of27 CL positive and 14.3% of28 CL negative
SLE subjects. A mean of 16.4% would thus be expected in a balanced sample ofaCL
positive and aCL negative subjects, compared with 25% binding found amongst Coombs'
positive subjects.
Clearly, the property ofneutral PL bindingmay be important in binding to the erythrocyte
membrane since the external leaflet is primarily composed of the neutral moieties.
Alternatively, the low levels ofnegatively charged PL (-ve PL) present on the external
surface of normal E may be the antigenic target for the commoner -ve PL binding
antibodies. I attempted to study this latter possibility directlyusing amonoclonal antibody
reactive with -ve PLs and polyclonal aCL antibodies affinitypurified by bindingwith
-ve PL liposomes. The monoclonal antibody BH1 showed no evidence of direct
erythrocyte binding despite extensive testing. BH, fromwhom this antibodywas isolated
had suffered thrombocytopaenia and complications typical ofthe 1 ° APL syndrome, but not
haemolytic anaemia. Further experimentswith both IgG and IgM polyclonal aCL support
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the hypothesis that aCLmay bind directly to erythrocytes (figure 51), though this has not
been exhaustively proven. The finding that polyclonal aCL binding is increased by
treatment of red cells with Na Tetrathionate (figure 52) suggests that it is the lipid-binding
properties ofthe antibodywhich determines binding. Na Tetrathionate oxidises SHgroups
and is capable of exposing the internal -ve PL, phosphatidylserine, to digestion by
exocellular pancreatic phospholipase C [236] in whole erythrocytes, suggesting that
treatment with methionine induces a reorientation ofPLs between the internal and external
lipid bilayers. It is also ofnote that quantitatively the binding ofaCL in this experiment is
equivalent to that ofE11 which recognises a specific cell surface ligand.
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Conclusions
The aim ofthis work was to study factors which may contribute to disease expression in
SLE by impairing the efficiency of complement- and erythrocyte CR1-mediated
mechanisms of immune complex clearance, specifically inherited partial deficiency ofC4A
and acquired reduction oferythrocyte CR1 expression.
Initial experiments employed a newly developed radioimmunoassay to measure semm
concentrations ofC4 isotypes separately and were intended to contribute to understanding
the physiology ofC4, specifically the complex relationship between C4 genotype and
phenotypic expression. Since semm levels ofC4 reflect both production and consumption
genotyped normal sera in which an acute phase response was excluded were employed. I
then investigated the pathophysiology ofC4 in SLE by studying C4 immune complex
binding in two models chosen to highlight the differences between C4A and C4B and to
reflect some ofthe complexities of in vivo immune complex processing. To conduct these
studies I developed a second new assay for the quantification ofC4A and C4B on HAGG
immune complexes.
After this, I considered factors contributing to reduction of erythrocyte CR1 numbers,
whichmay also reduce the efficiency of IC clearance in subjects with SLE. Specifically, I
investigated the association ofaCL antibodies with erythrocyte CR1 reduction and pursued
the physiological link underlying my findings by investigating the occurrence and
phospholipid binding ofaCL in other conditions characterised by a positive Coombs' test
and by experimentswith purified antiphospholipid antibodies.
The principal findings ofthese studies have been:
1. The difficulty in identifying C4 genotype from phenotype has been confirmed in these
studies and a number of factors relating to C4 expression have been explored including
age, gender, expression of homo-duplicated C4A genes and anomalous antigenic
recognition by anti-C4 monoclonals. I have confirmed that the C4B null allele encoded in
the extended haplotype linked with Felty's syndrome is associated with an expressed
homoduplicated C4A gene, making. The possibility that C4 isotypes respond differentialy
to acute phase stimuli was not resolved by the study undertaken here.
2. That an excess ofC4B is found on SLE erythrocytes in vivo, confirming previous
findings in vitro.
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3. That C4B may form amore efficient erythrocyte surface C3 convertase than C4A
4. That the relationship between C4 isotype levels and opsonisation ofprotein ICs ismore
complex in whole serum than is apparent when purified C4A and C4B are used in vitro.
While the predicted predominance ofC4A bindingwas not confirmed in these studies, the
finding that C4A levels correlate more closely with IC deposition may suggest a subtle
difference in the efficiency ofC4 isotype opsonisation ofICs ofprotein antigens.
5. That aCL antibodies contribute to reduced CR1 expression in patients with SLE, and
that IgM aCL are associated with erythrocyte complement deposition.
6. That aCL antibodies may be a common anti-eiythrocyte autoantibody in Coombs'
positive patients
7. That aPL antibodies in Coombs' positive patients shows increased cross-reactivitywith
neutral PLs, which are likely to be important antigens on the external eiythrocyte membrane
8. Some evidence was found that polyclonal aCL antibodies can bind directly to
erythrocytes and that modulation of the eiythrocyte surface lipid composition increases this,
providing further mechanistic support for the association ofaCLwith CR1 reduction.
The hypothesis summarising these data and linking the association ofaCL with E-CR1
reduction is that a subset of the heterogeneous population ofaPL immunoglobulins are
common anti-erythrocyte autoantibodies. These E-binding antibodies are cross-reactive
with CL and show increased binding to neutral PLs, a common erythrocyte surface
antigen. Alternatively, although negatively chaiged PLs comprise a small proportion ofthe
external erythrocyte membrane, IgG antibodies with this specificity are a frequent finding
and could be quantitatively important. IgM antibodies are associated with erythrocyte
complement fixation, opsonising the cell for interactionwith complement-receptorbearing
phagocytes of the MPS and resulting in secondary reduction ofE-CR1. The mechanism
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The numerical expression of complement receptor type 1 (CR1) is reduced on
erythrocytes ofpatients with several diseases including SLE and autoimmune haemolytic
anaemias. Amongst patients with SLE, anticardiolipin antibodies (ACA) have been
associated with positive direct antiglobulin tests. Because of these findings, we asked
whether the reduced erythrocyte CR1 numbers amongst 53 patients with SLE and 8 with
the "antiphospholipid syndrome" might be associated with the presence of ACA. A
negative correlation was observed between ACA levels and mean CR1 numbers (RSp =
-0.43, p =0.001) and a positive correlation between ACA levels and the levels of
erythrocyte C4d and C3d (RSp = 0.33 and 0.41, p = 0.01 and 0.001 respectively), but
no correlation of ACA levels with serum C4 levels. When the results were further
analysed according to the IgG or IgM class ofACA, levels of antibodies ofboth classes
were negatively correlated with CR1 numbers, but only IgM ACA levels were correlated
with erythrocyte C4d and C3d numbers. The levels of anti-dsDNA antibodies showed
no correlation with erythrocyte CR1, C4d or C3d numbers but were negatively
correlated with serum C4 levels (RSp = -0.43, p = 0.002). These data suggest that
ACA, or a closely related antibody specificity, may bind to erythrocytes and be directly




Primate erythrocytes bear a receptor for C3b, iC3b and C4b, named complement
receptor type 1 (CR1, CD35), which is believed to have two main physiological
activities on these cells (reviewed in 1). CR1 functions as a cofactor to the serine
esterase, Factor I, in the catabolism of C3b to iC3b, and of iC3b to C3c and C3dg. It
may also bind immune complexes and micro-organisms which bear fixed C3b, iC3b or
C4b, and transport them through the circulation to the fixed mono-nuclear phagocytic
system (reviewed in 2).
CR1 displays a numerical polymorphism on eiythrocytes which is controlled by both
inherited and acquired factors. Amongst normal humans, the number ofCR1 molecules
on erythrocytes varies between means of approximately 100 and 1500 molecules per cell
(reviewed in 3). The level of numerical expression is stable amongst normal subjects
and is, in part, regulated by a locus encoded in close vicinity to the CR1 structural gene
on Chromosome 1 (4, 5). It has been shown that CR1 numbers are reduced on the
erythrocytes of patients with several diseases including SLE (6, 7, 8, 9) autoimmune
haemolytic anaemias (10), paroxysmal nocturnal haemoglobinuria (11), AIDS (12), and
lepromatous leprosy (13). There has been dispute whether the mechanism for this
reduction amongst SLE patients is inherited or acquired (reviewed in 3, 14). Evidence
for the "inherited" hypothesis has come from family studies, both at the phenotypic and
genotypic level. However the majority of the evidence suggests that the low levels of
CR1 are acquired in patients with SLE. This evidence includes data from family studies
showing discrepancies between numerical phenotype and genotype; findings of
correlations of CR1 levels with indices of disease activity and measures of complement
activation; and experiments showing loss of CR1 from erythrocytes transfused into
patients with SLE.
It has previously been observed that there is an association between the presence of
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antibodies to negatively charged phospholipids, anticardiolipin antibodies, and the
presence ofpositive Coombs' tests in patients with SLE (15). In view of the finding that
patients with autoimmune haemolytic anaemias have low erythrocyte CR1 levels (10),
this led us to examine the association between anticardiolipin antibodies and reduced
levels ofCR1 amongst patients with SLE. Our results show an association between the
presence ofanticardiolipin antibodies and reduced levels ofCR1 on erythrocytes.
Materials and methods
Subjects
Thirty three laboratory personnel and hospital staffwere the control panel for this study.
Fifty three patients had systemic lupus erythematosus classified by the revised ARA
criteria. Eight patients had the clinical syndrome that has been associated with the
presence of anticardiolipin antibodies (16). These subjects all had raised ACA with
recurrent spontaneous abortions (n = 3), deep venous thrombosis (n = 3), pulmonary
hypertension (n = 1), haemolytic anaemia (n = 2), bone marrow necrosis (n = 1).
Assays for ACA and DNAb
Anticardiolipin antibodies of both IgG and IgM classes were measured on each serum
sample by an ELISA method as previously described (17). Abnormal results were
defined as greater than 5 standard deviations above the normal mean value defined in 150
normal subjects (normal IgG < 9.0 ACA ELISA units (AEU), normal IgM <8.0 AEU).
Anti-ds DNA antibodies were measured by Farr assay (18) with abnormal results greater
than 5 standard deviations above normal mean value.
Monoclonal antibodies
Monoclonal antibody to CR1 was Ell (19, donated by Dr N Hogg, ICRF, Lincoln's
Inn Fields, London). Antibody to C3d was Clone 3 (20, donated by Prof P Lachmann,
MRC Centre, Cambridge) and to C4d was T2.C5.12 (donated by ProfG Ross, Chapel
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Hill, N Carolina). Monoclonal antibodies were radio-iodinated using Iodogen (21) to a
measured specific activity, usually between 1 - 2 pCi/jig.
Enumeration of antigens on erythrocytes
The mean number of antigen sites on erythrocytes was measured using a radioligand
binding assay as previously described (9). All of the radiolabeled antibodies were
incubated at a final concentration of 5 pg/ml with erythrocytes suspended in PBS / 1%
BSA/ lOmM NaN3 at 3.3 x 10^/ml. Antigen sites were greater than 95% saturated
with antibody under these conditions.
Assay for C4 in serum
C4 concentration was measured by radioimmunossay. All incubations were performed
in PBS / NaN3 10mM / Tween 20 0.05% / BSA 0.2% / EDTA lOmM pH 7.2 in
polystyrene microtitre plates (Immulon II Removawells, Dynatech, Billingshurst,
Sussex). These plates were coated at 10 pg / ml for 24 hours at 4°C with rabbit anti-
human C4 (Serotec, Kidlington, Oxford) which had been affinity-purified on C4-
Sepharose CL4B (gift ofDr R A Harrison, MRC Centre, Cambridge) and subsequently
blocked using 6 washes of buffer. Test sera were diluted to a concentration of 1:1640
and 50pl samples were incubated in duplicate in wells for 4 hours at 37°C, washed 6
times, incubated with 50pl ofmurine monoclonal anti-C4 at 2 jug /ml, washed 6 times,
and probed with 50pl of 125j_aff}njty_pUrjfiec} rabbit anti-mouse IgG (100,000 dpm/
well, approximately 2 jig/ml). Results were expressed as % of the C4 concentration in
a pool of 20 normal sera.
Statistical methods
Non-parametric comparisons were performed throughout. Differences between
populations were assessed by the Mann-Whitney U test. Correlations were performed
by the Spearman Rank test.
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Results
Autoantibodies to cardiolipin and to dsDNA
Levels of ACA were measured amongst the 61 subjects with SLE and with the anti-
phospholipid antibody syndrome by ELISA. Twenty seven of these subjects (44%) had
levels of IgG or of IgM ACA greater than 5 standard deviations above the normal mean
for this assay (17). DNA binding was greater than 30% in 23 of the 57 (40%) subjects in
whom this measurement was obtained. There was no correlation between levels ofACA
and ofDNAb (Table 1).
CR1 levels
The mean number of CR1 molecules per erythrocyte amongst the 33 normal subjects
was 685 (1 SE = 49), compared with 430 (1 SE = 36) amongst the 34 SLE patients
without ACA, and 305 (1 SE = 25) amongst the 27 SLE patients with ACA (Figure 1).
These values were significantly different between each group (Figure 1).
Levels of C4d and of C3d on erythrocytes
The mean number of C4d molecules per erythrocyte amongst the normal subjects was
209 (1 SE = 17), compared with 961 (SE 128) amongst the SLE patients without ACA
(z = 6.5, p<0.001), and 1859 (1 SE = 562) amongst the SLE patients with ACA (ACA-
vs ACA+, z = 1.36, p = 0.09). Similarly the mean number of C3d molecules amongst
the normal subjects was 92 (1 SE = 10), amongst the SLE patients without ACA was
308 (1 SE = 51), and amongst the the SLE patients with ACA was 564 (1 SE = 134)
(Figure 2). The C3d values were significantly different between each group (Figure 2).
Correlations between ACA levels and CR1 and complement on cells and in serum
The hypothesis was tested that raised levels of ACA were associated with reduced
numbers ofCR1 and with increased C3d and C4d deposited on erythrocytes. In Table 1
are shown correlations (and their significance values) between ACA levels (highest value
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for IgM and IgG) and numbers of erythrocyte CR1, C4d, and C3d, and serum C4. A
highly significant negative correlation was observed between ACA levels and CR1
numbers and a highly significant positive correlation between ACA levels and
erythrocyte C3d numbers. These correlations remain significant even if corrected for the
total number of correlations performed in this study (19). There were only very weak
correlations observed between CR1 numbers and erythrocyte C3d and C4d levels (Table
1). These latter correlations did not alter when the analysis was restricted to those
subjects with abnormally elevated deposition ofC3d and C4d (> 2SD above the normal
mean) on erythrocytes: CR1 versus C4d: RSp = -0.198 (P > 0.05); CR1 versus C3d:
RSp = -0.177 (P> 0.05).
We then asked whether the effects of the IgM or IgG class of the ACA could be
distinguished with respect to CR1 and complement levels on erythrocytes. Both IgG
and IgM ACA levels were correlated inversely with CR1 numbers, and with each other
(Table 2). However, whereas IgG ACA levels showed no correlation with erythrocyte
C4d and C3d numbers, highly significant correlations were found between IgM ACA
levels and these antigens.
Correlations between DNAb and CR1 and complement on cells and in serum
The relationships between levels ofanti-DNA antibodies and erythrocyte CR1, C4d and
C3d and serum C4 concentration were examined in order to test whether the observed
correlations between ACA levels and these parameters could simply be explained by an
association beween the levels of ACA and disease activity. There was no correlation
between the levels ofACA and ofDNAb (Table 1). Similarly there were no correlations
between DNAb and erythrocyte CR1, C4d or C3d (Table 1). There was no correlation
between ACA levels and serum C4 levels (Table 1), but in contrast, the DNAb was
highly significantly negatively correlated with serum C4 levels (Table 1). This
correlation remained significant when corrected for the number of tests performed.
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Discussion
The factors controlling the numerical expression ofCR1 on erythrocytes ofpatients with
SLE are complex. Amongst normal subjects the level of CR1 expression correlates with
two alleles identified by a restriction fragment polymorphism using a cDNA probe for
the CR1 gene (6.9-kb allele associated with low expression and 7.4-kb with high
expression) (4). These alleles also influence the levels of expression of CR1 amongst
SLE patients. Patients homozygous for the 7.4-kb allele had higher CR1 numbers than
individuals heterozygous for the 7.4- and 6.9-kb alleles, but, within each genotype, SLE
patients were found to have lower CR1 numbers than their normal counterparts (5).
This observation strongly suggests that, superimposed on this genetic control
mechanism, there are other, as yet undefined, factors leading to reduced CR1 expression
on erythrocytes ofpatients with SLE.
Observations that CR1 numbers were also low in patients with autoimmune haemolytic
anaemias and in patients with paroxysmal nocturnal haemoglobinuria led to the
development of the hypothesis that erythrocytes bearing autoantibodies or opsonic
complement fragments may lose their CR1 by receptor proteolysis during the interaction
of erythrocytes with cells of the fixed mononuclear phagocytic system (10). Studies
showing that CR1 loss could be demonstrated on erythrocytes transfused into patients
with SLE and / or haemolytic anaemias (22) supported the hypothesis that loss ofCR1
from eiythrocytes occurs within the circulation.
Two sets of observations on SLE patients suggested that antiphospholipid antibodies
might be a factor associated with reduced CR1 levels on the erythrocytes ofpatients with
SLE. The presence of antiphospholipid antibodies was correlated with positive direct
antiglobulin reactions (15). Low CR1 numbers were similarly associated with positive
direct antiglobulin reactions (23). The authors of this latter study postulated that the link
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between low CR1 and the positive antiglobulin tests was the presence of immune
complexes bound to erythrocyte CR1.
In the present study a correlation was detected between ACA levels and CR1 numbers on
erythrocytes ofSLE patients. This correlation was highly significant despite no account
being taken of the subjects' CR1 numerical "genotype". Direct binding of ACA to
erythrocytes has not yet been unequivocally shown. The strongest evidence was the
observation ofACA activity in the eluate from erythrocytes of a single patient with high
serum ACA levels and positive direct antiglobulin reaction (15). This and the present
study suggest that either ACA or a closely related antibody bind to erythrocytes and may
be related to low CR1 numbers.
IgM, but not IgG, ACA were also found to be correlated highly significantly with the
number of C4d and C3d molecules on the patients' erythrocytes. Both IgG and IgM
ACA levels correlated inversely with erythrocyte CR1 numbers, and it is hard to
disentangle their relative contributions to the reduction of CR1. However it is
noteworthy that there was only a very weak inverse correlation between CR1 numbers
and levels of erythrocyte C4d and C3d in the present study. This observation implies
that IgG ACA, which were not correlated with levels of complement deposition on
erythrocytes, may be related to loss of CR1 by a mechanism independent of
complement. An extension of the original hypothesis (10) to incorporate this finding
would be that erythrocytes, opsonised with either IgG or complement, lose their CR1 on
interaction with cells of the fixed mononuclear phagocytic system. The inclusion of
many subjects with IgG ACA in the present study may explain the overall lack of
correlation between CR1 levels and C4d and C3d numbers on erythrocytes, differing
from previous observations (10).
In contrast to the studies of Norberg and colleagues (24) and Hazeltine and coworkers
(15) we found no association between ACA and reduced levels of serum C4, although
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we found the previously described inverse correlation between levels of anti-dsDNA
antibodies and serum C4 levels (25). This may be explained by our studying different
populations. Norberg and colleagues (24) compared C4 levels between patients with
ACA and recurrent spontaneous abortions and women with recurrent spontaneous
abortions and no antiphospholipid antibodies. Our population of patients with ACA
comprised mainly patients with SLE, amongst whom many other autoantibodies which
fix complement were present, eg anti-dsDNA antibodies.
The strength of the negative correlation (-0.43) between the level of ACA and mean
erythrocyte CR1 numbers suggests that ACA may be an important acquired factor
determining the reduction of erythrocyte CR1 in patients with SLE. Further studies are
required in order to verify that ACA can bind directly to erythrocytes and that IgM ACA
may fix complement to erythrocyte surfaces.
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Table 1.
Correlations between aCL level (highest reading of IgG or IgM), DNAb,
and levels of erythrocyte CRl, C4d, C3d, and serum C4 levels.
Spearman Correlation n correlation probability
aCL
CRl number 61 -0.43 0.001
erythrocyte C4d 61 0.33 0.01
erythrocyte C3d 61 0.41 0.001
serum C4 53 -0.09 0.533
DNAb
CRl number 57 0.15 0.27
erythrocyte C4d 57 0.08 0.58
erythrocyte C3d 57 0.16 0.24
serum C4 50 -0.43 0.002
CRl
erythrocyte C4d 61 -0.22 0.092
erythrocyte C3d 61 -0.20 0.123
DNAb
aCL 57 0.33 0.13
Table 1. Correlations between aCL level (highest reading of IgG or IgM), DNAb, and
levels of erythrocyte CR1, C4d, C3d, and serum C4 levels.
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Table 2.
Correlations between IgG and IgM aCL levels and erythrocyte CR1,
C4d and C3d numbers.
Spearman Correlation n correlation probability
IgG aCL
CRl number 61 -0.38 0.002
erythrocyte C4d 61 0.12 0.342
erythrocyte C3d 61 0.25 0.051
IgM aCL 61 0.37 0.004
IgM aCL
CRl number 61 -0.36 0.004
erythrocyte C4d 61 0.41 0.001
erythrocyte C3d 61 0.40 0.002
erythrocyte C4d
erythrocyte C3d 61 0.73 < 0.001
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Figure 1. Mean number of CR1 molecules, expressed as molecules per erythrocyte, in 33
normal subjects, 34 SLE patients without anticardiolipin antibodies, and 27 SLE patients
with anticardiolipin antibodies. The number of CR1 molecules per red cell amongst the
aCL-negative SLE patients was significantly lower than amongst the normal subjects (z =
3.77, p < 0.001). Similarly the mean CR1 number was significantly lower amongst the
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Figure 2: Mean number ofC3d molecules, expressed as molecules per erythrocyte, in 33
normal subjects, 34 SLE patients without anticardiolipin antibodies, and 27 SLE patients
with anticardiolipin antibodies. The number of C3d molecules per red cell amongst the
aCL-negative SLE patients was significantly higher than amongst the normal subjects (z =
5.1, p < 0.001). Similarly the mean C3d number was significantly higher amongst the
aCL-positive SLE patients compared with their aCL-negative counterparts (z = 2.49, p <
0.012).
